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   I 
Abstract 
KRAS is one of the most frequently mutated oncogenes in cancer and exhibits 
high prevalence in pancreatic, colon and lung cancers. The development of 
effective KRAS therapeutics has been challenging and only in recent years 
have promising targeted KRAS inhibitors been developed, including those that 
specifically target the oncogenic KRAS-G12C mutant commonly found in non-
small cell lung cancer (NSCLC). As with most targeted therapeutics, it is 
almost inevitable that resistance will develop and limit the clinical efficacy of 
these new targeted drugs. Therefore, understanding the molecular 
mechanisms of resistance associated with KRAS inhibitors is important for 
developing improved treatment options, including combination strategies.   
 
In this study different KRAS inhibitors were used to create a novel panel of 
NSCLC resistant cell lines, enabling multiple comparisons of acquired 
resistance mechanisms to be carried out. Surprisingly evidence of pathway 
rewiring to all KRAS inhibitors emerged within days of inhibitor treatment. 
Transcriptomic and proteomic approaches were used to interrogate resistance 
mechanisms associated with both acute and chronic treatments. Consistent 
up-regulation of receptor tyrosine kinases, RAS-GEFs as well as DNA damage 
repair and cell cycle signalling pathways were observed across resistant cells.   
 
Screening of 25 inhibitors targeting the pathways of these potential resistance 
mechanisms identified 15 inhibitors that showed differential sensitivities 
across the panel of resistant cells, with 3 inhibitors effective across all. This 
included the broad CDK inhibitor flavopiridol and two inhibitors of mTOR. To 
improve therapeutic potential, additional vertical and horizontal inhibitor 
combinations were evaluated. Additional promising strategies to re-sensitise 
cells with acquired resistance to KRAS-G12C inhibition included a 
combination of EGFR and mTOR inhibition. This strongly decreased cell 
viability and downstream pERK and pAKT signalling. Alternatively, the 
synergistic combination of FGFR1 and MEK inhibition was also able to re-
sensitise cells resistant to pan-KRAS inhibition, though this was not as 
effective as mTORi. Evaluation of inhibitor combinations in naïve parental cells 
identified a number of combinations which slowed the emergence of 
resistance. Treatment with flavopiridol and combinations targeting EGFR with 
mTOR or SHP2 inhibition were particularly effective alongside all KRAS 
inhibitors.  
 
These results demonstrate a wider understanding of resistance to KRAS 
therapeutics and present potential clinical significance through effective 
combination strategies that maximise the efficacy of KRAS inhibition and slow 
the emergence of resistance. 
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Cancer is a complex disease caused by the acquisition of key genetic 
alterations which drive unregulated cell survival and proliferation. During 
tumorigenesis cancer cells overcome the normal control mechanisms for cell 
growth and acquire the ability to divide indefinitely whilst evading cell death 
signals. The process is characterised by the accumulation of genetic or 
epigenetic mutations in proto-oncogenes, tumour suppressor genes and DNA 
repair genes. Over time cancer cells become better equipped to survive and 
proliferate in the hostile tumour microenvironment with adaptive advantages 
such as the ability to tolerate hypoxic conditions, metabolic alterations and 
evasion of immune responses. As tumours grow, they stimulate angiogenesis 
to supply oxygen and nutrients via the formation of new blood vessels, which 
eventually enables malignant cancer cells to invade beyond normal tissue 
boundaries and metastasise to other sites around the body; this stage is 
generally associated with poor prognosis.  
 
1.1.1 The hallmarks of cancer 
The complexity of cancer is highlighted by the fact there are more than 100 
distinct types of cancer and diverse sets of risk factors. Typically tumours are 
classified according to their tissue of orgin, however the Pan Cancer Atlas – 
the largest and most comprehensive cross-cancer study to date, analysed and 
re-characterised 33 different types of cancer from over 10,000 patient tumour 
samples according to their molecular profiles [1]. The results of the study 
highlighted that 28 distinct molecular subtypes were identified across the 
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different cancers studied and the majority of these clusters contained different 
histological tumour types [1]. This highlighted that cancers originating from the 
same tissue can have very different genetic profiles. During the course of 
tumorigenesis solid tumours become more heterogeneous, with the tumour 
encompassing subpopulations of cells harbouring a range of distinct mutations 
and molecular signatures [2]. This spatial and temporal intra-tumour 
heterogeneity can enable cancer cells to adapt to the changing tumour 
microenvironment [3]. As a result, tumorigenesis is referred to as an 
evolutionary process. In two landmark papers, Hanahan and Weinburg 
proposed that the complexity of cancer could be defined by eight underlying 
capabilities shared by all human cancers that enable cells to progress towards 
a neoplastic state [4, 5]. These were termed the hallmarks of cancer and 
include self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, evasion of cell death, limitless replicative potential, sustained 
angiogenesis, tissue invasion and metastasis, reprogramming of energy 
metabolism and evading immune destruction. Additionally, two final 
characteristics underpinning these hallmarks were identified; genome 
instability and inflammation [5].   
 
1.1.2 Oncogene addiction 
Cancer cells exhibit extensive genome instability and are driven by the 
progressive accumulation of many mutations and epigenetic alterations that 
activate a variety of oncogenic functions and can evolve over an extended 
period of time [6]. Analysis of Pan Cancer Data identified a total of 299 different 
cancer driver genes of which 116 occured across two or more different cancer 
types [7]. Despite this, evidence from preclinical studies and application of 
targeted therapeutics has shown that cancer cell survival can often be 
dependent on one or relatively few key genetic ‘driver’ events and inactivation 
of these oncogenes can inhibit cancer cell growth [8]. This phenomenon was 
termed ‘oncogene addiction’. Clinical evidence for oncogene addiction is 
widely recognised from the impressive clinical responses and therapeutic 
efficacy of targeted agents in patients [9]. One of the earliest examples of this 
is the antibody trastuzumab, which targets the HER2 receptor, and shows 
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clinical success in HER-2 positive breast cancer patients [10]. Furthermore 
clinical responses with imatinib, which targets the protein kinase fusion BCR-
ABL responsible for the majority of chronic myeloid leukaemia, demonstrated 
remarkable effectiveness and drastically improved patient survival  [11]. In 
NSCLC patients with EGFR activating mutations, treatment with targeted 
EGFR inhibitors gefitinib and erlotinib also improves survival rates [12, 13], as 
does treatment with BRAF inhibitors such as vemurafenib for BRAF-mutant 
melanoma [14]. Such findings provide strong rationale for targeted anti-cancer 
therapies and significant efforts have been made to develop inhibitors that 
target specific driver oncogenes.  
 
1.2 The RAS signalling pathway 
The RAS family of proto-oncogenes are important intracellular signalling 
proteins involved in signal transduction pathways regulating numerous cellular 
processes including cell survival, cell growth, differentiation, proliferation, 
migration and apoptosis. RAS proteins were one of the earliest oncogenes 
described and were originally identified from studies investigating sarcoma-
inducing retroviruses in rats [15, 16]. Later RAS oncogenes were identified 
within the human genome and were found to transform normal human cells 
into tumours [17-19]. Since these early discoveries, intensive research efforts 
in RAS structure, biochemistry and biology helped to further elucidate its 
importance and contribution to many human cancers. Notably mutations in 
RAS genes are one of the most common events driving tumorigenesis and 
overall occur in up to 20% of human cancers  [20, 21]. As a result, RAS is a 
major target for drug discovery.  
 
1.2.1 RAS structure 
RAS proteins are small GTPases which act as molecular switches 
downstream of receptor tyrosine kinases (RTKs) and play a key regulatory role 
in cytoplasmic signalling networks controlling cellular processes. All human 
cells express three RAS isoforms: HRAS, KRAS (comprising two alternative 
splice variants KRAS4A and KRAS4B) and NRAS which are encoded by 
Introduction   4 
separate genes. Despite RAS isoforms sharing approximately 82-90% primary 
amino acid sequence identity they have overlapping yet distinct functions [22, 
23]. The N-terminus exhibits the highest sequence similarity across isoforms 
and contains the G-domain (aa 1-165) which is involved in GTP binding and 
hydrolysis [23] (Figure 1.1). Within this domain are switch I (aa 30-38) and 
switch II (aa 59-76) regions which undergo major conformational changes 
upon nucleotide exchange and subsequently reveals an effector binding site 
[24-26]. Thr-35 and Gly-60 are crucial residues for GTP binding and form 
hydrogen bonds with the g-phosphate, which is subsequently released upon 
GTP hydrolysis allowing the switch regions to return to a GDP-bound 
conformation using a spring-loaded mechanism [27]. The allosteric lobe (aa 
87-166) shares approximately 82% sequence similarity across the RAS 
isoforms and has been suggested to contribute to membrane interactions, as 
well as containing hotspots for protein-ligand interactions [28, 29]. In contrast, 
the hypervariable region (HVR) at the C-terminus is poorly conserved and 
contains the membrane anchor sequence and terminal CAAX motif. Ras 
isoforms display different post-translational lipid modifications at this region, 
thus directing differential Ras trafficking and subcellular localisation [30-34]. 
All four Ras isoforms are prenylated at the CAAX cysteine residue with the 
addition of a farnesyl lipid via a thioether linkage catalysed by 
farnesyltransferase (FTase) [35, 36]. The remaining AAX residues are 
subsequently cleaved by Ras converting enzyme 1 (Rce1) and the carboxyl 
group on the cysteine is methylesterified by isoprenylcysteine 
carboxylmethyltransferase (ICMT) [37]. In addition both KRAS and NRAS 
isoforms can undergo alternative prenylation by geranylgeranyltransferase I 
(GGTase I) in the presence of FTase inhibitors [38]. The membrane 
association of Ras also requires a second localisation signal from 
palmitoylation of an additional C-terminal cysteine upstream of the CAAX 
motif, with the exception of KRAS4B which lacks a second cysteine residue 
and therefore isn’t palmitoylated [36, 39]. Alternatively, KRAS4B has a 
polylysine region which creates electrostatic interactions with the phospholipid 
head groups of the plasma membrane [40]. Consequently, these interactions 
promote Ras isoforms to associate with distinct signalling nanoclusters that 
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are suggested to mediate preferential coupling to effector signalling pathways 
[41, 42].  
 
 
Figure 1.1: RAS protein structure and homology across isoforms 
The RAS G-domain includes the effector and allosteric lobes and encompasses the switch I 
(SW-I) and switch II (SW-II) regions. The main area of RAS isoform sequence divergence is 
in the hypervariable region (HVR) which encodes the majority of membrane binding motifs. 
The key oncogenic mutations at codons 12, 13 and 61 are highlighted in nucleotide binding 




1.2.2 RAS signalling  
RAS proteins are regulated by a wide range of cell surface receptors which 
upon stimulation switch RAS from an inactive GDP-bound to an active GTP-
bound state [43, 44]. The nucleotide binding state of RAS is tightly regulated 
by guanine nucleotide exchange factors (GEFs) which promote GDP 
dissociation and GTP binding, along with GTPase-activating proteins (GAPs) 
which catalyse GTP hydrolysis [45]. The activation state of RAS is determined 
by the balance of these proteins.  Once activated, GTP-bound RAS interacts 
with a variety of downstream effectors, for instance RAF proteins, 
phosphoinositide 3-kinase (PI3K), RAL guanine nucleotide dissociation 
stimulator (RAL-GDS), phospholipase C and Tiam1 to name a few. These 
effectors interact via RAS-binding (RBD) or Ras-association (RA) domains 
which promote effector recruitment to the plasma membrane and 
subsequently facilitates pathway activation [46].  
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1.2.2.1 Signalling upstream of RAS  
RAS can be activated by several cell surface receptor types including receptor 
tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs) which 
activate RAS through the stimulation of exchange factors [47]. Signal 
transduction between RTKs and RAS is mediated by adaptor proteins such as 
GRB2 which contain a SH2 domain that binds to the phosphorylated tyrosine 
sites on activated RTKs [48]. Through SH3 domains GRB2 can bind to the 
SOS-family RAS-GEFs, SOS1 and SOS2, which are recruited to the plasma 
membrane where RAS is localised and facilitate nucleotide exchange on RAS 
[49, 50]. SOS1/2 promotes dissociation of bound GDP from RAS, enabling 
GTP to bind and activate it. The mechanism of RTK mediated SOS-activation 
of RAS has been well characterised, yet other families of RAS-GEFs that are 
controlled under different conditions can also be involved in the activation of 
RAS [51]. For example, enhanced calcium influx as a result of GPCR 
stimulation can also activate the RAS-GRF family of RAS-GEFs, via calcium-
dependent calmodulin association [52, 53]. Additionally, phospholipase C 
activation and diacylglycerol (DAG) production can directly activate the RAS-
GRP family of RAS-GEFs and recruit them to the plasma membrane [54]. 
Consequently, the diversity of RAS-GEFs enables RAS to become activated 
by a varied collection of stimuli. On the other hand, this activation is 
counteracted by RAS-GAPs which rapidly inactivate RAS following its 
activation. There are 14 predicted RAS-GAPs with the most documented 
examples including p120 and NF1 [55]. Conversely the loss of RAS-GAP 
activity, such as the loss of NF1, is associated with activated RAS signalling 
and tumour development which is consistent with tumour suppressor 
characteristics [56-58].  
 
1.2.2.2 RAS effectors  
Once in its active GTP-bound state, RAS interacts with and activates several 
effectors of distinct signalling cascades controlling cell proliferation, survival 
and other cell behaviours. The signal transduction and pathway components 
of the major RAS effector pathways are described below. 
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The RAS-RAF-MEK-ERK pathway 
Once activated, RAS binds to and recruits three closely related RAF proteins 
– CRAF, BRAF and ARAF, from the cytosol to the plasma membrane [59] 
(Figure 1.2). The three isoforms share a common structure and three 
conserved regions (CR). In the N-terminus, the CR1 contains a RAS binding 
domain (RBD) and cysteine-rich domain required for RAS interaction and 
membrane recruitment [60]. CR2 contains important Ser/Thr phosphorylation 
sites involved in the negative regulation of RAS binding and RAF activation 
[61]. Whereas CR3 located in the C-terminus contains the kinase domain and 
activation segment featuring phosphorylation sites important for kinase 
activation [60]. In an inactive state, RAF exists in a closed conformation where 
the N-terminal region interacts with the kinase domain, obstructing the 
catalytic site [62]. These inhibitory interactions are thought to be further 
stabilised by the binding of scaffold protein 14-3-3 to phosphorylated S259 and 
S621 sites located in the N-terminus and C-terminus respectively [63]. 
Although the process of RAF activation is not fully understood, it is thought 
that upon RTK activation, the RBD of RAF binds to the effector loop of 
activated RAS-GTP and the cysteine rich domain also forms additional 
interactions with the farnesyl groups on the C-terminus of RAS [62, 64]. RAS 
binding also promotes the dephosphorylation of 14-3-3 inhibitory binding sites 
which is mediated by protein phosphatase-1 (PP1) and protein phosphatase-
2A (PP2A) [65].  The subsequent release of 14-3-3 from RAF induces its 
transition into an open kinase formation [60, 63, 66]. Consequently, RAS 
binding promotes RAF translocation to the plasma membrane, which 
promotes RAF interaction with additional kinases such as SRC kinases and 
casein kinase 2 (CK2), which phosphorylate key activating sites in the 
negatively charged N-region up-stream of the RAF kinase domain [62]. This 
region differs slightly between the RAF isoforms allowing divergent regulation 
and consists of four amino acid residues (SSYY, residues 338-341 in CRAF 
and SSDD, residues 446-449 in BRAF). In BRAF, the N-region exhibits a 
constitutive negative charge due to the aspartic acid residues, and this 
promotes a higher basal kinase activity compared to the other RAF isoforms 
[67]. In addition, RAF dimerisation has emerged as an important activation 
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event [68], with BRAF-CRAF heterodimers predominating in RAS signalling 
which possess higher kinase activity compared to their respective homodimers 
[69, 70]. It was also identified that catalytically impaired oncogenic BRAF 
mutants could still promote downstream ERK1/2 signalling through 
transactivation of CRAF [71, 72].  This phenomenon has also been found to 
be crucial for the paradoxical ability of RAF inhibitors to induce RAF 
dimerisation and ERK signalling [73] (also discussed in section 1.3.3.1). In 
addition 14-3-3 proteins bound to phosphorylated S621 on CRAF and S729 
on BRAF are also thought to be involved in RAF dimerisation by providing a 
scaffold for their interaction [70, 72].   
 
In turn activated RAF kinase phosphorylates and activates mitogen-activated 
protein kinase kinases 1 and 2 (also known as MEK1 and MEK2), which 
subsequently phosphorylate and activate the MAPKs ERK1 and ERK2 [74]. 
MEK1 and MEK2 are the only known activators of ERK1/2, and function to 
direct multiple upstream signals to induce ERK1/2 activation [75]. This three-
tiered signalling system promotes substantial signal amplification, with 
phosphorylation of Thr and Tyr residues, T202/Y204 in ERK1 and T183/Y185 
in ERK 2, stimulating a 1000-fold activation of kinase activity [76]. ERK1/2 are 
proline-directed kinases which catalyse the phosphorylation of substrates 
containing a PxS/TP sequence, with the proline directly after the 
phosphorylation site is a consistent determinant of ERK1/2 substrates [77]. 
Activated ERK1/2 has a wide substrate specificity with thousands of 
cytoplasmic and nuclear substrates estimated, although incomplete 
knowledge and validation of ERK targets and their effects under different 
biological contexts remains a challenge. Additional substrate specificity is also 
determined through separate functional ERK1/2 docking domains (known as 
the D-domain and F-domain) that are found independently or together within 
ERK1/2 substrates [78, 79]. The D-domain contains the motif DEJL, whereas 
the F-domain (also known as DEF) is characterised by the motif FxFP [80]. 
These docking domains bind to distinct recruitment sites within ERK1/2 called 
the D-site or F-site which are spatially distinct from the catalytic site [80].  
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Many substrates among signalling molecules are often low abundance, have 
transient interactions and regulation of their subcellular localisation as well as 
involvement in complex feedback and crosstalk pathways. Several studies 
using phosphoproteomics and analog-sensitive kinases have helped to 
identify many additional novel ERK1/2 substrates [81-83]. Typically these 
include transcription factors and additional kinases which are involved in a 
number of cellular processes related to cancer development including cell 
survival, proliferation, cell cycle progression, metabolism, cell migration and 
adhesion [84].   
 
ERK activation is however tightly regulated through additional feedback 
controls providing a precise level of signalling depending on the cellular 
context. ERK1/2 can phosphorylate MEK1 at Thr292, preventing its 
dimerisation to MEK2 which decreases MEK1/2 kinase activity [85]. In 
addition, activated ERK1/2 can also phosphorylate specific S/TP sites on RAF 
proteins (S151, T401, S570 and T753) to inhibit their interaction with RAS and 
disrupt RAF dimerisation [76, 86, 87]. However this negative feedback loop is 
ineffective against specific BRAF-mutants such as BRAF-V600E which do not 
require RAS signalling or RAF dimerisation for activation [62]. Another 
upstream feedback target includes the RAS-GEF SOS1, where ERK1/2 
phosphorylation inhibits SOS1 interaction with GRB2, downregulating 
activation from RAS [88-90]. ERK1/2 feedback controls also include 
transcriptional induction of dual-specificity phosphatases (DUSPs) and 
sprouty (SPRY) proteins. DUSPs inactivate ERK1/2 by dephosphorylating the 
conserved Thr/Tyr motif within the ERK1/2 catalytic domain [91, 92].  On the 
other hand, SPRY proteins bind to and inhibit GRB2 as well as inhibiting the 
RAF catalytic domain [93, 94]. Overall the relationship between high signal 
amplification and negative feedback control mechanisms, enables dynamic 
regulation of this signalling pathway. However, it is also one of the most 
dysregulated in human cancers and is a major mediator of RAS-induced 
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oncogenesis. Many cancers exhibit dysregulated MAPK pathway activation as 
well as increased dependency upon its signalling [95]. 
 
Figure 1.2: Overview of the RAS-RAF-MEK-ERK signalling pathway 
Growth factor binding to receptor tyrosine kinases (RTKs) causes autophosphorylation of 
specific tyrosine residues which associate with adaptor proteins such as GRB2. Subsequent 
recruitment of RAS-GEFs such as SOS1/2 to the plasma membrane activate RAS by 
promoting nucleotide exchange and GTP binding. Activated RAS binds to RAF kinases and 
promotes their activation through dimerisation. In turn, active RAF kinases phosphorylate 
MEK1/2 kinases which then phosphorylate and activate ERK1/2. Activated ERK1/2 
phosphorylates many cytoplasmic and nuclear substrates which control a wide variety of 
cellular processes including proliferation and cell survival. ERK1/2 activity is also regulated by 
several negative feedback controls, including inhibitory phosphorylation of RAF, MEK1/2 and 
SOS1/2. ERK1/2 also induces transcriptional upregulation of DUSPs which inhibit ERK1/2 
activity in both the cytoplasm and nucleus, thus negatively regulating RAS activity.  
 
The PI3K pathway 
Another signalling pathway that RAS can interact directly with is the PI3K 
pathway, which plays an important role in cell growth, proliferation and survival 
(Figure 1.3). Phosphatidylinositol 3-kinase (PI3K) are a family of important lipid 
kinases that deliver signals in the PI3K/AKT pathway. Inactive PI3Kα is a 
stable heterodimer which consists of a regulatory p85a subunit and a catalytic 




















Figure? The RAS-RAF-MEK-ERK signalling pathway
Substrates
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and promotes its recruitment to the plasma membrane leading to its activation 
[97]. Here PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) 
to phosphatidylinositol-3,4,5-trisphosphate (PIP3) which propagates 
intracellular signalling by directly binding to a number of proteins with 
pleckstrin homology (PH) domains, such as the kinases phosphoinositide-
dependent kinase 1 (PDK1) and AKT (also known as PKB) [98]. This 
association with PIP3 at the plasma membrane facilitates the phosphorylation 
and activation of AKT by PDK1 [99]. On the other hand, PIP3 signalling is 
regulated by the tumour suppressor phosphatase and tensin homolog (PTEN) 
which dephosphorylates PIP3 and converts it back to PIP2, reducing PIP3-
dependent signalling [100].  
 
One way in which the PI3K pathway promotes cell growth and survival is from 
AKT phosphorylation and subsequent inhibition of the proapoptotic protein 
BAD [101, 102]. Phosphorylation creates a binding site for 14-3-3 proteins and 
prevents BAD from binding to Bcl-2 and Bcl-XL, promoting cell survival. In 
addition, AKT can also phosphorylate MDM2, which antagonises p53-
mediated apoptosis [103]. Another target of AKT is glycogen synthase kinase 
3 (GSK3) which is inhibited upon phosphorylation by AKT and as a result 
pathways usually repressed by GSK3 become activated [104]. For example, 
GSK3 inhibition allows accumulation of cyclin D1 and thus promotes cell cycle 
progression [105]. GSK3 inhibition also activates glycogen synthase, 
contributing to increased glycogen synthesis [106]. AKT can also 
phosphorylate TSC2, inhibiting the RHEB GTPase activity of the TSC1-TSC2 
complex, enabling accumulation of active RHEB which in turn activates the 
mechanistic target of rapamycin (mTOR) [107, 108]. Activation of mTOR 
mediates increased protein synthesis via phosphorylation and activation of 
p70 S6 kinase and 4E-BP1 [109]. 
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Figure 1.3: Overview of the PI3K signalling pathway 
PI3K is activated by receptor tyrosine kinases (RTKs), G-protein-coupled receptors (GPCRs) 
as well as activated RAS. At the plasma membrane PI3K phosphorylates phosphatidylinositol-
4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) which then recruits 
and activates PDK1 and AKT kinases. Active AKT inhibits TSC2 activity through direct 
phosphorylation, driving activation of mechanistic target of rapamycin (mTOR) and increased 
protein synthesis. AKT also phosphorylates downstream effectors MDM2 and BAD leading to 
increased cell survival. Additionally, AKT also inhibits GSK3, increasing cell cycle progression 
and glucose metabolism.  
 
The RAL-GDS pathway 
A third major RAS effector pathway involves the RAS-related RAL proteins; 
RALA and RALB (Figure 1.4). These small GTPases also cycle between an 
active GTP-bound and inactive GDP-bound state. Activated RAS recruits RAL 
exchange factors (RAL-GEFs), such as RAL-GDS, to the plasma membrane 
and promotes the formation of active RAL-GTP [110]. Three additional RAL-
GEFs have been identified and named RAS-GDS-like (RGL1, RGL2 and 
RGL3) [111]. RAL-GTPases interact with a range of effectors involved in 
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For example, RAL-GTP binds RAL-binding protein 1 (RAL-BP1) which 
regulates actin cytoskeleton organisation through its regulation of CDC42 and 
RAC1 [111]. RAL-GTP also binds to Sec5 and Exo84 subunits of the exocyst 
- a molecular tether that is recruited for plasma membrane exocytosis [112]. 
This interaction has also been shown to regulate macroautophagy which is 
involved in cellular adaptation to nutrient restriction [113]. Activated RAL can 
also regulate gene expression through activation of the transcription factors 
NFkB [114] and FOXO4 [115] amongst others. Overall there is growing 
evidence that aberrant RAL activation occurs in human cancers [116, 117], 
and has been shown to promote tumour invasiveness and metastasis [118].  
 
 
Figure 1.4: Overview of the RAL-GDS pathway 
Activated RAS recruits RAL-GEFs, such as RAL-GDS and RGL1-3, promoting RAL nucleotide 
exchange to generate active RAL-GTP. Activated RAL interacts which a variety of 
downstream effectors involved in promoting actin organisation, gene transcription, cell 
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1.2.3 RAS mutations 
Of the RAS isoforms, KRAS is the most frequently mutated isoform (69%), 
followed by NRAS (22%) and HRAS (9%) [119] . These mutations typically 
occur at one of three mutational hotspots located at codons G12, G13 and 
Q61, which subsequently favour GTP binding. These mutations decrease RAS 
intrinsic GTPase activity and have been shown to impair the normal GTP-
hydrolysis by RAS-GAPs, resulting in accumulation of active GTP-bound RAS 
and subsequent signalling to downstream effectors [21]. Despite these 
mutations being activating, they possess differences in their oncogenic 
potential [120-124]. For example, analysis of commonly occurring KRAS 
mutations (G12A, G12C, G12D, G12R, G12V, G13D, Q61L, and Q61H) 
highlighted differences in nucleotide exchange, GTP hydrolysis and RAF 
affinity [123]. Cell-based studies have also identified differences in 
transforming phenotypes between KRAS G12 and G13 mutations, with G12 
mutations exhibiting resistance to apoptosis and favouring anchorage 
independent growth [125],  as well as differential metabolic reprogramming, 
protein trafficking and kinase signalling [126].  
 
RAS isoforms also exhibit distinct associations with particular tumour types as 
well as differences in the mutational frequency at these mutation hotspots [21]. 
For example, pancreatic ductal adenocarcinomas, lung adenocarcinomas and 
colorectal adenocarcinomas are greatly associated with mutated KRAS [127]. 
In contrast, NRAS is predominantly mutated in cutaneous melanoma and 
haemopoietic cancers, whilst HRAS mutations are primarily linked to head and 
neck squamous cell carcinomas. Additional complexity arises as each isoform 
shows bias towards specific codon mutations; G12 mutations predominant in 
KRAS (81%), Q61 mutations are the most frequent mutation in NRAS (62%), 
whereas HRAS mutations are more evenly split between codons G12, G13 
and Q61 (26%:23%:38%) [119]. 
 
In addition to mutation frequency across isoforms, specific mutations can also 
be linked to certain mutagen exposure, with NSCLC representing a key 
example. In non-smokers, the majority of KRAS G12 mutations are caused by 
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a G-to-A transition resulting in an amino acid change from glycine to aspartic 
acid (G12D mutation). However, in smokers G-to-T transversions predominate 
producing a cysteine at codon 12. This specific G12C mutation is associated 
with DNA adduct formation [74]. According to Cancer Research UK 
approximately 35,600 deaths occur every year due to lung cancer, which is 
still the most common cancer related death in the UK  [128] and tobacco 
smoking remains the greatest single cause accounting for 72% of cases [129]. 
Approximately 15-25% of lung adenocarcinomas contain mutations in KRAS 
[130] and of these 65% have G12C mutations [131].  
 
The explanation for these varying RAS mutation frequencies observed in 
human cancers remains poorly understood, and it is likely that many factors 
are involved such as differences in RAS effectors, RAS expression levels, 
epistatic interactions, isoform structural differences and cellular context [119]. 
Overall it suggests that some RAS variants are able to achieve an optimum 
level of RAS signalling, whereas others may conduct too little or too much RAS 
signalling to effectively drive tumorigenesis under certain conditions.  
 
1.2.4 Additional RAS pathway mutations  
Activating mutations in RTKs and RAS effector genes such as BRAF and 
PIK3CA are also common occurrences in human tumours, further highlighting 
the importance of Ras signalling pathways in driving tumour growth [127].  
 
Upstream of RAS, RTKs such as EGFR, ERBB2 (HER2) and MET are often 
abnormally activated in many human cancers, particularly lung and breast 
cancers through genomic amplification, gain of function mutations, 
chromosomal rearrangements and autocrine activation [132]. In NSCLC, the 
most common EGFR mutations are small in-frame deletions located in exon 
19 or an L858R point mutation in exon 21 both situated within the tyrosine 
kinase domain [133]. This results in constitutive activation of the receptor as 
well as downstream signalling pathways. Notably EGFR mutations and KRAS 
mutations appear to be mutually exclusive, although KRAS mutation can 
confer resistance to EGFR inhibitors [134].  
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BRAF is also frequently mutated in approximately 7% of human cancers, 
particularly in melanomas, thyroid and colorectal cancers, whereas mutations 
in CRAF and ARAF are exceptionally rare [135, 136]. The majority of BRAF 
mutations occur in the kinase domain, in particular the activation loop or 
phosphate binding loop regions, of which the most common encodes a V600E 
mutation [135, 136]. This gain-of-function mutation increases kinase activity 
500-fold compared to BRAF-WT cells and produces a BRAF kinase capable 
of signalling as a monomer [71, 136]. Similarly, BRAF V600E and KRAS 
mutations also appear to be mutually exclusive, and concomitant mutations in 
both proteins are extremely rare [136, 137]. This suggests that activating 
mutations in either of these proteins has comparable effects on tumorigenesis 
[137]. Additional BRAF mutations include gene fusions and in-frame deletions 
which promote constitutively activated BRAF-mutants capable of dimerisation 
independent of RAS activation [138].  
 
Unlike RAS and RAF, MEK activating mutations are found at a much lower 
prevalence in the cancer genome, making it an attractive therapeutic target for 
cancers with aberrant RAS-ERK1/2 signalling [139]. The majority of MEK 
mutations cluster in the N-terminal negative regulatory region and N-terminal 
kinase domain [75], highlighting that some MEK mutations not only increase 
kinase activity but also modulate MEK regulation such as dephosphorylation 
[140].  
 
Alternatively, the PI3K pathway can be activated by amplification or mutation 
of the PI3KCA gene, encoding the PI3K p110a subunit, which occurs at high 
frequency in many common human cancers [141]. Furthermore, the tumour 
suppressor PTEN, which dephosphorylates PIP3 and thus terminates PIP3-
dependent downstream signalling, is also commonly mutated. Loss of PTEN 
function can occur through gene mutation, deletion, transcriptional silencing 
or protein instability, resulting in constitutive activation of the PI3K pathway 
[142]. 
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1.3 Targeting RAS 
Since the discovery over 30 years ago that RAS genes are frequently mutated 
within a large variety of tumours, the RAS GTPase family and associated 
signalling pathways have presented attractive targets for cancer therapeutics 
and significant efforts have been committed to inhibiting RAS [139]. However 
direct pharmacological inhibition of RAS has been a major challenge, primarily 
due to a small inaccessible GTP binding pocket which exhibits intrinsically high 
affinity for GTP, thus rendering displacement by small molecules a difficult 
task. Consequently, major strategies of RAS inhibition have focused on 
indirect inhibition through blocking post-translational modification, localisation 
and signalling cascades (Figure 1.5).  
 
Figure 1.5: Approaches of targeting mutant RAS 
Strategies for anti-RAS drug development include direct inhibition of RAS, inhibition of 
upstream receptor tyrosine kinases, inhibition of enzymes that promote RAS membrane 
association and localisation at the plasma membrane and inhibition of RAS downstream 






















Figure?: Approaches of targeting mutant RAS
Strategies for anti-RAS drug development include direct inhibition of RAS, inhibition of
upstream receptor tyrosine kinases, inhibition of enzymes that promote RAS membrane
association and localisation at the plasma membrane and inhibition of RAS downstream
effector signalling, particularly signalling through RAF and PI3K.
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1.3.1 RAS Localisation inhibitors 
Given the essential requirement for RAS signalling at the plasma membrane, 
early efforts to target RAS involved disrupting its membrane localisation 
through inhibition of the FTase responsible for membrane-targeting 
prenylation of the C-terminal CAAX motif [39].  Despite FTase inhibitors (FTIs) 
demonstrating promising anti-tumour effects in preclinical in vitro and in vivo 
studies [143], they failed to show anti-tumour activity in tumours harbouring 
KRAS and NRAS mutations [144]. The underlying basis for this lack of efficacy 
is due to the alternative prenylation of KRAS and NRAS by GGTase I in the 
presence of FTase inhibition, which also supports membrane association and 
promotes oncogenic signalling [38, 145]. However, several FTIs including 
lonafarnib and tipifarnib have progressed into clinical trials for HRAS-driven 
tumours [146, 147]. Alternatively, combination approaches of FTase and 
GGTase inhibitors present toxicity challenges due to the finding that more than 
100 other proteins are also targets of these enzymes [148]. Despite this 
concern, studies with genetic mouse models have supported the anti-tumour 
effects of GGTase inhibitors [149, 150]. Approaches targeting the two other 
RAS processing enzymes, RCE1 and ICMT also generate similar toxicity 
concerns from affecting other additional substrates. In a study using KRAS-
G12D mutant pancreatic mouse models, ablation of ICMT was demonstrated 
to instead accelerate pancreatic neoplasia [151]. More recently, targeting 
palmitoylation and depalmitoylation has also been considered as an 
alternative approach to destabilising NRAS and HRAS membrane association 
[152, 153]. Additional approaches have entailed disrupting RAS from binding 
to chaperone proteins and so preventing its subsequent trafficking to the 
plasma membrane. An example includes targeting of phosphodiesterase-6d 
(PDE6d) which can bind to both farnesylated and geranylgeranylated proteins, 
although not to those that are also palmitoylated [154, 155]. As a result, PDE6d 
inhibition selectively effects KRAS trafficking compared to HRAS. 
Alternatively, other studies have investigated existing inhibitors which disrupt 
RAS nanoclustering at the plasma membrane and promote RAS mis-
localisation. These include fendiline an L-type calcium channel blocker [156], 
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staurosporines which inhibit phosphatidylserine trafficking [157] and 
metformin [158, 159].  
 
1.3.2 Inhibitors targeting upstream of RAS 
Over the past two decades, inhibitors of growth factor receptor tyrosine 
kinases have represented a large group of targeted drugs which have been 
used clinically for cancer treatment. They typically target either the receptor-
ligand interaction such as monoclonal antibody inhibitors or they target the 
receptor kinase domain and competitively inhibit ATP binding sites [160]. 
Overall this prevents subsequent phosphorylation and activation of 
downstream signalling cascades. EGFR and ERBB2 receptors in particular 
have an important role in the activation of RAS pathways and are able to 
stimulate RAS via GRB2 and SOS interactions. In NSCLC EGFR inhibitors 
such as gefitinib and erlotinib show robust efficacy in EGFR-mutant tumours, 
however their effectiveness can often be limited by the development of 
resistance [161]. The protein tyrosine phosphatase SHP2 (PTPN11) is an 
important mediator of signal transduction from RTKs, particularly in mutant 
KRAS-driven cancers [162, 163]. The development of SHP2 inhibitors 
provides an alternative strategy to prevent the activation of RAS. The SHP2 
inhibitor SHP099 alone or in combination with MEK inhibition demonstrated 
effective inhibition of downstream ERK signalling in some RAS-mutant 
preclinical models [164]. Several combinations of SHP2 inhibitors with direct 
RAS inhibitors are also being explored [165]. Efforts have also been in the 
development of RAS-GEF inhibitors such as BI 1701963 (Boehringer 
Ingelheim) which selectively inhibits RAS-SOS1 interactions and thereby 
hinders the formation of active GTP-bound KRAS. Phase I clinical trials are 
being conducted as a monotherapy and in combination with a MEK inhibitor 
(NCT04111458). Overall these agents offer the potential to switch off all RAS 
mutants by hitting targets at the beginning of the signal cascade.  
 
1.3.3 Inhibitors of RAS effector pathways 
In RAS driven cancers, the downstream RAF/MEK/ERK and PI3K/AKT/mTOR 
signalling cascades become aberrantly activated and the inhibition of these 
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pathway nodes have presented attractive targets. However due to multiple 
points of crosstalk and negative feedback loops, single agent inhibition has 
not been successful clinically and thus combinational inhibition has been the 
primary treatment strategy to overcome potential resistance mechanisms 
[166]. 
 
1.3.3.1 BRAF inhibitors  
Despite RAF functioning as a key downstream effector of RAS, 
pharmacological inhibition of BRAF by ATP-competitive inhibitors in RAS-
mutant and RAS/RAF-WT tumours unexpectedly enhanced downstream 
ERK1/2 signalling and enhanced tumour growth [167, 168]. In these cells, 
inhibitor binding promoted RAF dimerisation and transactivation of CRAF in 
RAF heterodimers and homodimers, consequently leading to increased 
pathway signalling via CRAF [167]. Clinical studies also confirmed these 
findings with the development of RAF-inhibitor induced keratoacanthomas and 
cutaneous squamous cell carcinomas in patients with mutant RAS [169]. 
Nethertheless, several BRAF inhibitors including vemurafenib and dabrafenib 
have been clinically approved specifically for the treatment of BRAF-mutant 
metastatic melanoma [14, 170]. In these patients, single agent BRAF inhibitor 
treatment significantly improved overall and progression-free survival 
compared to standard chemotherapy, although the development of acquired 
resistance often limits their responsiveness. The development of pan-RAF 
inhibitors such as Belvarafenib may prove to be more effective for the 
treatment of both BRAF and RAS mutant tumours [171].  
 
1.3.3.2 MEK inhibitors  
The majority of MEK1/2 inhibitors act as non-ATP competitive inhibitors 
binding to a novel allosteric binding pocket adjacent to the ATP binding site 
[172]. As a result, this enables higher specificity of MEK1/2 inhibitors 
compared to ATP competitive inhibitors. In the presence of allosteric inhibitors, 
MEK1/2 adopts an inactive conformation where the ERK1/2 activation loop 
becomes displaced and causes disruption of the catalytic domains in the 
ERK1/2 binding site [172]. As observed with BRAF inhibitors, MEK inhibitors 
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are most effective in tumours which exhibit strong dependency upon ERK1/2 
signalling such as those with BRAF-V600E mutations [173, 174]. Three 
MEK1/2 inhibitors, trametinib, cobimetinib and binimetinib have been 
approved for the treatment of BRAF-mutant metastatic melanoma, as single 
agents or combined with BRAF inhibitors [175-177]. In KRAS-mutant cancers, 
multiple phase I and phase II clinical trials have been conducted with the 
MEK1/2 inhibitor selumetinib, both as a single and combined agent [178]. 
Despite showing initial promise in the phase II SELECT-1 clinical trial in 
combination with docetaxel in KRAS-mutant NSCLCs, the subsequent phase 
III trial determined that the addition of selumetinib was not clinically effective 
[179, 180]. In RAS-mutant tumours MEK inhibitors induce pathway feedback 
loops by relieving ERK-dependent negative feedback loops resulting in RAF 
activation and therefore display variable sensitivity to MEK inhibition [173]. The 
MEK inhibitor GDC-0623 which blocks MEK activation by RAF underwent 
clinical evaluation but was later discontinued [181, 182]. Due to complex 
feedback reactivation, targeting multiple nodes within the MAPK pathway has 
also been explored through combined RAF and MEK inhibition in studies with 
KRAS-mutant cancer cell lines [183, 184]. Increased GTP-RAS and RAF 
dimerisation in KRAS-mutants was suggested to enhance the synergy of this 
therapeutic combination [184]. As a result, two clinical trials are currently 
investigating this combination in KRAS-mutant tumours (NCT03284502, 
NCT02974725).  
 
1.3.3.3 ERK inhibitors  
In order to overcome some of the difficulties faced with RAF and MEK 
inhibitors, inhibitors of the downstream kinase ERK represent an alternative 
approach to overcome reactivation of the MAPK pathway. In comparison to 
the upstream RAF and MEK inhibitors, the development and clinical 
progression of selective ERK1/2 inhibitors has lagged behind with no ERK 
inhibitors yet clinically approved [185]. Several are under clinical investigation, 
though results from early clinical trials for KRAS-mutant tumours have been 
largely disappointing. Similar to MEK inhibitors, ERK inhibitors prevent ERK 
feedback phosphorylation of RAF, subsequently leading to enhanced MEK 
signalling [127]. In phase I trials, the ERK1/2 inhibitor MK-8353 showed no 
Introduction   22 
anti-tumour effects on KRAS-mutant cancers as monotherapy, although some 
responses were observed in patients with BRAF-mutant tumours [186]. As a 
result of lower response rates, clinical trials are currently taking place 
combining MK-8353 with MEK inhibition (NCT03745989) as well as with the 
immunotherapeutic agent pembrolizumab (NCT02972034). A preclinical study 
combining the ERK1/2 dual inhibitor GDC-0994 with MEK inhibition showed 
promising efficacy in KRAS-mutant lung and pancreatic tumour mouse 
models, with MAPK pathway suppression greater than with either single agent 
alone [187]. However, in a phase I clinical trial the combination was not 
tolerated and the trial was terminated [188]. On the other hand, the reversible 
ATP competitive ERK1/2 inhibitor ulixertinib has shown promising clinical 
evidence in NRAS-mutant and BRAF-mutant tumours [189], and is also 
undergoing further clinical trials in combination with CDK inhibition 
(NCT03454035) and as part of the MATCH precision medicine cancer 
treatment clinical trial for BRAF non-V600 mutation tumours (NCT02465060). 
In a recent preclinical study, the combined inhibition of RAF and ERK was 
found to be more synergistic and effective at supressing ERK signalling in 
KRAS-mutant cells than combined ERK/MEK inhibition or MEK/RAF inhibition 
[190]. This RAF/ERK inhibitory combination also decreased ERK feedback 
signalling [190]. As part of an ongoing clinical trial (NCT02974725) this 
combination is being clinically investigated using a pan-RAF inhibitor in 
combination with the ERK1/2 inhibitor LTT462.  
 
1.3.3.4 PI3K pathway inhibitors  
Several PI3K inhibitors have also been developed, including dual PI3K and 
mTOR inhibitors, and many of these are undergoing preclinical development 
and clinical evaluation. Early preclinical mouse studies highlighted that PI3K 
signalling is required for RAS-driven tumourgenesis [191, 192]. As observed 
with other inhibitors of RAS effector pathways, they showed limited efficacy as 
monotherapies in KRAS-driven tumours, although preclinical studies 
suggested combined inhibition of PI3K and MEK would be efficacious [193-
195]. However translation of these findings into clinical trials demonstrated the 
challenges of overlapping monotherapy toxicities and demonstrated low 
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response rates and little efficacy at tolerable drug doses [196, 197]. Several 
AKT inhibitors are also undergoing clinical evaluation, as both monotherapies 
and as combinative therapeutics, although currently no AKT inhibitors have 
yet been approved for cancer treatments [198]. As observed with PI3K-MAPK 
inhibition, the combination of AKT and MEK inhibitors in phase I/II trials has 
indicated poor tolerability and limited efficacy in patients with advanced solid 
tumours including those with RAS or BRAF mutations [199-201]. Additionally, 
mTOR and dual mTOR/PI3K inhibitors combined with MEK inhibition also 
failed to provide efficacy at acceptable drug tolerable doses [202, 203].  
 
1.3.4 Direct RAS inhibitors                                                                                                                                                                     
Despite decades of research, only in recent years with advances in drug 
discovery approaches and technology have direct RAS inhibitors been 
developed, including the discovery of small molecules that selectively bind to 
the KRAS-G12C mutant most frequently present in NSCLC tumours [204]. A 
variety of high throughput strategies have been used to identify such 
compounds including screening strategies to assess the disruption of GEF 
interaction and effector binding [205, 206]. These molecules irreversibly bind 
to the reactive thiol group of the mutated cysteine at position 12 and therefore 
do not inhibit KRAS-WT or other mutated forms. Inhibitor binding occupies a 
switch-II pocket only accessible when GDP is bound which disrupts the 
adjacent switch I and switch II regions and promotes a shift in nucleotide 
affinities of KRAS-G12C to favour GDP over GTP [204, 207]. Consequently, 
this leads to an accumulation of mutant RAS in the inactive state and impairs 
binding to downstream RAF. Following the success and further development 
of initial compounds, two KRAS-G12C inhibitors AMG-510 (Amgen) and 
MRTX849 (Mirati Therapeutics) have entered into clinical trials to treat KRAS-
G12C cancers and show promising early results in NSCLC [208, 209]. 
Currently KRAS-G12C inhibitors are the only targetable mutant specific KRAS 
inhibitors which have entered the clinic, however there is emerging evidence 
that other KRAS mutants might one day be druggable. For example 
therapeutic peptides targeting KRAS-G12D have been developed as well as 
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pan-mutant KRAS macromolecule degraders, although currently these 
strategies are limited therapeutically by suitable delivery systems [210, 211].  
 
Another approach of direct RAS inhibition is targeting RAS expression using 
antisense oligonucleotides (ASOs). These are short strands of 
deoxyribonucleotides that are complementary to mRNA sequences. This 
therapeutic approach therefore enables the development of highly specific and 
selective inhibitors according to gene sequence information and offers the 
potential to target molecules that have previously been difficult to inhibit by 
conventional drugs [212]. Upon binding to mRNA, ASOs downregulate their 
molecular target by inducing RNase H endonuclease activity to cleave the 
DNA-RNA duplex thus reducing target gene translation [213]. ASOs can also 
prevent translation by steric hindrance of ribosomal activity, reducing mRNA 
stability and inhibition of mRNA splicing [213]. Improvements in ASO 
pharmacology and chemistry have enhanced compound stability and potency 
[214]. Examples of ASOs targeting RAS include ISIS-2503 (Isis 
Pharmaceuticals) targeting HRAS mRNA and AZD4785 (Ionis 651987) 
targeting KRAS mRNA [215, 216]. Despite demonstrating safety and 
tolerability in phase I/II clinical trials, both compounds have since failed to 
progress and enter the clinic as a cancer treatment. 
 
1.4 Mechanisms of resistance to targeted 
therapeutics 
The development of targeted therapeutics has undoubtably transformed the 
treatment of many cancers and improved overall prognosis of cancer patients, 
such as EGFR-mutant NSCLC treated with EGFR inhibitors, BRAF-mutant 
melanomas treated with BRAF inhibitors and HER2-amplified breast cancer 
treated with HER2 inhibitors. However, despite initially responding to 
treatment, most patients treated with targeted therapies acquire resistance to 
these agents. As targeted therapies for RAS-mutant tumours are developing 
and undergoing clinical evaluation, understanding potential resistance 
mechanisms is becoming important for improving these treatments. Drug 
resistance can be classified as intrinsic, existing before treatment, or as 
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acquired where resistance develops following drug treatment among patients 
whom were initially responsive [217, 218]. Adaptive resistance to KRAS-G12C 
inhibitors AMG-510 and MRTX849 has been observed in early preclinical 
models [219, 220] and overcoming this could be an important step for 
improving treatment efficacy.  
 
1.4.1 Intrinsic resistance to RAS inhibitors 
The heterogeneity of tumours can promote intrinsic resistance to develop, 
whereby alternative non-targeted genetic mutations exist within some tumour 
cells, such as other RAS mutations [221, 222], creating subpopulations which 
are resistant to allele-specific or RAS isoform-specific inhibitors. This 
heterogeneity severely limits the success of targeted therapeutics by selecting 
for and promoting the outgrowth of resistant cancer cells. Pre-existing 
mutations in RAS which increase nucleotide exchange (Y40A, N116H, A146V) 
or alternatively impair GTPase activity (A59G, Y64A) could also reduce the 
interaction of current KRAS-G12C inhibitors which bind to GDP-KRAS [223]. 
As well as alternative mutations within tumours, differing dependencies of 
tumours for KRAS signalling could also promote intrinsic resistance to KRAS 
inhibitors [224], for example those that may not rely primarily on ERK signalling 
for cell viability. For example, even complete knockout of the KRAS gene using 
CRISPR genome editing enabled a subset of KRAS-mutant cell models to 
survive [225]. At present there is little evidence of what de novo mutations may 
arise and cause resistance to KRAS inhibitors, though ongoing clinical 
responses will help to clarify this. 
 
1.4.2 Adaptive resistance to RAS inhibitors  
Acquired resistance mechanisms that have been previously observed for other 
inhibitors targeting the MAPK pathway, such as EGFR, BRAF and MEK 
inhibitors, may provide some insight into potential acquired resistance 
mechanisms associated with direct KRAS inhibitors (summarised in Table 
1.1). These can be broadly categorised into secondary alterations of the 
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target, reactivation of signalling pathways and phenotypic transformation 
[226]. 
 
1.4.2.1 Alteration of the target  
The use of targeted inhibitors can select for the emergence of mutations within 
the primary drug target, often abrogating drug binding or enhancing oncogenic 
signalling. For example, as observed in 50-60% of EGFR-mutant NSCLC, the 
gatekeeper T790M mutation within the EGFR kinase domain can arise 
following EGFR inhibitor treatment, which enhances ATP affinity and 
subsequently kinase activity despite the presence of inhibitor [227, 228]. 
Furthermore, the majority of mutations that confer resistance to MEK inhibition 
occur in its allosteric drug binding pocket which provides approximately 100-
fold resistance to MEK inhibition [229, 230]. As such alternative oncogenic 
KRAS-G12 mutations, such as G12D or G12V, could be expected to occur 
with targeted KRAS-G12C inhibitors [185]. Alternatively, in BRAF-V600E 
mutant melanoma, amplification of BRAF-V600E itself was identified as a 
mechanism of resistance to BRAF inhibitors [231, 232]. Elevated signalling 
from the CRAF isoform was also identified as an acquired resistance 
mechanism to BRAF inhibition [233]. Subsequently amplification of KRAS, or 
alternatively HRAS or NRAS could drive RAS dimerization and activation in 
the presence of RAS inhibitors.  
 
1.4.2.2 Alternative signalling pathways 
To maintain cell homeostasis, cell signalling pathways are regulated by a finely 
controlled network of protein interactions, feedback mechanisms and crosstalk 
within signalling networks [234]. Mechanisms of feedback control help to 
precisely tune signalling outcomes through post-translational modifications 
such as phosphorylation that alter protein activity [235, 236]. While these 
mechanisms help cells to survive under dynamic physiological conditions, they 
can also enable cancer cells to adapt to pharmacological pathway 
perturbations. Drug resistance can evolve through dynamic re-wiring of cell 
signalling networks to circumvent the initial drug blockade [237]. This adaptive 
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response can occur extremely quickly following treatment, promoting cell 
adaptation and continued cell survival in the presence of drug through parallel 
activation of alternative signalling pathways that are not targeted by the drug. 
The majority of acquired resistance mechanisms to MAPK pathway inhibitors 
promote recovery of the MAPK pathway through rebounded ERK1/2 
activation. In EGFR-mutant lung cancer the amplification of alternative EGFR-
family receptors such as MET and HER2 have been identified [227, 238, 239]. 
Similarly, in BRAF-mutant tumours this can be achieved by activating 
mutations in NRAS and MEK1/2 [229, 232, 240-242], as well as inactivating 
mutations in CDKN2A [243]. In addition, amplification of the upstream 
oncogene BRAF-V600E was observed in CRC and melanoma cell lines 
resistant to MEK inhibitors [242, 244, 245], as well as amplification of mutant 
KRAS in KRAS-mutant CRC cell lines resistant to selumetinib [244]. In 
addition loss of NF1, resulting in reduced RAS-GAP protein neurofibromin and 
thus increased RAS activity, has also been identified as a mechanism of 
resistance to targeted inhibitors in both BRAF-mutant and EGFR-mutant 
tumours [246, 247]. 
 
In addition to increased MAPK pathway signalling, cancer cells can activate 
alternative signalling pathways such as the PI3K pathway to bypass signalling 
in response to targeted MAPK pathway inhibitors. For example in BRAF-
mutant tumours the overexpression of upstream receptor PDGFRb was 
associated with lower reactivation of the MAPK signalling pathway, and 
instead promoted activation of other signalling pathways for cell survival [240]. 
Mutations in AKT1/3 and PTEN were identified in BRAF-mutant melanoma 
resistant to BRAF inhibition [243], whilst loss of PTEN contributed to 
resistance to targeted EGFR inhibition in EGFR-mutant NSCLC [248]. As a 
result, reactivation of MAPK or PI3K signalling pathways can undertake 
numerous mechanisms of resistance through alteration of upstream signalling 
and downstream signalling, and subsequently similar resistance mechanisms 
are also likely to occur with targeted RAS inhibition. 
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NSCLC Target Mutation EGFR T790M 
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[227, 249] 
Amplification MET  [238] 












Mutation MEK1/2  [232, 241, 
242, 251] 




Down regulation NF1 [247] 
PTEN [243] 
CRC Mutation MEK1/2  [252] 





Melanoma Mutation  MEK1/2 [229] 
Amplification BRAF [242] 
CRC Mutation MEK1/2 [230] 
Amplification BRAF [244, 245] 
KRAS [244] 
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1.4.2.3 Phenotypic transformation 
Cancers may also acquire resistance through phenotypic transformation via 
epithelial-to-mesenchymal reprogramming. Several transcriptions factors, 
including ZEB1/2, TWIST1/2 and SNAI1/2 are involved in mediating gene 
expression and regulating epithelial-to-mesenchymal transition (EMT) which 
increases cell migration and invasiveness [253]. In NSCLC an EMT phenotype 
has been associated with resistance to EGFR inhibitors [254-256] and 
similarly in melanoma, resistance to BRAF inhibitors was associated with 
ZEB1-mediated phenotype switching [257]. It is suggested that EMT 
reprogramming may rewire the expression of RTKs promoting cells to activate 
alternative survival signalling pathways driving EMT-mediated drug resistance 
[258, 259]. For example, in KRAS-mutant NSCLC treated with MEK inhibitors, 
a mesenchymal phenotype activated the PI3K pathway independent of HER3 
and instead FGFR1 was dominantly expressed, whilst cells with an epithelial 
phenotype activated the PI3K pathway in a HER3-dependent manner [258]. 
Alternatively in mesenchymal cells treated with AMG-510, PI3K activation was 
mediated by IGFR [259]. Histologic transformation, such as a switch from 
NSCLC to small-cell lung cancer (SCLC) has also been observed as a 
mechanism of resistance to EGFR inhibitors in patients with EGFR-mutant 
tumours [227, 260]. In these cases, the original EGFR driving mutation 
observed in the original NSCLC is also retained in the SCLC phenotype, 
indicating an evolutionary transformation of the original tumour cells to adopt 
the genetic features of SCLC, rather than its de novo development.  
 
1.4.3 Emergence of resistance  
Despite numerous mechanisms of drug resistance to targeted therapeutics 
being identified, the underlying emergence and evolution of these resistant 
cells remains unclear. One suggestion is that a small subpopulation of 
reversibly drug-tolerant cells emerges as an acute response to drug exposure 
[261]. These cells are able to maintain viability in the presence of the drug 
through epigenetic alterations and adopting a quiescent-like state [261]. They 
likely function as a transition state, actively supporting the development of 
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more permanent resistance mechanisms to be established, before culminating 
into fully drug-resistant cells [261]. From monitoring resistant clones over time, 
this process was observed during the development of acquired resistance 
caused by an EGFR-T790M mutation within initially EGFR-T790M negative 
drug-tolerant NSCLC cells [262].The emergence of drug-tolerant cells can be 
attributed to branched tumour evolution giving rise to subpopulations of cancer 
cells with varying treatment responsive phenotypes, with some bearing 
selective advantages [263]. When sudden selective pressures are imposed by 
therapeutics, this process is particularly evident. Whole exome-sequencing 
identified that diverse resistance mechanisms could emerge from a single 
drug-tolerant NSCLC clone treated with an EGFR inhibitor [264]. This 
branching evolutionary process is integral to underlying tumour heterogeneity.  
 
1.5 Aims of this project 
Recent advances in the development of direct KRAS inhibitors, including those 
that specifically target the KRAS-G12C mutation frequently observed in lung 
cancers, provides promising therapeutic strategies for KRAS-driven tumours. 
Although this development is hugely exciting and two KRAS-G12C inhibitors 
have already entered clinical trials with encouraging initial results [208, 219], 
drug resistance against these new inhibitors poses a significant challenge that 
may limit their clinical efficacy. Acquired resistance commonly emerges in 
response to other RAS pathway targeted therapeutics, and these mechanisms 
are likely to be seen with these new classes of direct RAS inhibitors. Therefore, 
understanding the molecular mechanisms involved in the survival of drug 
resistant cancer cells treated with KRAS inhibitors is critical for helping to 
develop improved treatment options. If critical signalling pathways involved 
can be predicted and targeted in patients, there is greater potential for delaying 
or preventing the emergence of resistance by using appropriate combination 
therapies. This will enable a more promising approach to personalised 
treatment for RAS-driven cancers.  
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Using a panel of KRAS-mutant and KRAS-WT NSCLC cell lines, alongside 
direct KRAS inhibitors with distinct inhibitory mechanisms and a MEK inhibitor 
with previously identified resistance, I had the following aims for this project: 
• To validate the efficacy of direct KRAS inhibitors in a panel of NSCLC 
and to generate drug-resistant cell lines. 
• To identify gene and protein signatures associated with emerging 
KRAS inhibitor resistance and to determine potential signalling 
pathways involved that could also be therapeutically targeted. 
• To determine if there are differences in resistance mechanisms 
between different mechanisms of RAS pathway inhibition. 
• To identify potential combination therapies that could delay or 
overcome the development of acquired resistance. 





Chapter 2  
 
Materials and Methods 
 
 
2.1 Cell Biology 
 
2.1.1 Cell biology reagents 
The reagents used in the cell biology experiments are listed in Tables 2.1 - 
2.5. 
 
Table 2.1: Reagents used for cell biology  
Reagent Supplier Catalogue number 
RPMI 1640 Medium with 
Glutamax™ Thermo Fisher Scientific 61870036 
Fetal Bovine Serum (FBS) Thermo Fisher Scientific 10270 
Trypsin-EDTA (0.5%) Thermo Fisher Scientific 15400054 
Phosphate buffered saline 
(PBS) ThermoFisher Scientific 14200067 
CellTitre-Glo ® 2.0 assay Promega G9242 
CellTox™ Green Promega G8743 
IncuCyte® Nuclight Rapid 
Red Reagent Sartorius 4717 
IncuCyte® Cytotox Green 
Reagent Sartorius 4633 
MOWIOL Merck 475904 
e-Myco™ PLUS 
Mycoplasma PCR Detection 
Kit 
Boca Scientific 25237 
 
Table 2.2: Details and characteristics of the lung cancer cell lines  










[H1792] ATCC® CRL-5895™ 
Pleural effusion 
metastasis from lung 
adenocarcinoma 
G12C 3D 
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NCI-H2030 














G12C 2D (partial 3D) 
SW 1573 
[SW-1573] ATCC® CRL-2170™ 
Epithelial alveolar 
carcinoma cells G12C 3D 
NCI-H1793 
[H1793] ATCC® CRL-5896™ 
Epithelial NSCLC 








effusion metastasis WT - 
 
 
Table 2.3: Details of inhibitors used to treat cells. 
Inhibitor Target Supplier Catalogue number 
Adavosertib Wee1 Generon HY-10993 
ARS1620 KRAS-G12C Generon HY-U0041 
AZD0156 ATM Generon HY-100016 
AZD4547 FGFR1-4 Generon HY-13330 
AZD4785 (ASO) KRAS Ionis n/a 
AZD549148 (ASO 
CTRL) n/a AstraZeneca n/a 
AZD5438 CDK1, -2, -9 Generon A11105 
AZD8055 mTOR Generon A8214 
AZ6813 KRAS-G12C AstraZeneca n/a 
BAY-293 KRAS-SOS1 Generon HY-114398 
Berzosertib ATR Generon HY-13902 
BI-3406 KRAS-SOS1 Generon HY-125817 
Crenolanib PDGFR Generon HY-13223 
CP-673451 PDGFR Generon HY-12050 
Deltarasin KRAS Tocris Bioscience 5424 
Erlotinib EGFR Generon HY-50896 
Everolimus mTORC1 Generon HY-10218 
Fendiline KRAS Santa-Cruz Biotechnology SC-239988 
Flavopiridol CDK2, -4, -6 Generon HY-10005 
Gefitinib EGFR Generon HY-50895 
Infigratinib FGFR1-4 Generon HY-13311 
Lapatinib EGFR, ERBB2 Generon HY-50898 
Niraparib PARP1/2 Generon HY-10619 
NVP-ADW742 IGF-1R, INSR Generon HY-10252 
Olaparib PARP1/2 Generon HY-10162 
Palbociclib CDK4, -6 Generon HY-50767A 
Ribociclib CDK4, -6 Generon HY-15777 
RMC-4550 SHP2 Generon HY-116009 
Roscovitine CDK5, -2, cdc2 Generon HY-30237 
Sapanisertib mTOR1/2 Generon HY-13328 
Selumetinib MEK1/2 AstraZeneca n/a 
SHP099 SHP2 Generon HY-100388 
Talazoparib PARP1/2 Generon HY-16106 
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Table 2.4 Primary antibodies used for Immunofluorescence 
Antibody Species of origin 
Blocking 




(24E10) Rabbit 5% Marvel/TBST 1:1000 
Cell 
Signalling 3195 
N-cadherin Mouse 5% Marvel/TBST 1:1000 BD Bioscience 610921 
 
Table 2.5 Secondary antibodies used for Immunofluorescence 








serum/PBS 1:1000 Invitrogen A21202 
 
2.1.2 Cell culture 
All cell cultures were grown in RPMI 1640 Medium supplemented with 10% 
fetal bovine serum (FBS). Cells were cultured at 37°C in a humidified incubator 
at 95% O2 and 5% CO2 and were routinely passaged at 80% confluency. For 
passaging, existing growth medium was aspirated, and the cells washed in 
room temperature (1X) Phosphate buffered saline (PBS). Cells were then 
incubated in 1.5ml of pre-warmed 0.5% (1X) trypsin-EDTA at 37°C for 2-4 
minutes depending upon the cell line. Detached cells were then re-suspended 
in fresh pre-warmed growth medium and a 1:5 dilution transferred to a new 
T75 cell culture flask and cultured at 37°C in a humidified incubator.  
 
2.1.2.1 Mycoplasma testing 
All cell lines were tested for mycoplasma contamination. To prepare samples, 
5x104 cells were pelleted, washed twice in PBS and resuspended in 100µl of 
PBS. Samples were then heated for 10 minutes at 95°C, vortexed for 10 
seconds and centrifuged at 13,000rpm for 2 minutes. An aliquot was then 
transferred to a fresh tube and used as PCR template. Samples were 
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2.1.2.2 Cell line storage 
To preserve cells for long term storage, cells were trypsinised as above, 
resuspended in fresh RPMI 1640 medium and pelleted by centrifugation at 
120g for 5 minutes. Existing growth medium was aspirated, and the pellet was 
resuspended in freezing medium (RPMI-1640 with 15% (v/v) FBS and 5% (v/v) 
DMSO). 1ml of cell suspension was added to each cryovial (Corning) and 
stored in an insulating freezing container at -80°C overnight. Cryovials were 
then transferred to liquid nitrogen for long term storage. When required cells 
were thawed at 37°C in a water bath, resuspended in growth medium and 
centrifuged as above to remove traces of DMSO. The cell pellet was then 
resuspended in fresh growth medium and cells transferred to a new T25 cell 
culture flask (Corning).  
 
2.1.3 Inhibitor treatments 
Small molecule inhibitors were dissolved in dimethyl sulfoxide (DMSO) to yield 
30mM or 10mM stocks and stored at -80°C. Inhibitors were stable at -80°C for 
6 months or -20°C for 1 month. Antisense oligonucleotides were dissolved in 
phosphate-buffered saline (PBS) to yield 10mM stocks and stored at 4°C with 
stability under these conditions beyond 1 year. Drug stocks were diluted in 
growth medium to provide a dosing solution that was applied to cells to yield 
the final drug concentration. Drug dilutions were prepared to ensure each well 
contained a final vehicle concentration of 0.1%. Growth medium containing 
vehicle-only (DMSO or PBS) was used as a control. Cells were treated in 
triplicates or otherwise stated, and incubated at 37°C at 95% O2 and 5% CO2 
for the length of time indicated in experiments.  
 
2.1.4 IncuCyte Analysis  
For monitoring dose responses, cells were seeded in 96-well TC-treated 
plates (Corning, #3595) for 2D culture and 96-well cell repellent surface plates 
(Greiner Bio-One, #650979) for 3D culture. Cells were seeded at a density of 
1000 cells per well in 100µl of RPMI-1640 with 10% FBS medium. Spheroid 
plates were incubated overnight in the IncuCyte S3 (Essen Bioscience) and 
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2D plates were incubated in the IncuCyte Zoom (Essen Bioscience), both at 
37°C inside a humidified incubator at 95% O2 and 5% CO2. Cells were allowed 
to adhere or form spheroids overnight and the following day a 10-fold dilution 
series of indicated inhibitors were applied to give a final volume of 150µl per 
well. AZ6813 and Selumetinib were dosed using the HP D300e dispenser, 
whilst AZD4785 dilutions were dosed manually and cells were incubated in the 
IncuCyte for 7 days following treatment. Spheroid images were collected every 
6 hours and 2D images every 4 hours. Spheroids were analysed using the 
IncuCyte S3 2018A software (Essen Bioscience) using the spheroid module, 
whereas 2D cells were analysed using the IncuCyte Zoom 2016A software 
(Essen Bioscience).  
 
For monitoring inhibitor combination assays, H358-R cells were seeded in 
384-well TC-treated plates (Corning, #3712) at a density of 2000 cells per well 
in 40µl of 10% FBS RPMI-1640 medium. Plates were incubated overnight in 
the IncuCyte S3 (Essen Bioscience) at 37°C inside a humidified incubator at 
95% O2 and 5% CO2. The following day H358-R cells were treated with 
corresponding IC90 inhibitor concentrations, IncuCyte® Nuclight Rapid Red 
Reagent and IncuCyte® Cytotox Green Reagent. A 5-fold dilution series of 
combination inhibitors were applied, giving a final assay volume of 80µl. Cells 
were incubated in the IncuCyte for 4 days following treatment and images were 
collected every 6 hours. Cells were analysed using the IncuCyte S3 2020B 
software (Essen Bioscience).  
 
For triple combination assays, H358 cells were seeded in 96-well TC-treated 
plates (Corning, #3595) at a density of 1000 cells per well in 100µl of 10% FBS 
RPMI-1640 medium. Plates were incubated overnight in the IncuCyte S3 
(Essen Bioscience) at 37°C inside a humidified incubator at 95% O2 and 5% 
CO2. The following day H358 cells were dosed manually with inhibitor 
concentrations to give a final assay volume of 150µl. Cells were incubated in 
the IncuCyte for 14 days following treatment and were re-dosed with fresh 
media and inhibitors every 5 days. Images were collected every 6 hours. Cells 
were analysed using the IncuCyte S3 2020B software (Essen Bioscience).  
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2.1.5 Cell viability and cytotoxicity assays 
Cells were seeded in 96-well black walled TC-treated plates (Corning, #3603) 
for 2D culture and 96-well black walled ultra-low attachment plates (Corning, 
#4515) for 3D culture. Cells were seeded at a density of 1000 cells per well in 
60µl of 10% FBS RPMI-1640 medium. Cells were allowed to adhere or form 
spheroids overnight and the following day a 3-fold dilution series of indicated 
inhibitors were applied to give a final volume of 80µl per well. Cell cytotoxicity 
and cell viability were measured respectively using a multiplex of the 
CellTox™ Green assay and the CellTiter-Glo® 2.0 assay. A CellTox™Green 
(5X) reagent was prepared using a 1:200 dilution of CellTox™Green Dye to 
Assay Buffer. 20µl of CellTox™Green reagent was added to each well 
containing 80µl of medium. The plate was mixed on an orbital shaker at 
300rpm for 1 minute and incubated for 15 minutes at room temperature. The 
fluorescence was measured at 485-500nmEx/520-530nmEm using the 
GloMaxÒ Plate Reader (Promega) with the built-in CellTox™Green Promega 
protocol. 100µl of CellTiter-Glo® reagent was then added to each well. For 2D 
cell cultures the plate was mixed on an orbital shaker at 300rpm for 2 minutes 
and incubated at room temperature for 10 minutes, whereas for 3D culture 
mixing was extended to 5 minutes followed by a 25-minute incubation. The 
luminescence was recorded using the GloMaxÒ Plate Reader (Promega) with 
the built-in CellTitre-GloÒ Promega protocol.  
 
2.1.6 Generation of KRAS inhibitor resistant cell populations 
(H358-R) 
H358 cells were seeded into T75 flasks (1 x106 cells per flask) and the 
following day the media was replaced with media supplemented with the 
indicated concentration of inhibitor. Resistant cell populations were generated 
using two dosing schedules determined from target engagement assays; a 
dose escalation starting from the IC50 concentration which is doubled at each 
passage and a constant IC90 high concentration. Media changes were carried 
out every 2-3 days for small molecule inhibitors and every 4-5 days for 
AZD4785 until the cells reached 80% confluency. The cells were then 
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trypsinised and re-seeded at the original density and aliquots of remaining 
cells were prepared for liquid nitrogen storage. IC50 dose escalations were 
continued until the IC90 concentration was achieved and cells were then 
maintained at this concentration (2.63 µmol/L AZ6813, 830 nmol/L ARS1620, 
87 nmol/L Selumetinib, 2.34 µmol/L AZD4785). An additional flask where the 
dose was doubled to above the IC90 concentration was also established 
alongside. The development of emerging resistance was monitored by shifts 
in the cell viability dose responses treated with increasing drug concentrations 
(see cell viability and cytotoxicity assays).  
 
2.1.7 Immunofluorescence 
Cells were seeded onto sterile 22x22mm coverslips in a 6-well plate. Following 
treatment, the coverslips were washed twice in PBS and fixed using 4% 
paraformaldehyde (PFA) in PBS for 15 minutes at RT. The PFA was discarded 
and the cells washed twice again with PBS, followed by 50mM ammonium 
chloride for 10 minutes. The coverslips were again washed with PBS three 
times and then the cells were permeabilised with 0.2% (v/v) Triton X-100 in 
PBS for 5 minutes at RT. The coverslips were washed three times in PBS and 
then blocked in 10% (v/v) goat serum in PBS for 30 minutes. The primary 
antibodies were diluted in 10% (v/v) goat serum in PBS (see Table 2.4) and 
added to the cells for 1 hour at RT. Following three PBS washes, the cells 
were incubated with secondary antibodies diluted in 10% (v/v) goat serum in 
PBS for 20 minutes (see Table 2.5). The coverslips were washed with a final 
three PBS washes, followed once by MilliPore water, and then mounted onto 
slides using Mowiol containing DAPI (1:1000 ratio). The slides were left to dry 
overnight and then visualised on the Zeiss LSM 800 confocal microscope. 
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2.2 Transcriptomics  
2.2.1 Transcriptomics reagents  
The reagents used for transcriptomic experiments are listed in Tables 2.6 and 
2.7. 
Table 2.6: Reagents and kits used for transcriptomics 
Reagent Supplier Catalogue number 
SingleShot Cell Lysis Kit Bio-Rad 1725080 
iTaq Universal SYBR® 
Green One-Step Kit Bio-Rad 1725151 
RNeasy Mini Kit Qiagen 74106 
RNA 6000 Nano Kit Agilent 5067-1511 
TRIzol Thermo Fisher Scientific 15596026 
Phosphate buffered saline 
(PBS) ThermoFisher Scientific 14200067 
 
Table 2.7: qRT-PCR primer sequences 
Primer Sequence (5’ – 3’) 
KRAS forward GATGTACCTATGGTCCTAGTAG 
KRAS reverse CATCATCAACACCCTGTCTTG 
DUSP6 forward CGGAAATGGCGATCAGCAAG 
DUSP6 reverse TGTGCGACGACTCGTATAGC 
ACTIN forward CACCTTCTACAATGAGCTGCGTGTG 
ACTIN reverse ATAGCACAGCCTGGATAGCAACGTAC 
 
2.2.2 Quantitative Reverse Transcription PCR (qRT-PCR) 
Cells were seeded in 96 well TC-treated plates (Corning, #3595) at a density 
of 2000 cells per well in 60µl of 10% FBS RPMI-1640 medium. Cells were 
allowed to adhere overnight and the following day a 3-fold dilution series of 
indicated inhibitors were applied to give a final volume of 80µl per well. Cells 
treated with small molecule inhibitors were incubated for 24 hours and those 
treated with ASO were incubated for 72 hours. Cell lysates were prepared 
using the SingleShot Cell Lysis Kit. Existing culture medium was removed from 
each well and cells were washed in 125µl of room temperature PBS. 50µl of 
SingleShot Cell Lysis Buffer was added to each well and the plate was 
incubated at room temperature for 10 minutes. Cell lysates were transferred 
to a 96-well PCR plate, incubated at 37°C for 5 minutes followed by 75°C for 
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5 minutes and stored at -20°C until required. Cell lysates were used directly in 
a one-step RT-qPCR reaction using the iTaq Universal SYBR® Green One-
Step Kit according to the manufacturer’s instructions. Primers that were used 
are shown in Table 2.7. Reactions were carried out in triplicates with the 
following reaction mixture and reaction protocol shown in Table 2.8 and Table 
2.9. Reactions were run on the CFX Connect™ Real-Time PCR Detection 
System (Bio-Rad). Gene expression was normalised to ACTIN housekeeping 
gene Ct values and quantified using the comparative Ct (-∆∆Ct) method.  
 
Table 2.8: iTaq Universal SYBR® Green One-Step qRT-PCR reaction mixture 
Reagents Volume 
iTaq Universal SYBR® Green reaction mix (2X) 10µl 
iScript Reverse Transcriptase 0.25µl 
Forward Primer (20µM) 0.3µl 
Reverse Primer (20µM) 0.3µl 
Cell lysate (RNA Template) 2µl 
Water 7.15µl 
Total Volume 20µl 
 
Table 2.9: iTaq Universal SYBR® Green One-Step qRT-PCR protocol 
Step No. of cycles Temperature Time Duration 
Reverse Transcription 1 50°C 10 min 
Polymerase Activation 
and DNA Denaturation 1 95°C 1 min 
Denaturation 
X 39 
95°C 10 sec 
Annealing and 
Extension 
60°C 30 sec 
Melt 1 Tm gradient (60°C - 95°C) 0.5°C increment 





2.2.3.1 RNA extraction 
Cells were trypsinised and resuspended in PBS. 2x105 cells were pelleted and 
resuspended in 1ml TRIzol reagent. Cell lysates in TRIzol were stored at -
80°C until required. Cells were thawed at room temperature, 200µl of 
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chloroform added and centrifuged at 12,000g for 15 minutes. The upper 
aqueous phase was removed and transferred to a fresh Eppendorf tube. An 
equal volume of 70% ethanol was added, and samples were immediately 
loaded onto a RNeasy Mini Spin Column and RNA extraction performed 
according to the manufacturer’s instructions. RNA was eluted in 30µl of RNase 
free water. A Nanodrop 1000 spectrophotometer (Labtech) was used to 
assess RNA purity and concentration. RNA integrity was measured using the 
RNA 6000 Nano Kit according to the manufacturer’s instructions and samples 
run on the Agilent 2100 Bioanalyzer.  
 
2.2.3.2 RNA-Sequencing Quantification Library 
RNA-sequencing was performed and bioinformatically analysed by BGI Tech 
Solutions (Hong Kong) using the Illumina-HiSeq2500/4000 platform. 
Sequencing reads which contained low-quality, adaptor polluted and high 
unknown base (N) reads were first filtered out. Clean reads were mapped to 
the reference genome using HISAT [265]. After genome mapping StringTie 
[266] was used to reconstruct transcripts and with genome annotation novel 
transcripts were identified using Cuffcompare. Novel transcripts were then 
merged with reference transcripts to achieve a complete reference. Clean 
reads were mapped using Bowtie2 [267] and gene expression levels 
calculated with RSEM [268]. Based on gene expression levels, possion 
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2.3 Protein biochemistry 
 
2.3.1 Protein biochemistry reagents 
The reagents used for protein biochemistry are listed in Tables 2.10 - 2.12. 
 
Table 2.10: Reagents used for protein biochemistry  
Reagent Supplier Catalogue number 
BCA Protein Assay Pierce Biotechnology 23225 
Bovine IgG Sigma Aldrich I9640 
Protease inhibitor cocktail Sigma-Aldrich P8340 
PhosSTOP (protease 
inhibitor cocktail) Roche-Sigma 
4906837001 
 
Tris-Acetate SDS running 
buffer Invitrogen LA0041 
NuPAGE MOPS buffer Invitrogen NP0001-02 
NuPAGE MES buffer Invitrogen NP0002-02 
AmershamÔ full range 
molecular weight rainbow 
marker 




Sigma Aldrich GE10600002 
Ponceau-S Sigma Aldrich P7170 
 
Table 2.11: Primary antibodies used for Western Blotting 
Antibody Species of origin 
Blocking 
solution Dilution Supplier 
Catalogue 
number 















b-actin Mouse 5% Marvel/TBST 1:10000 Proteintech 66009-1-Ig 
DUSP6 Rabbit 5% Marvel/TBST 1:500 Abcam ab76310 









H-Ras Rabbit 5% Marvel/TBST 1:300 Santa Cruz sc-520 













N-Ras Mouse 5% Marvel/TBST 1:300 Santa Cruz sc-31 
Ras Rabbit 5% Marvel/TBST 1:1000 Abcam ab52939 







N-cadherin Mouse 5% Marvel/TBST 1:1000 
BD 
Bioscience 610921 
Vimentin Rabbit 5% Marvel/TBST 1:1000 
Cell 
Signalling 5741 











































Table 2.12: Secondary antibodies used for Western Blotting 
Antibody Blocking solution Dilution Supplier Catalogue number 
IRDye®800CW Donkey 
anti-Mouse IgG 5% Marvel/TBST 1:15000 LI-COR 926-32212 
IRDye®800CW Donkey 
anti-Rabbit IgG 5% Marvel/TBST 1:15000 LI-COR 926-32213 
IRDye®680CW Donkey 
anti-Rabbit IgG 5% Marvel/TBST 1:15000 LI-COR 926-68023 
 
2.3.2 Cell lysis  
Cell lysis was performed on ice. The cell culture medium was removed, and 
the cells were washed twice with ice-cold PBS. Cells were lysed with RIPA 
buffer (10mM Tris pH7.5, 150mM NaCl, 1% sodium deoxycholate, 0.1% SDS, 
1% Triton X-100) supplemented with protease inhibitor cocktail (1:250 ratio) 
(Sigma-Aldrich) and PhosSTOP phosphatase inhibitors (1:100 ratio) (Roche) 
for 10 minutes. Cells were scraped and the lysate collected. Lysates were then 
clarified by centrifugation at 13,000g for 20 minutes at 4°C to pellet insoluble 
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2.3.3 Protein quantification and sample preparation  
Protein concentration of cell lysates was measured using the Pierce™ BCA 
assay (Thermo Scientific) according to manufacturer’s instructions. A standard 
curve using bovine IgG (Sigma-Aldrich) was carried out alongside triplicate 
repeats of sample lysates in a 96 well plate. The BCA reagents A and B were 
mixed (1:50 ratio) and added to the wells. After 30 minutes incubation at 37°C, 
the plate was read at OD562 using a Thermo Labsystems Multiskan spectrum 
plate reader. Samples were prepared for western blotting in 5X sample buffer 
(15% SDS, 321.5mM Tris-HCL pH6.8, 50% Gylcerol, 16% 2-Mercaptoethanol, 
1.25% Bromophenol blue) and diluted in RIPA lysis buffer to the desired 
concentration. Samples were heated at 95°C for 5 minutes and stored at -
20°C.  
 
2.3.4 Western Blotting  
2.3.4.1 SDS-PAGE  
Equal concentrations of protein samples were resolved by SDS-PAGE. 
Samples were loaded into pre-cast NuPAGE® 4-12% Bis-Tris gels (Invitrogen) 
using a XCell Sure Lock gel tank (Thermo Fisher Scientific). Gels were 
typically ran with 1X MOPs SDS running buffer (Invitrogen), although 1X MES 
SDS running buffer (Invitrogen) was used to separate low molecular weight 
proteins. The AmershamÔ full range molecular weight rainbow marker 
(Sigma-Aldrich) was ran alongside samples to measure molecular weight. The 
protein gels were initially ran at 100V until the samples had passed into the 
gel, then raised to 180V for approximately 1 hour.  
 
2.3.4.2 Protein transfer and immunostaining  
Proteins were transferred onto an AmershamÔ ProtranÒ 0.45µM pore size 
nitrocellulose membrane (Sigma) using a Genie blotter system (Idea 
Scientific). The transfer tanks were filled with transfer buffer (25mM Tris, 
192mM glycine, 20% (v/v) methanol) and ran at 0.9A and 24V for 1 hour at 
RT. The quality of protein transfer was assessed by staining the nitrocellulose 
membrane with Ponceau-S (Sigma-Aldrich), and then washed multiple times 
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in PBS to remove the stain. Membranes were then blocked in 5% (w/v) 
powered milk in Tris-buffered saline with Tween (TBS-T)(10mM Tris pH 7.4, 
150mM NaCl, 0.1% (v/v) Tween 20) for 1 hour and then probed with primary 
antibodies diluted in 5% milk TBS-T at 4°C overnight (see Table 2.11 for 
dilutions). Membranes were washed three times for 5 minutes with TBS-T to 
remove unbound antibody and then probed with IRDye® secondary antibodies 
in 5% milk TBS-T for at least an hour (Table 2.12). Following two 5-minute 
TBS-T washes and a final TBS (10mM Tris pH 7.4, 150mM NaCl) wash, the 
membranes were scanned on the LICOR Odyssey® CLx imaging system. 
Images were analysed using ImageStudio software.  
 
2.3.5 Ras activity assay 
Cells were seeded in 15cm dishes and allowed to adhere overnight. The 
following day cells were treated with inhibitors for the indicated amount of time. 
The Ras Activation Assay BioChem Kit (Cytoskeleton Inc, #BK008) was used 
to pull-down active GTP-bound RAS. As according to the manufacturer’s 
instructions, cells ready to harvest were washed with ice-cold PBS, then lysed 
on ice with cells lysis buffer supplemented with protease inhibitor cocktail. 
Samples were clarified by centrifugation at 10,000rpm and lysates snap frozen 
and stored in liquid nitrogen until required. 20µl of lysate was saved for BCA 
protein quantification. Subsequently samples were equalised to give identical 
protein concentrations at 1mg/ml. For the pull-down assay, 200µg of cell lysate 
was added to 30µl of beads and incubated with rotation at 4°C for 1 hour. The 
beads were pelleted at 5000g at 4°C for 1 minute. The supernatant was 
removed, and the beads washed with wash buffer. Following centrifugation at 
5000g at 4°C for 3 minutes, the supernatant was once again removed, and the 
beads resuspended in 20µl 2X Laemmli sample buffer and heated at 95°C for 
2 minutes. Samples were then analysed by SDS-PAGE and Western Blot 





Materials and Methods   46 
2.4 Proteomics  
2.4.1 Reverse Phase Protein Array (RPPA) 
Cells were trypsinised, centrifuged and the cell pellets washed twice with PBS. 
Remaining PBS was removed, and the dry cell pellets stored at -80°C until 
samples were submitted to the Functional Proteomics RPPA Core Facility at 
the MD Anderson Cancer Center in The University of Texas. Here samples 
were serially diluted two-fold for 5 dilutions and arrayed on nitrocellulose-
coated slides to produce sample spots. Sample spots were then probed with 
466 antibodies by a tyramide-based signal amplification approach and 
visualised by DAB colorimetric reaction to produce stained slides which were 
scanned on a Huron TissueScope scanner to generate 16-bit images. Sample 
spots were identified from the images and the densities quantified by Array-
Pro Analyzer 6.3. Relative protein levels for each sample were determined by 
interpolating each dilution curve produced from the densities of the 5-dilution 
sample spots using SuperCurve_1.5.0 R script. The relative protein levels 
were designated as log2 values which were then normalised for protein loading 



































Since the discovery that RAS genes are frequently mutated in a large variety 
of tumours, the RAS GTPase family have been considered attractive targets 
for cancer therapeutics and significant efforts have been committed to the 
development of targeted inhibitors [127, 269]. However direct inhibition of RAS 
has presented a major challenge, primarily due to a small inaccessible GTP 
binding pocket which exhibits intrinsically high affinity for GTP, making it 
difficult to design effective competitive inhibitors. Secondly the smooth protein 
surface has a lack of known allosteric regulatory sites and pockets that can be 
targeted [270]. Nevertheless, recent progress has been made in the 
development of covalent inhibitors that selectively bind to the KRAS-G12C 
mutant [204]. These compounds directly bind to the chemically reactive thiol 
group of Cys-12 and project into an adjacent allosteric pocket beneath the 
effector binding switch-II region. This switch-II pocket (S-IIP) is only accessible 
in the GDP-bound form of KRAS-G12C. Such compounds were found to impair 
RAS activity by blocking SOS-mediated nucleotide exchange and altering the 
relative affinity of KRAS to favour GDP binding, subsequently leading to the 
accumulation of RAS in its inactive GDP-bound state. This mechanism of 
action consequently blocks effector and regulatory protein interactions helping 
to reduce downstream KRAS signalling. Following the initial discovery by 
Shokat and colleagues, KRAS-G12C targeting compounds were further 
developed by several groups to improve cellular activity and potency within a 
drug candidate range [207, 271]. From these successes, pharmaceutical 
companies Mirati Therapeutics and Amgen have developed their own similar 
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KRAS-G12C compounds, MRTX849 and AMG 510, which are the first 
compounds to have entered phase I/II clinical trials for the treatment of KRAS-
G12C mutant tumours [208, 209].  
 
Although these compounds show promise, they only have the potential to treat 
a small subset of KRAS mutant tumours. Nucleic acid-based approaches 
which are designed according to the target protein gene sequence have the 
ability of targeting a wider array of RAS oncogenes and present an alternative 
strategy to small molecule inhibitors [272]. Antisense oligonucleotides (ASOs) 
are short single-stranded oligodeoxynucleotides that bind to and degrade 
target mRNA, leading to a reduction in target gene translation and reduced 
protein expression. Advances in ASO pharmacology and chemistry have 
yielded new generations of ASO compounds with improved stability and 
potency, resulting in the progress of ASO-based strategies into therapeutics 
[214]. For example AZD4785 (Ionis 651987) is an advanced chemistry ASO 
targeting the KRAS mRNA 3’ untranslated region (UTR) and therefore reduces 
both wild-type and mutant KRAS expression [215]. In preclinical models, 
AZD4785 demonstrated productive uptake without the need for delivery 
agents, although anti-tumour responses varied between cell lines as a result 
of differences in KRAS dependency [215].  
 
Other attempts to target oncogenic RAS include disrupting its cellular 
localisation given that RAS oncogenic activity is dependent upon its 
association at the plasma membrane. Farnesyl-transferase inhibitors (FTIs) 
were the first to be developed, inhibiting the post-translational addition of a 
farnesyl group onto the C-terminus of RAS required for its membrane 
association [273]. However, in phase III trials FTIs failed to elicit a clinical 
benefit for cancers with high frequency KRAS mutations, which was found to 
be due to alternative prenylation of KRAS4B and NRAS by geranylgeranyl 
transferase I (GGTase I) retaining membrane association under FTI treatment 
[38]. In recent years interest in targeting RAS membrane association has 
increased again following the identification of fendiline, an L-type calcium 
channel blocker which acts by non-specifically inhibiting acid 
sphingomyelinase and therefore reducing phosphatidylserine in the plasma 
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membrane [156, 274]. Another approach to disrupting RAS membrane 
association has been blocking the prenyl-binding protein phosphodiesterase 
6d (PDE6d), which regulates RAS trafficking from recycling endosomes or the 
Golgi to the plasma membrane [155]. Deltarasin, a small molecule inhibitor 
which binds to the farnesyl-binding pocket of PDE6d, results in impaired RAS 
trafficking to the plasma membrane which was shown to disrupt its cellular 
activity and reduce KRAS mutant tumour growth [275].  
 
Currently the majority of anti-RAS strategies have focused on inhibiting RAS 
effector pathways as a mechanism of blocking RAS activity, which has led to 
the development of many selective and potent inhibitors of different RAS 
effector signalling cascades. At least 11 different classes of RAS effectors 
have been identified, although the nodes within the RAF-MEK-ERK mitogen 
activated protein kinase (MAPK) pathway and the PI3K-AKT-mTOR pathway 
have seen the greatest attention [139, 276].  However due to multiple points 
of crosstalk and negative feedback loops, single agent inhibition has not been 
successful clinically and thus combinatorial inhibition has been the primary 
treatment strategy to delay or overcome potential resistance mechanisms 
[166].  
 
Despite decades of research, effective anti-RAS therapeutics have yet to 
successfully reach the clinic but renewed advances in RAS function, new 
therapeutic strategies and drug design give hope for RAS-directed therapies 
to be attainable in the not so distant future [269]. However as is the case with 
most targeted therapeutics, adaptive and acquired resistance is likely to 
emerge with new classes of direct RAS inhibitors, although this has not yet 
been formally tested. Decreased drug responsiveness and recurrence of 
cancer can be caused by pre-existing intrinsic resistance which is present 
before the administration of treatment or from acquired resistance generated 
following therapy [217, 218]. RAS effector signalling is highly complex and 
dynamic, and as is the case with many other RAS pathway inhibitors, 
compensatory rewiring of signalling and secondary genetic alterations often 
occur in response to pharmacological inhibition [139]. For example, the 
reactivation of downstream ERK1/2 signalling is common following both RAFi 
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and MEKi [75]. In colorectal cancer cells (CRC), acquired resistance to the 
MEK1/2 inhibitor selumetinib (AZD6244) was shown to develop by 
intrachromosomal amplification of the driving KRAS-G13D oncogene enabling 
cells to maintain ERK1/2 activity in the presence of inhibitor  [244]. 
Furthermore, in both KRAS-mutant lung and colon cancer cells, intrinsic 
resistance to selumetinib was associated with strong PI3K-AKT pathway 
activation via increased expression and activation of the receptor tyrosine 
kinase (RTK) ERBB3 [277, 278]. The signalling networks involved in mutant 
RAS-driven cancers can also be activated by RAS-independent mechanisms 
such as activation of YAP1 via inactivation of the Hippo signalling pathway, 
providing an alternative route to cell proliferation and survival [279]. Such 
preclinical studies have established a strong rationale for multiple pathway 
inhibition and combinations of MEK and PI3K inhibitors show increased 
efficacy compared to monotherapy in KRAS-driven tumours [193].  
 
In order to investigate the potential drug resistance mechanisms induced in 
response to KRAS therapeutics, a selection of direct KRAS inhibitors was 
validated. Included was AZ6813 (WO2015054572), the only KRAS-G12C 
inhibitor available at the time of starting, as well as the KRAS antisense 
oligonucleotide AZD4785 [215], fendiline [156] and deltarasin [275]. By using 
a variety of KRAS inhibitors, it is also possible to gain insight and compare 
differences in resistance mechanisms between different approaches of KRAS 
inhibition. In addition, the MEK1/2 inhibitor selumetinib (AZ6244) was included 
as part of this comparison in order to represent a clinically approved 
comparator with known resistance in KRAS mutant cells. This enables the 
identification of any overlap in KRAS inhibition with resistance associated with 
downstream MEK inhibition.  
 
In order to understand the molecular mechanisms underlying nascent 
resistance, there is a need for relevant cancer models and experimental 
approaches to analyse and recapitulate drug sensitivities, and for in vitro and 
in vivo systems to predict clinically relevant resistance mechanisms [280]. 
Experimental approaches include target-based mutagenesis in cell lines, in 
vivo studies using xenografts or genetically engineered mice, as well as the 
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gold standard characterisation of patient tumour samples. Primarily one of the 
most common methods to study drug resistance involves the culturing of drug-
sensitive cancer cell lines with the selected inhibitor for an extended period of 
time until resistant subpopulations that survive and proliferate in the presence 
of high drug concentrations emerge [281]. Comparison to parental cells 
enables the genetic and biochemical differences that account for resistance to 
be identified. Large numbers of cancer cell lines are available and ease of 
culture and suitability for high-throughput genomic and proteomic analysis 
makes them favourable models [280]. In order to study RAS therapeutics, 
additional considerations regarding the cell type and genetic context of cancer 
cell lines is important, due to the heterogeneity observed between RAS-mutant 
cancers. Within different cancer types there are striking differences in both the 
frequency of RAS mutations and the distribution of specific mutations [21].  
 
Aims 
In this study a panel of KRAS-G12C mutant and KRAS-WT non-small cell lung 
cancer (NSCLC) cell lines was used to determine the initial sensitivity to, and 
development of resistance against, our panel of KRAS targeted inhibitors. 
Lung cancer cell lines were chosen as a suitable model due to the fact that 
KRAS-G12C mutations account for 65% of KRAS-mutant lung 
adenocarcinomas [131]. The high frequency of KRAS-G12C mutations in lung 
cancer is linked to mutagen exposure from tobacco causing DNA adduct 
formation and a G-to-T transversion at this mutational hotspot [74]. To 
generate resistant cell lines two inhibitory doses, an IC50 escalating dose and 
a constant IC90 dose, will be used in parallel to compare the development of 
resistance. Following treatment, the surviving resistant cells can be compared 
to parental cells using cell viability assays to analyse changes in drug 
sensitivity [282].  
 
Using these approaches, I aimed to: 
• Validate the efficacy of a panel of direct RAS inhibitors in NSCLC cells 
• Compare drug sensitivities between 2D and 3D cell culture 
• Generate drug-resistant cell lines 
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3.2 Results 
 
3.2.1 Down-regulation of DUSP6 and KRAS mRNA by 
KRAS inhibitors 
 
Target validation is a crucial step in drug discovery and ensures that the 
interaction of inhibitors with their target biomolecules is specific and has 
potential therapeutic benefit. As a first step it was important to establish that 
the assembled panel of RAS targeted drugs directly engaged with their targets 
in NSCLC cells as predicted. The measure of substrates or biomarkers that 
are directly linked to the levels of target can be used as a measure of the level 
of target inhibition. KRAS mRNA expression was measured for the ASO 
inhibitor AZD4785 and DUSP6 mRNA expression was measured as a readout 
for changes in RAS-MAPK pathway activation that would indicate RAS or MEK 
inhibition. H358 cells (KRAS-G12C) were treated with small molecule inhibitors 
(AZ6813, deltarasin, fendiline and selumetinib) for 24 hours and with the ASO 
AZD4785 and a control ASO (CTRL ASO) for 72 hours to ensure maximal 
knock-down of KRAS mRNA and KRAS protein depletion. mRNA expression 
was analysed by quantitative reverse transcription polymerase chain reaction 
(qRT-PCR).  
 
A dose dependent decrease in both KRAS and DUSP6 mRNA expression was 
observed in cells treated with AZD4785 (Figure 3.1A).  This effect was not 
observed in cells treated with CTRL ASO, which does not bind to any target 
mRNA, highlighting the dose response is a specific effect of AZD4785 rather 
than general toxicity of adding increased concentrations of any ASO. The loss 
of KRAS mRNA expression also corresponded with reduced DUSP6 mRNA 
expression as expected and confirmed DUSP6 as a suitable choice of 
biomarker for measuring changes in RAS pathway activation in these cells.  
 
The KRAS-G12C inhibitor AZ6813 also showed a dose dependent decrease 
in DUSP6 mRNA expression with increasing inhibitor concentration indicating 
good pathway inhibition and evidence of target engagement (Figure 3.1B). The 
MEK1/2 inhibitor selumetinib shows a similar albeit more potent dose  
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Figure 3.1: Down-regulation of DUSP6 and KRAS mRNA by small molecule inhibitors 
and ASOs targeting KRAS. 
H358 cells were seeded at 2000 cells/well and treated with a dose response of (A) ASOs 
(AZD4785 and CRTL ASO) for 72hrs and (B) small molecule inhibitors (AZ6813, selumetinib, 
Deltarasin and Fendiline) for 24hrs. Relative DUSP6 and KRAS mRNA expression was 
measured by one-step quantitative reverse transcription PCR (RT-qPCR). Expression is 
relative to vehicle-only controls and normalised to ACTIN mRNA expression. Data shown is 




Fig 3.1: Down-regulation of DUSP6 and KRAS mRNA by small molecule
inhibitors and ASOs targeting KRAS
H358 cells were seeded at 2000 cells/well and treated with a dose response of (A)
small molecule inhibitors (AZ6813, Selumetinib, Deltarasin and Fendiline) for 24hrs
and (B) ASOs (AZD4785 and CRTL ASO) for 72hrs. Relativ DUSP6 and KR
mRNA expression was measured by one-step quantitative reverse transcription
PCR (RT-qPCR). Expression is relative to vehicle-only controls and normalised to
ACTIN mRNA expr ssion. Data shown is presented as means from triplicates of two
independent experiments.
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• Shows a dose dependent decrease in both KRAS and DUSp6 mRNA expression with AZD4785.
• Not observed with CTRL ASO which highlights specific effect of AZD4785 and not just from
increasing any ASO
• Highlights loss of KRAS corresponds with loss of DUSP6
• AZ6813 (G12Ci) and Selumetinib show dose dependent decrease in DUSP6 mRNA
• Change not observed with deltarasin and fendiline. Higher 10uM shows off target effect.
• From this focused on certain inhibitors and calculated IC90 concentrations
• Next check how inhibitors affect cell growth
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dependent decrease in DUSP6 mRNA expression. The fact that both 
AZD4785 and AZ6813 RAS inhibitors follow a similar trend to MEKi provides 
further confidence of upstream RAS target engagement and moving forward 
both the IC50 and IC90 concentrations calculated from this assay will be used 
to establish drug resistant cell lines.  No change in DUSP6 mRNA expression 
was observed with increasing concentrations of deltarasin and fendiline and 
higher doses >10µM show an off-target effect represented by a dramatic 
increase of DUSP6 mRNA expression. As a result, fendiline and deltarasin 
were not included in any further experiments due to the lack of evidence for 
target engagement.  
 
3.2.2  AZ6813, AZD4785 and selumetinib inhibit cell growth  
 
Having observed good target engagement with three inhibitors (AZ6813, 
AZD4785 and selumetinib), dose responses in a panel of 7 NSCLC cell lines 
(see Table 2.2) were carried out in order to determine how effective these 
inhibitors are at preventing cell growth. Cells were cultured as both 2D and 3D 
spheroid cultures in order to compare the effect of the inhibitors between 
growth conditions and to observe any phenotypic issues that would hinder their 
suitability for making resistant cells. Changes in confluency and spheroid area 
were monitored using IncuCyte technology over 7 days following inhibitor 
treatment. A lower concentration range (1µM-0.01µM) was used for 
selumetinib due to the increased potency of this inhibitor previously observed.  
 
From the 2D assay the majority of cell lines demonstrated a dose dependent 
inhibitory effect to the three inhibitors, with the exception of SW1573 which 
appeared particularly insensitive to KRAS-G12C inhibition (Figure 3.2). 
SW1573 cells also express PIK3CA-K111E; a gain of function mutation which 
may enable them to be KRAS-mutant independent [283]. However, a higher 
concentration of 10µM AZ6813 was shown to have a toxic effect on growth of 
all cell lines, including KRAS-WT cells. Cell confluency and morphology was 
also observed by microscopy (Figure 3.3). This further highlighted that all cell 
lines showed fewer cells and reduced confluency with inhibitor treatment 
compared to vehicle controls, particularly with selumetinib. H2122 cells grew 
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more slowly compared to the other KRAS-G12C cell lines and were also semi-
adherent, making them less desirable to take forward for drug resistance 
studies.  
 
Cells were then tested for their ability to form 3D spheroids in vitro using 96-
well round bottom low attachment plates to facilitate cell-cell contact. When 
grown as spheroids distinct morphologies were also observed between cell 
lines (Figure 3.4). H358, H1792 and SW1573 cells formed tightly packed round 
spheroids, whereas H2122 and H2030 were loosely packed and did not form 
3D structures, and KRAS-WT cell lines H1437 and H1793 formed spheroids 
with an irregular shape. Following treatment for 7 days, there were clear 
differences between vehicle controls (DMSO and PBS) and inhibitor treated 
cells (Figure 3.5). Firstly, the majority of cells showed a decrease in spheroid 
size following treatment with 1µM AZ6813 or selumetinib. In line with 2D cell 
culture, spheroids also appeared most sensitive to selumetinib with the 
exception of SW1573 cells, which showed reduced sensitivity to selumetinib 
and an increase in spheroid size.  A similar effect is seen with AZD4785 
treatment in KRAS-G12C cells in relation to the PBS control, however both 
KRAS-WT cell lines showed no inhibitory effect and SW1573 cells again 
showed little change. Furthermore there are often variations in drug responses 
between 2D and 3D spheroid cultures from differences in drug penetration and 
exposure, differences in morphology and altered gene  and surface receptor 
expression [284]. This is highlighted by comparison of NSCLC KRAS-G12C 
cell lines which demonstrate differential sensitivities to RAS pathway inhibition 
when grown as 3D spheroids and 2D cell culture (Figure 3.6). Overall following 
the generation of spheroids with different KRAS-G12C cell lines, H358 cells 
were chosen as the most suitable for subsequent experiments due to their 
ability to form reproducible spheroids. Other cell lines, particularly H2122 and 
H2030 demonstrated a lack of cell-cell attachment rendering them unsuitable 
for spheroid drug resistance experiments. 
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Figure 3.2: Cell confluency after 7 days treatment with small molecule inhibitors or 
AZD4785. 
The growth of 2D cell cultures was measured using IncuCyte technology which monitored cell 
confluency (%) at 4-hour intervals over a period of 7 days. Cells were treated with 
concentrations of (A) AZ6813, (B) selumetinib and (C) AZD4785. Graphs are presented as 
mean percentages of vehicle controls (DMSO or PBS) SEM from duplicates of two 











































































































































































A CBAZ6813 Selumetinib AZD4785
Figure 3.2: Growth curves for 2D lung cancer cell lines following treatment with
small molecule inhibitors and ASO.
The growth of 2D cell cultures was measured using IncuCyte technology which
monitored cell confluency (%) at 4-hour intervals over a period of 7 days. Cells were
treated with concentrations of (A) AZ6813, (B) Selumetinib and (C) AZD4785. Graphs
ar p esented as mean percent ges of vehicle controls (DMSO or PBS) from duplicat s
of two independent experiments.
• Most cell lines observed a dose dependent inhibitory effect on cell proliferation, exception of
SW1573
• Higher concentration of 10uM showed toxic effect on all cell types including WT
• AZ6813 G12C inhibitor showed dose dependent inhibitory effect on KRAS WT cells, therefore
highlights off target toxicity effects
• Will validate a new G12C inhibitor ARS1620 which shows increased potency
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Figure 3.3: KRAS small molecule inhibitors and AZD4785 (ASO) reduce 2D cell 
confluency and alter cell morphology. 
Cells were seeded in 96-well cell plates at 1000 cells/well and treated with a dose response 
of small molecule inhibitors and AZD4785. Images were taken on the IncuCyte Zoom following 
7 days of treatment. A representative figure of two repeats is shown here from cells treated 







Fig 3.3: Effect of KRAS small molecule inhibitors and ASOs on 2D cell confluency
and morphology
Cells were seeded in 96-well cell repellent surface plates at 1000 cells/well and treated with
a dose response of small molecule inhibitors and ASO. Images were taken on the IncuCyte
Zoom following 7 days of treatment. A representative figure of two repeats is shown here
from cells treated with 1uM AZ6813, 1uM Selumetinib, 10uM ASO and 0.1% DMSO/PBS
controls.
• Decreased cell number with inhibitory treatment
• SW1573 less sensitive
• Cells more sensitive to Selumetinib
• Is the reduction in cell number due to decreased proliferation or increased cell death

























Figure 3.4: Differences in spheroid morphology between lung cancer cell lines. 
Images represent 1000 cells seeded in 96-well cell repellent surface plates and incubated on 









Fig 3.4: Differences in spheroid morphology in a
panel of lung cancer cell lines
Images represent 1000 cells seeded in 96-well cell
repellent surface plates and incubated on the
IncuCyte S3 for 24hrs. A representativ figur from




• Cells form distinct morphologies, G12C mutant are tightly packed or
grape like
• KRAS WT form more irregular shape spheroids
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Figure 3.5: Effect of KRAS small molecule inhibitors and AZD4785 (ASO) on spheroid 
morphology. 
 Cells were seeded in 96-well cell repellent surface plates at 1000 cells/well and treated   with a 
dose response of small molecule inhibitors and AZD4785 (ASO). Images were taken on the 
IncuCyte S3 following 7 days of treatment. A representative figure of three repeats is  shown 










Fig 3.5: Effect of KRAS small molecule inhibitors and ASOs on spheroid morphology
Cells were seeded in 96-well cell repellent surface plates at 1000 cells/well and treated with
a dose response of small molecule inhibitors and ASO. Images were taken on the IncuCyte
S3 following 7 days of treatment. A representative figure of three repeats is shown here from
cells treated with 1uM AZ6813, 1uM Selumetinib, 10uM ASO and 0.1% DMSO/PBS
controls.
• Differences in spheroid diameter and debris following inhibitor treatment
• Spheroids appear more sensitive to selumetinib with exception of SW1573 which increased in size
• ASO showed no inhibitory effect in KRAS WT cells and SW1573
Selumetinib
(MEKi)





Figure 3.6: Comparison of 2D and 3D spheroid cell growth  
NSCLC cell lines grown as 2D adherent monolayers or ultra-low adherent 3D spheroids 
following 7 days of drug treatment with 1uM AZ6813, 1uM selumetinib, 10uM AZD4785. 
Graphs are presented as mean percentages of vehicle controls (DMSO or PBS) SEM from 




3.2.3 AZ6813, AZD4785 and selumetinib induce cell death 
 
In order to determine whether inhibitors are specifically inducing cell death 
rather than causing general toxicity to cells, a multiplex of cell viability and 
cytotoxicity assays were performed on both 2D and 3D cultured H358 cells. 
The CellTiter-Glo assay (Promega) measures the amount of ATP present as 
an indicator of metabolically active cells correlating to the number of viable 
cells. Alternatively, the CellTox Green assay (Promega) binds to DNA of cells 
with impaired membrane integrity and thus measures cytotoxicity.  
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In 2D culture both AZ6813 and selumetinib show a similar dose-dependent 
decrease in cell viability coupled with no change in cytotoxicity at 
concentrations <10µM, indicating cell growth inhibition (Figure 3.7A). Only at 
concentrations ≥10µM did the inhibitors, particularly AZ6813, have a cytotoxic 
effect. AZD4785 also shows a gradual decline in cell viability at concentrations 
between 300nM and 10µM, however the CellTox Green assay proved 
incompatible for multiplexing with ASOs due to the assay directly binding to 
the oligonucleotide. In comparison, H358 spheroids showed greater sensitivity 
to both AZ6813 and selumetinib observed by the decrease in cell viability IC50 
concentrations and increased cytotoxic effect at concentrations >1µM (Figure 
3.7B). A shift towards increased sensitivity was also observed with AZD4785 
but not with CRTL ASO, highlighting the specificity of this inhibitor. 
 
Cell viability and cytotoxicity assays were then performed on additional lung 
cancer cell lines grown as spheroids, which are understood to demonstrate 
greater KRAS dependency when grown under these conditions (Table 2.2). In 
the KRAS-G12C mutated cell lines H1792 and H2122 all three inhibitors 
demonstrated good potency from a dose-dependent decrease in cell viability 
(Figure 3.8). This was also coupled with no change in cytotoxicity for small 
molecule inhibitors at concentrations <3µM. As seen previously with H358 
cells, these other cell lines also showed greater sensitivity to selumetinib. 
H2030 cells also showed a decrease in viability with increasing inhibitor dose 
although demonstrated similar sensitivity to both AZ6813 and selumetinib. 
These cells also appeared less sensitive to AZD4785 in comparison. 
Corresponding with the previous spheroid Incucyte analysis in section 3.2.2, 
SW1573 cells also showed increasing viability with selumetinib concentrations 
£3µM, and similarly with AZ6813 and AZD4785 little or no change in viability 
was observed, highlighting that this cell line is particularly insensitive to these 
inhibitors. In comparison the control KRAS-WT cell line H1793 showed no 
change in cell viability and cytotoxicity, indicating the specific action of AZ6813 
and selumetinib to induce cell death in mutated KRAS cell lines.  
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Figure 3.7: Spheroid H358 cells demonstrate greater sensitivity to KRAS inhibitors than 
2D cultures. 
H358 cells were seeded as (A) 2D cell cultures and (B) 3D spheroid cell cultures at 1000 
cells/well and treated in triplicates with a dilution series of AZ6813, Selumetinib, AZD4785 and 
ASO CTRL. Cell viability and cytotoxicity were measured following 7 days of treatment. 










Fig 3.6: H358 2D versus 3D cell viability and cytotoxicity responses
H358 cells were seeded as (A) 2D cell cultures and (B) 3D spheroid cell cultures at 1000
cells/well and treated in triplicates with a dilution series of AZ6813, Selumetinib, AZD4785
and ASO CTRL. Cell viability and cytotoxicity were measured following 7 days of treatment.
Graphs are presented as mean percentages of vehicle controls ±SEM from two-three
independent experiments.






















































• 2D H358 cells show similar dose-dependent decrease in cell viability, no change in
cytotoxicty less than 10uM, indicates cell growth inhibition
• ASO gradual decline, CTRL no change
• Greater sensitivity as spheroids, decrease in IC50 concentrations
• Compare cell viability of other cell lines as spheroid cultures




Figure 3.8: 3D spheroid dose responses of KRAS small molecule inhibitors or AZD4785 
(ASO) in additional cell lines. 
Cells were seeded as 3D cell cultures at 1000 cells/well and treated with concentrations of 
small molecule inhibitors and AZD4785. (A) Cell viability and (B) cytotoxicity of cells treated 
with AZ6813 and Selumetinib. (C) Cell viability of cells treated with AZD4785. Measurements 
were recorded following 7 days of treatment. Graphs are presented as mean percentages of 
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Fig 3.7: 3D spheroid dose responses of KRAS small molecule inhibitors and ASO in
additional cell lines.
Cells were seeded as 3D cell cultures at 1000 cells/well and treated with concentrations of
small molecule inhibitors and ASO. (A) Cell viability and (B) cytotoxicity of cells treated with
AZ6813 and Selumetinib. (C) Cell viability of cells treated with AZD4785. Measurements were
recorded following 7 days of treatment. Graphs are presented as mean percentages of vehicle
controls ±SEM from triplicates of two independent experiments.
• Demonstrate greater KRAS dependency as spheroids
• All inhibitors show good potency in KRAS G12C cell lines H1792 and H2122, greatest
sensitivity to selumetinib
• H2030 show similar sensitivity to both selumetinib and AZ6813, also less sensitive to ASO
• As with spheroid Incucyte analysis SW1573 showed increasing viability with selumetinib, little
or no change with AZ6813 and ASO, cell line insensitive.
• KRAS WT H1793 showed no change in cell viability
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3.2.4  ARS-1620 is a more potent KRAS-G12C inhibitor 
 
Since the KRAS-G12C inhibitor AZ6813 demonstrated evidence of off-target 
toxicity from both the dose response in KRAS-WT cells lines (Figure 3.2) and 
increased cytotoxicity at concentrations ≥10µM across all cell lines (section 
3.2.3), an additional KRAS-G12C inhibitor was validated. ARS1620 is a 
second-generation S-IIP binding KRAS-G12C small molecule inhibitor which 
has improved potency and pharmacological properties [271]. The addition of 
a fluorophenol hydrophobic binding moiety revealed an additional interaction 
to His-95 and a more favourable covalent interaction compared to prior 
compounds [271].   
 
Firstly, ARS1620 showed a more potent down-regulation of DUSP6 mRNA 
expression in H358 cells (Figure 3.9) with a reduced IC50 concentration 
compared to the dose response observed previously with AZ6813 (Figure 










Figure 3.9: Down-regulation of DUSP6 by ARS-1620. 
H358 cells were seeded at 2000 cells/well and treated with a dose response of ARS-1620 for 
24hrs. Relative DUSP6 mRNA expression was measured by one-step quantitative reverse 
transcription PCR (RT-qPCR). Expression is relative to vehicle-only controls and normalised 
to ACTIN mRNA expression. Data shown are presented as means from triplicate repeats of 































Fig ?: Down-regulation of DUSP6 by ARS-1620
H358 cells were seeded at 2000 cells/well and treated with a dose response of ARS-1620
for 24hrs. Relative DUSP6 mRNA expression was measured by one-step quantitative
reverse transcription PCR (RT-qPCR). Expression is relative to vehicle-only controls and
normalised to ACTIN mRNAexpression. Data shown is presented as means from triplicate
repeats of two independent experiments.
Fig?: H358 2D versus 3D cell viability and cytotoxicity responses
H358 cells were seeded as (A) 2D cell cultures and (B) 3D spheroid cell cultures at
1000 cells/well and treated in triplicates with a dilution series of ARS-1620. Cell viability
and cytotoxicity were measured following 7 days of treatment. Graphs are presented as
mean percentages of vehicle controls from triplicate repeats of two independent
experiments.
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ARS1620 also showed a greater decrease in cell viability with increasing 
concentration in 2D H358 cells, although toxicity was still observed at 
concentrations ≥10µM (Figure 3.10). Consistent with previous observations, 
spheroid H358 cells showed increased sensitivity to ARS1620 by a decrease 
in cell viability IC50 and increased cytotoxic effect at concentrations >1µM 
(Figure 3.10, Table 3.1). A dose response of ARS1620 was also carried out in 
KRAS-WT cell lines, H1793 and H1437, grown as both as 2D and 3D spheroid 
cultures (Figure 3.10). In both cell lines no effect of ARS1620 on cell viability 
and cytotoxicity was observed at concentrations <10 µM.  
 
Going forward, the KRAS-G12C inhibitor ARS1620 was included in further 
experiments and despite displaying off-target toxicity, AZ6813 was still 
included as it enabled a comparison between two KRAS-G12C inhibitors with 
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Figure 3.10: 2D versus 3D cell viability and cytotoxicity responses of ARS1620 in KRAS-
G12C mutant and KRAS wild type cell lines. 
H358, H1793 and H1437 cells were seeded as 2D cell cultures and 3D spheroid cell cultures 
at 1000 cells/well and treated in triplicates with a dilution series of ARS-1620. Cell viability (A) 
and cytotoxicity (B) were measured following 7 days of treatment. Graphs are presented as 











Fig?: H358 2D versus 3D cell viability and cytotoxicity responses
H358 cells were seeded as (A) 2D cell cultures and (B) 3D spheroid cell cultures at
1000 cells/well and treated in triplicates with a dilution series of ARS-1620. Cell viability
and cytotoxicity were measured following 7 days of treatment. Graphs are presented as
mean percentages of vehicle controls from triplicate repeats of two independent
experiments.
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3.2.5  Generation of resistant H358 cells 
 
To identify an appropriate inhibitor concentration for treating cells to generate 
resistance, the IC50 and IC90 concentrations from the target engagement, 2D 
and 3D viability assays of H358 cells were compared (Table 3.1). H358 cells 
were chosen as a suitable cell line to start generating resistance due to their 
observed KRAS dependency in both a 2D and 3D context. Comparison 
between 2D and 3D viability assays showed the IC50 and IC90 of spheroids 
were approximately 4-fold, 5-fold and 6-fold less for ARS1620, AZ6813 and 
AZD4785 respectively, whereas a dramatic decrease of approximately 175-
fold is observed for selumetinib. On the other hand, 3D and target engagement 
assays showed the most similar concentrations with <2-fold differences 
between the assays for AZ6813, AZD4785 and selumetinib. Whereas 
ARS1620 displayed a greater difference between these two assays, showing 
more potent pathway inhibition compared to decreased spheroid viability. 
Overall, it was decided that the pathway inhibition IC50 and IC90 
concentrations would be the most appropriate to use going forward, knowing 
that at these concentrations, pathway inhibition and good target engagement 
is achieved, as well as a decrease in cell viability without off-target toxicity. 
 
  

















AZ6813 0.29 2.63 2.5 22.4 0.48 4.27 
ARS1620 0.092 0.83 1.55 13.80 0.34 3.09 
AZD4785 0.42 3.72 4.95 44.7 0.79 7.08 
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To generate resistant H358 cells (H358-R) two independent dosing schedules 
were carried out for each inhibitor using either a dose escalation starting from 
the IC50 concentration or a constant IC90 dose. Following challenge with 
inhibitor dose responses, the IC90 treated H358-R cells showed the better 
resistance profile from increased cell viability in comparison to naïve cells, and 
as a result these cells were continued to be treated. A timeline of H358-R 
generation using IC90 inhibitor concentrations is presented in Figure 3.11 for 
each inhibitor. All of the H358-R cells maintained resistance to the 
corresponding inhibitors over time. This was observed by comparing the IC50 
concentration between inhibitor treated and naïve cells at each time point, 
which resulted in a high fold-resistance change of at least ~ 100-fold (Appendix 
1). There were some occasions when no change in viability was observed 
when the cells were assayed, specifically Batch 1 AZ6813 Day 88 (Figure 
3.11A), AZD4785 Day 88 (Figure 3.11D) and Selumetinib Day 75 (Figure 
3.11E). However successive viability assays continued to show altered drug 
sensitivity as expected and so these observations were likely to be due to 
anomalous assays. The time points when cells were thawed was also 
recorded as some effects from thawing were observed, particularly with 
AZD4785 treated cells which took much longer to recover from this process. 
This is demonstrated by the increased time until these cells were ready for the 
next passage. Importantly all H358-R cell lines did recover following thawing 
and resistance was retained. A summary of the different cell lines that have 








































Figure 3.11: Generation of AZ6813, ARS1620, AZD4785 and selumetinib, H358-R cells. 
Batches of AZ6813 (A)(B), ARS1620 (C), AZD4785 (D) and selumetinib (E)(F) H358 resistant 
cells were generated by continuously treating cells with an IC90 concentration of each 
respective inhibitor or vehicle control. Each point on the timelines represents when cells were 
passaged after reaching confluency. Over time these cells were assayed to determine 
changes in cell viability when treated with varying concentrations (10nM-10uM) of each 
respective inhibitor. The time of assay is marked red on the corresponding timeline and the 
time point where cells were frozen and later thawed is marked blue. Cell viability assays were 
performed using CellTiter-Glo (Promega) and each inhibitor dose was carried out in 
duplicates. Cell viability graphs are presented as mean percentage of vehicle control from a 
single experiment. Figure continued on next two pages. 
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Fig ?: Generation of AZ6813, Selumetinib, AZD4785 and ARS1620 H358 resistant cells
Two separate batches of AZ6813 (A)(B), Selumetinib (C)(D) AZD4785 (E)(F) and ARS1620 (G)
H358 resistant cells were generated by continuously treating cells with an IC90 concentration
of each respective inhibitor or vehicle control. Each point on the timelines represents when cells
were passaged after reaching confluency. Over time these cells were assayed to determine
changes in cell viability when treated with varying concentrations (10nM-10uM) of each
respective inhibitor. The time of assay is marked red on the corresponding timeline and the time
point where c lls were froze and later thawed is marked blue. Cell viability ass ys were
performed using CellTiter-Glo (Promega) and each inhibitor dose was carried out in duplicates.
C ll viability graphs are pres nted as me n percentage of vehic e control.
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Table 3.2: Summary of different cell lines generated and relevant treatments. 
Name of cell line Number of Batches 
Total number of days 
treated with inhibitor or 
vehicle 
H358-R (long-term resistant)   
H358-R AZ6813 2 112, 96 
H358-R ARS1620 1 103 
H358-R AZD4785 2 108, 81 
H358-R selumetinib 2 94, 97 
H358-R selumetinib_DMSO 1 
69 days Selumetinib 
followed by 32 days DMSO 
H358-R DMSO 2 112, 97 
H358-R PBS 2 112, 97 
H358-A (acute)   
H358-A AZ6813 - 7 days AZ6813 
H358-A ARS1620 - 7 days ARS1620 
H358-A AZD4785 - 7 days AZD4785 
H358-A Selumetinib - 7 days selumetinib 
H358-A DMSO - 7 days DMSO 
H358-A PBS - 7 days PBS 
 
3.2.6  Monitoring RAS pathway changes over time as an 
indication of resistance development 
 
To monitor the response of resistance over time, changes in protein 
abundance of major RAS pathway components were analysed by 
immunoblotting. The different RAS isoforms, along with the RAS downstream 
effectors DUSP6, ERK, MEK, AKT and their phosphorylated counterparts 
were analysed. To measure phosphorylated AKT, two phosphorylation sites 
were detected, Thr-308 (T308) which is phosphorylated by PDK1, and Ser-
473 (S473) phosphorylated by the mTORC2 complex [99, 285]. 
 
In order to determine how quickly resistance was emerging following inhibitor 
treatment, an initial time course of inhibitor treatment was carried out for a 
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Figure 3.12: Acute inhibitor time course over 96hrs in H358 cells. 
H358 cells were treated with vehicle control (-) or IC90 concentrations of each inhibitor (A) 
AZ6813, (B) ARS1620 (C) AZD4785 and (D) Selumetinib for a total period of 96hrs. Cells 
were re-dosed after 48 hours and lysates prepared at the indicated time points. Ras pathway 


























































































































Fig 4.7: Acute inhibitor time course over 96hrs
H358 cells were treated with vehicle control (-) or IC90 concentrations of each inhibitor (A)
AZ6 13, (B) Selumetinib, (C) AZD4785, (D) ARS1620) for a total period 96hrs. Cells
were re-dose and lysates prepared at the indicated time points. Ras pathway components
were analysed by immunoblotting.
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total of 96 hours, with a drug re-dose at 48 hours (Figure 3.12). Treatment with 
the KRAS-G12C inhibitor AZ6813 showed an initial decrease in levels of 
DUSP6, p-ERK, p-MEK and p-AKT(S473) (Figure 3.12A). Reduced p-MEK 
abundance was maintained throughout the time course, whereas p-
AKT(S473) levels began to increase at 24 hours, p-ERK at 72 hours and 
DUSP6 at 96 hours. On the other hand, no changes in RAS isoform protein 
expression was observed. Changes in protein levels were similar for cells 
treated with the other KRAS-G12C inhibitor ARS1620 (Figure 3.12B). 
Treatment with AZD4785 also showed an initial decrease in DUSP6, p-ERK, 
p-MEK and p-AKT(S473) abundance, although of these only p-AKT(S473) 
levels began to increase again at 48 hours (Figure 3.12C). As expected KRAS 
protein expression decreased with this treatment, although unexpectedly an 
initial decrease in NRAS was observed which then increased again at 96 
hours. In comparison treatment with selumetinib showed an initial decrease in 
DUSP6, p-ERK and p-MEK abundance although no initial change in 
pAKT(S473) levels (Figure 3.12D). Protein levels started to increase again 
following 48 hours for DUSP6, p-MEK and p-AKT(S473) and 52 hours for p-
ERK.  
 
In order to determine if these acute changes in RAS pathway protein levels 
were maintained over time, an extended time course of 10 days with repeated 
inhibitor dosing every 48 hours was carried out (Figure 3.13). The previously 
generated long-term cultured H358-R cells were used as a comparison. 
Treatment with AZ6813 replicated the initial decrease in DUSP6, p-ERK, p-
MEK and p-AKT(S473) abundance (Figure 3.13A) previously observed with 
acute 4-day treatment (Figure 3.12). DUSP6, p-ERK and p-AKT(S473) 
abundance appeared to fluctuate a little, although generally protein levels 
increased following 4 days of treatment, and by day 8 matched similar protein 
levels of the long-term chronically treated cells. Again, a similar pattern of 
protein abundance changes was observed for cells treated with ARS1620 
(Figure 3.13B). With the addition of AZD4785, no initial change in DUSP6, p-
MEK or p-AKT(S473) abundance was observed, whereas p-ERK levels 
decreased more slowly following 24 hours (Figure 3.13C). However, at day 6, 
both p-ERK and p-AKT(S473) protein levels increased which was again 
Validating targeted KRAS inhibitors 76 
maintained throughout the remaining time course and matched the protein 
levels of the long-term treated cells. With selumetinib treatment protein levels 
of p-ERK, p-MEK and p-AKT(S473) started to increase at day 2 and also 
matched levels of chronically treated cells (Figure 3.13D).  
 
Overall these two independent time courses of inhibitor treatment highlight that 
mechanisms of pathway rewiring and potential resistance started occurring 
within days of the cells being treated, and that the elevated expression levels 
were generally maintained and matched similar levels of long-term chronically 
treated H358-R cells. Furthermore, the addition of fresh inhibitor every 48hrs 
did not prevent p-ERK rebound, indicating that the loss of pathway inhibition 
was not due to drug metabolism or instability over time. 
 
 
Figure 3.13: Acute inhibitor time course over 10 days in H358 cells. 
H358 cells were treated with vehicle control (-) or IC90 concentrations of each inhibitor (A) 
AZ6813, (B) ARS1620, (C) AZD4785) and (D) selumetinib for 10 days with cells re-dosed 
every 48 hours. Cell lysates were prepared at the indicated time points and Ras pathway 
components were analysed by immunoblotting. Lysates from H358-R (R) cells were carried 
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Fig? Time course analysis of Ras pathway components following acute inhibitor treatment
H358 cells were treated with vehicle control (-) or IC90 concentrations of inhibitor and
re-dosed following 48 hours of treatment. Cell lysates were prepared at the indicated time points and Ras
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Figure 3.14: Acute inhibitor time course over 10 days in KRAS-G12C mutant H1792 
cells. 
H1792 cells were treated with vehicle control (-) or IC90 concentrations of each inhibitor (A) 
AZ6813, (B) ARS1620, (C) AZD4785 and (D) selumetinib for 8 or 10 days with cells re-dosed 
every 48 hours. Cell lysates were prepared at the indicated time points and Ras pathway 
components were analysed by immunoblotting. 
 
To see if results were consistent in another KRAS-G12C mutant cell line, a 
time course was repeated in H1792 cells (Figure 3.14). Similar trends with an 
initial decline in p-ERK and p-AKT(S473) protein levels, followed by a rise in 
abundance which is maintained over the remaining time course, were 
observed with AZ6813 and ARS1620 treatment (Figure 3.14A and B). 
However, in H1792 cells, treatment with AZD4785 showed no change in p-
ERK levels, although p-AKT still increased at day 4 (Figure 3.14C). Treatment 
with selumetinib also showed a similar trend to H358 cells, with a rise in p-
MEK levels from day 2, and p-AKT(S473) and p-ERK from day 4 and day 6 
respectively (Figure 3.14D). Although no long-term treated cell lines were 
made using H1792 cells, overall increased protein abundance of these key 
RAS pathway components was observed and maintained over the time course 
highlighting similar trends between different lung cancer cells with KRAS-
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Fig? Time course analysis of Ras pathway components following acute inhibitor treatment
H1792 cells were treated with vehicle control (-) or IC90 concentrations of inhibitor and
re-dosed following 48 ho rs of treatment. Cell lysates were prepared at the indicat d time points and Ras
pathway components were analysed by immunoblotting.
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Figure 3.15: Acute inhibitor time course over 10 days with KRAS WT H1793 cells.  
H1793 cells were treated with vehicle control (-) or IC90 concentrations of each inhibitor (A) 
AZ6813, (B) ARS1620, (C) AZD4785, (D) Selumetinib for 10 days with cells re-dosed every 
48 hours. A time match DMSO control was carried out alongside (E), arrows indicate when 
cells were split. Cell lysates were prepared at the indicated time points and Ras pathway 
components were analysed by immunoblotting. Results are from a single experiment.  
 
 
To ensure these trends were KRAS-G12C specific and a consequence of 
targeted KRAS inhibition, a 10-day time course was repeated in KRAS-WT  
H1793 cells (Figure 3.15). Reactivation of p-MEK was still observed with 
selumetinib treatment (Figure 3.15D) however, unlike previous experiments, 
minimal change in p-ERK levels was observed for any inhibitor treatment 
(Figure 3.15A-D). On the other hand, p-AKT(S473) levels initially increased 
upon inhibitor treatment and then continued to fluctuate in all conditions Figure 
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Fig 4.9: KRAS WT cells with acute inhibitor time course over 12 days
H179 cells were treated with vehicle control (-) or IC90 concentrations of each inhibitor (A)
AZ6813, (B) Selumetinib, (C) AZD4785, (D)ARS1620 for a total period of 12 days. A time match
DMSO control was carried out alongside (E), arrows indic te when cells were split. Cells wer
re-dosed every 48hrs and lysates prepared at the indicated time points. Ras pathway
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alongside the inhibitor treatments which also showed fluctuations in p-
AKT(S473) levels (Figure 3.15E). The time points at which cells were 
passaged during the time course was also recorded. Evaluating the 
relationship between these variables, it was hypothesised that p-AKT(S473) 
levels changed according to cell confluency.  
 
3.2.7  H358-R cells exhibit permanent signalling rewiring  
 
In order to determine whether cells were permanently rewired, continually 
treated H358-R cells were subject to inhibitor withdrawal, where dosing of 
inhibitor was replaced with vehicle control over a time course of 10 days 
(Figure 3.16). Naïve H358 cells that had never been treated with inhibitor were 
used as a control. In H358-R AZ6813 cells (R-AZ6813) protein levels of p-ERK 
and p-AKT(S473) remained high throughout the DMSO washout time course 
compared to untreated cells, although there were some fluctuations at day 2-
4 (Figure 3.16A). In comparison to inhibitor treatment, p-MEK increased with 
DMSO washout, however no change in DUSP6 expression was observed 
compared to untreated control cells. Overall the changes in p-ERK and p-
AKT(S473) levels observed previously in figure 3.13 were sustained following 
the absence of inhibitor. Despite previous p-AKT(S473) levels fluctuating with 
cell confluency, the fact that higher protein levels remains in the absence of 
inhibitor compared to untreated cells provides confidence that this change is 
due to signalling rewiring in long-term treated H358-R cells. In H358-R 
ARS1620 cells (R-ARS), DMSO washout provided similar trends in protein 
levels (Figure 3.16B). In H358-R AZD4785 cells (R-ASO), p-ERK and p-
AKT(S473) levels remain elevated during PBS washout, whereas no general 
trend was observed with p-MEK and in fact DUSP6 levels appeared higher in 
untreated cells (Figure 3.16C). Similarly, H358-R selumetinib cells (R-Sel) also 
showed increased p-ERK and p-AKT(S473) abundance compared to 
untreated cells during DMSO washout, highlighting more permeant rewiring of 
these RAS pathway components (Figure 3.16D). Whereas the previously 
observed increase in p-MEK with inhibitor treatment actually decreased during 
washout, indicating this feedback signalling is transient in these cells.  
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Figure 3.16: Inhibitor washout time course over 10 days in H358-R cells 
H358-R cells that had been continually treated with inhibitor (-) were cultured in media 
containing only appropriate vehicle control (DMSO or PBS) for a total period of 10 days. Cells 
were re-dosed every 48hrs and lysates prepared at the indicated time points. Ras pathway 
components were analysed by immunoblotting. Lysates from H358 naive cells (N) were ran 
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Fig 4.10: Resistant H358 inhibitor washout time course over 10 days
H358-R cells that had been continually treated with inhibitor (-) were cultured in media
containing only appropriate vehicle control (DMSO or PBS) for a total period of 10 days. Cells
were re-dosed every 48hrs and lysates prepared at the indicated time points. Ras pathway
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3.3 Discussion 
 
In this chapter I have selected three inhibitors (AZ6813, ARS1620 and 
AZD4785) which directly target KRAS, and carried out validation of the 
selectivity and sensitivity of these inhibitors in a panel of NSCLC cell lines with 
different endogenous KRAS mutation status. The MEK inhibitor selumetinib 
was compared alongside. Target validation was required to determine the 
appropriate concentrations for drug dosing to generate resistant cells. DUSP6 
mRNA expression is a marker of ERK signalling and was measured as a 
readout to indicate RAS or MEK inhibition. DUSP6 has been shown to be 
consistently upregulated in mutant KRAS cells and tissues and elevated 
expression levels are associated with poor prognosis in NSCLC [286, 287]. 
This dual specificity phosphatase acts as a negative feedback regulator 
induced by ERK signalling and attenuates MAPK signalling by 
dephosphorylating and inactivating ERK. It has been shown that in 
comparison to the phosphorylation status of ERK and MEK, DUSP6 mRNA 
levels more accurately reflect MAPK pathway activation [288]. Additionally, 
cell viability and cytotoxicity assays were used for inhibitor validation and 
provided insight into the biological effect and efficacy of compounds. The 
inhibitors demonstrated good inhibition of cell growth and specifically induced 
cell death in mutant KRAS tumour cells, although concentrations ³3µM 
induced cytotoxicity (Figures 3.7 and 3.8).  
 
As a result of the KRAS-G12C inhibitor AZ6813 showing evidence of off-target 
toxicity in KRAS-WT cells (Figure 3.2), a second generation allosteric KRAS-
G12C inhibitor ARS1620 was included in the study and demonstrated greater 
potency and specificity (Table 3.1). Of the effective KRAS inhibitors the ASO 
AZD4785 was the least potent, presumably due to its mechanism of action 
targeting KRAS mRNA and the delay of inhibition to KRAS protein production. 
At the start of this study, AZD4785 was undergoing phase I clinical trials but 
has since been discontinued by the developers AstraZeneca. Despite this, 
AZD4785 represents an alternative mechanism of direct KRAS inhibition in 
this study and is a useful comparator for resistance mechanisms as it targets 
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both mutant and wildtype KRAS. The MEK inhibitor selumetinib was the most 
potent inhibitor in the study and represented a clinically approved comparator 
with known resistance in KRAS mutant cells. On the other hand, the inhibitors 
fendiline and deltarasin which target RAS membrane localisation showed no 
evidence of RAS pathway inhibition (Figure 3.1). The non-specific action and 
lack of specificity of fendiline [274, 289] are likely factors underlying this 
observation. Additionally, it is unclear how dependent KRAS is on PDE6d for 
membrane trafficking, as PDE6d interacts with a number of other farnesylated 
proteins [289, 290]. Therefore, this raises concerns of the ability of PDE6d 
inhibitors, such as deltarasin, to selectively target RAS. Consequently, 
fendiline and deltarasin were not included in any further experiments. Despite 
AZ6813 exhibiting some off-target toxicity, this KRAS inhibitor was still 
included in the study as good pathway inhibition was still observed in KRAS-
mutant cells (Figure 3.1) and it also provides a direct comparison to ARS1620 
which has a similar mechanism of action. The inhibitors AZD4785 and 
selumetinib were also taken forwards.  
 
A direct comparison between 2D adherent monolayer cells and 3D ultra-low 
adherent spheroids was performed, as it was previously identified by Fujita-
Sato and colleagues that differences in culture adherence affect KRAS mutant 
cells [291]. In the study KRAS mutant cells were found to be more dependent 
on KRAS in 3D cell culture as a result of enhanced expression of the receptor 
MET under these growth conditions, which is regulated by RAS-RAF-MEK-
ERK pathway signalling [291]. In this study H358 cells grown as spheroids 
demonstrated greater sensitivity to the panel of KRAS inhibitors compared to 
2D monolayer culture (Figure 3.7). This was also represented by the 
decreased cell viability IC50 and IC90 values of 3D cell culture, which were 
more comparable to concentrations determined from the pathway inhibition 
assay (Table 3.1). It is now well accepted that culturing cells in 3D systems is 
more biologically representative of the in vivo environment compared to 
monolayer cultures, with more clinically relevant gene expression profiles and 
responses to treatment [284, 292-294]. As observed in tumours, spheroid 
models exhibit normoxic, hypoxic and necrotic zones with layers of 
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proliferating, quiescent and apoptotic cells highlighting greater physiological 
relevance [295]. In this study, ultra-low attachment plates were used to 
produce spheroids given the flexibility for use in cellular assays, although this 
simple 3D model lacks the heterogeneity and interaction of cancer cells with 
the surrounding extracellular matrix (ECM) and stroma observed in vivo. 
Alternative 3D models can incorporate scaffolds, matrices and co-culture to 
recapitulate these interactions [296]. However, the major challenges of 3D cell 
culture for drug discovery include lack of reproducibility as well as low cost and 
time effectiveness. Despite being one of the fastest growing experimental 
approaches, there is little published information on the long-term culturing of 
spheroid cells and their use to generate resistant models. With the use of ultra-
low attachment flasks to generate bigger cell populations, many questions 
remained unknown regarding whether spheroids should be passaged and how 
to obtain reproducible cultures. As a result of the challenges faced with 
spheroid culturing, it became apparent that it was important to proceed with 
cells that demonstrated KRAS dependency in 2D cell culture. Of the cell lines 
in the KRAS-G12C NSCLC panel, H358 cells demonstrated good KRAS 
dependency as 2D culture and were the easiest cell line to grow and passage. 
Subsequently resistant cells were generated using this cell line.    
 
In the laboratory drug resistant cell models are developed by repeat exposure 
of cancer cells to drugs, and after a period of time the surviving daughter cells 
are then compared to the parental sensitive cells using cell viability assays 
[282, 297]. In this study resistant cells were developed from H358 (KRAS-
G12C) cancer cells using this approach (Figure 3.11). However publications 
in this research field place little emphasis on the exact methodology of 
generating resistant cells and some of the key decisions involved, particularly 
with regard to the dosing strategies, treatment intervals and optimisation of 
doses [282]. Typically dose escalating schedules starting at the IC50 
concentration are more routinely used to generate resistant cells [297-299]. 
Currently no publications on generating resistant cells to direct KRAS 
inhibitors have been published, although generation of selumetinib resistant 
cells have been previously generated by using both dose escalation and a 
chronic maximum dose [244]. In the CRC cell lines used, a similar or greater 
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degree of selumetinib resistance occurred following the chronic dosing 
schedule [244].   As a result, a comparative strategy was adopted and H358 
cells were initially treated with either IC50 or IC90 inhibitor concentrations in 
parallel for each inhibitor to determine the optimum dosing strategy for 
generating resistance. This selection strategy identified that IC90 treated cells 
displayed increased viability in comparison to IC50 treated cells upon inhibitor 
challenge. Furthermore, the chemical stability of the inhibitors was considered 
for an appropriate dosing schedule. Due to continually growing cells in the 
presence of inhibitor and the relatively short half-lives of the small molecule 
inhibitors, a repeat dosing of 48 hours was performed. During the timeline of 
generating resistant cells, an additional control cell line was generated, H358-
R selumetinib_DMSO, which represents cells treated long-term with 
selumetinib, followed by DMSO only treatment. This comparison originated 
from the finding that withdrawal of selumetinib in CRC cells can either reverse 
acquired resistance in BRAF-600E mutant cells or further promote 
chemoresistance in KRAS-G13D driven cells [300]. It would therefore be of 
interest to see how H358-R selumetinib_DMSO cells compare to other H358-
R cells in this study, particularly as transient p-MEK signalling was observed 
in R-Sel washout cells (Figure 3.16D).  
 
As is the case with many MEK inhibitors, relief of feedback inhibition and 
pathway reactivation of ERK1/2 occurs and limits MEKi monotherapy [75, 
244]. This was confirmed in H358 and H1792 cells, with the increased 
abundance of pERK1/2 and pMEK1/2 following acute selumetinib treatment 
(Figures 3.12 - 3.13). Increases in protein levels of p-ERK1/2 were also 
observed with direct KRAS inhibitors, indicating the reactivation of ERK1/2 
signalling and the development of pathway rewiring underlying resistance. 
With KRAS-G12C inhibitors, pMEK1/2 appeared to gradually increase, though 
this was not as strongly as observed with selumetinib treatment and no 
changes were observed with AZD4785 treatment. Upon inhibitor withdrawal 
different responses in pMEK1/2 levels occurred. Following selumetinib 
withdrawal, pMEK1/2 protein abundance gradually declined overtime in spite 
of increased pERK1/2 levels (Figure 3.16). Whereas with KRAS-G12C 
inhibitor withdrawal, pMEK1/2 protein levels gradually increased alongside 
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pERK1/2. It has previously been identified that gene amplification of the 
addicted oncogene in KRAS-mutant CRC cells is a common mechanism to 
maintain ERK1/2 signalling under selumetinib resistance [244], and following 
inhibitor withdrawal cells are able to maintain resistance to selumetinib [300]. 
The increased abundance of pERK1/2 signalling under both KRAS and MEK 
inhibition, as well as during inhibitor withdrawal confirms reactivation of 
pERK1/2 as a common resistance mechanism, albeit differences in pMEK1/2 
levels might suggest this can occur via different signalling pathways in 
chronically treated cells. These protein changes were also coupled with 
changes in pATK(S473) levels which generally increased with the inhibitor 
treatments and was maintained over time and during inhibitor withdrawal. 
However, surprisingly fluctuations in pAKT(S473) was also observed in KRAS-
WT cells with the targeted KRAS-G12C inhibitors, and a matched DMSO time 
course indicated p-AKT(S473) abundance was also influenced by changes in 
cell confluency (Figure 3.15). This observation has been identified in several 
other studies, suggesting that cells with higher cell confluency exhibit lower 
pAKT protein levels as a result of increased contact inhibition, whereas the 
opposite is observed in cells that have high proliferative ability [301, 302]. In 
spite of this, the sustained increased abundance of pAKT(S473) following 
acute and chronic inhibitor treatment, as well as during inhibitor withdrawal 
(Figure 3.16), gives confidence that this increase is a result of resistance-
mediated signalling rewiring. Overall since pERK and pAKT rewiring occurred 
within just a few days of KRAS inhibitor treatment, a comparison of acutely 
treated cells for 7 days (H358-A) would be compared to the long-term 
chronically treated H358-R cells generated, enabling any changes in 
resistance mechanisms over time to also be compared.  
 
Previously there were no models for monitoring resistance to direct KRAS 
inhibitors, and from this study I now have different batches of H358 cells that 
are resistant to each of the inhibitors (AZ6813, ARS1620, AZD4785 and 
selumetinib) (Table 3.2). As well as comparisons between different inhibitors, 
comparisons between different cell batches could also be carried out to 
identify if different sub-populations arise and whether similar or different 
resistance mechanisms develop in independently treated cells [303]. 
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Furthermore, comparisons between the length of drug treatments will provide 
the ability to compare short-term drug tolerances with long-term permanent 
resistance mechanisms and help to identify any changes that are selected for 
over time. Previous modelling of acute responses highlights intrinsically drug 
tolerant subpopulations play a crucial role in promoting long-term acquired 
drug resistance [304]. In the future it would also be insightful to generate 
resistant cells from the other NSCLC cell lines in this panel, as well as 
potentially from 3D spheroid models.  
 
In summary, the aims of validating a set of direct KRAS inhibitors in a panel of 
NSCLC cells, as well as generating resistant cell lines, have been successfully 
met. As a result, I can now apply the resistant cells I have generated to 














































As detailed in the previous chapter, H358-R cells showed an increased cell 
viability compared to naïve cells and immunoblotting demonstrated they 
maintained altered p-ERK1/2 protein abundance levels, suggesting more 
permanent signalling rewiring mechanisms (Figures 3.11, 3.13 and 3.16). 
Previous clinical efforts to target the RAS-RAF-MEK pathway have been 
hindered by adaptive feedback reactivation of pathway signalling, resulting in 
incomplete suppression of the pathway targeted and many of the crosstalk 
mechanisms involved have been well documented (See Table 1.1). For 
example, MEK inhibitors have shown limited clinical activity as mono-therapies 
in KRAS-mutant tumours due to mechanisms of feedback activation via the 
PI3K pathway [305], as well as upregulation of multiple RTKs and their ligands 
[278]. Furthermore wild-type RAS isoforms present in cells harbouring mutant 
RAS can still promote and sustain oncogenic signalling of downstream effector 
pathways when oncogenic RAS is depleted [306]. Such studies highlight that 
direct RAS inhibitors will not be broadly effective across all RAS-mutant 
tumours, and suggests alternative signals can support cell growth and survival 
when mutant KRAS is absent [225, 307]. As a result, vertical inhibition of the 
RAS pathway and targets of other RAS effector pathways that can be used 
alongside RAS inhibitors should be explored to increase therapeutic efficacy. 
In mutant KRAS mouse models combined inhibition of MEK and PI3K caused 
more dramatic tumour regression than either inhibitor alone [193, 308]. 
Similarly, MEK and PI3K-mTOR inhibition in mouse xenograft NSCLC models 
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demonstrated greater antitumor efficacy than the respective monotherapies 
[309]. Despite promising preclinical studies and manageable toxicity, the 
combination of MEK and PI3K inhibitors in clinical trials has demonstrated 
mixed response rates for KRAS-mutant tumours [196, 200, 310]. Alternatively, 
other pathways such as the cell cycle, apoptosis and upstream RTKs have 
presented alternative targets for therapeutic combination with RAF-MEK-ERK 
inhibitors in KRAS mutant cancers [311-313]. Following good efficacy in 
preclinical studies [314, 315], the combined inhibition of CDK4/6 and MEK is 
currently undergoing clinical trial in KRAS-mutant NSCLC (NCT03170206). 
Furthermore there is increasing evidence to support the combination of MEK 
and PI3K inhibitors with pharmacological inhibition of antiapoptotic proteins 
BCL-XL and BCL-2 in several KRAS-mutant cancers [313, 316, 317]. 
Additionally, RTKs of the HER family and FGFR1 have been identified as 
additional targets for combination with MEK inhibitors [278, 311]. Therefore, it 
is important to investigate the potential resistance mechanisms associated 
with direct KRAS inhibition in order to identify new opportunities to improve 
these therapies from understanding how and when certain combination 
therapeutics should be given. 
 
Advances in molecular profiling approaches and the integration of multi-omics 
data offer a more compressive insight into the cellular changes associated with 
resistance mechanisms. RNA-sequencing (RNA-Seq) presents a powerful 
tool for genome-wide transcriptome profiling, using high throughput 
sequencing technologies to detect differentially expressed genes, of both 
known and novel transcripts, to better understand the biological context of a 
drug treatment or disease phenotype [318]. RNA-seq is widely used during 
drug discovery and development, and has previously been used to identify 
genes associated with drug resistance [319]. In comparison to microarrays, 
RNA-Seq has several advantages including very low background signal and 
high resolution, as well as covering a large dynamic range with both high 
sensitivity and reproducibility [320]. However challenges include the 
bioinformatic analysis of large amounts of sequence data, requiring complex 
informatics for mapping reads, reducing errors in base-calling and removing 
low-quality reads [320]. Additionally, sequence coverage is an important issue 
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and in order to detect rarer transcripts considerable depth is required [320]. It 
also remains a challenge to interpret genome-wide transcriptomic data to 
extract biologically meaningful insights. As a result, functional annotation tools, 
such as gene ontology (GO) enrichment analysis, are widely used to reduce 
complexity and to identify functionally related gene groups that differentially 
expressed genes are enriched for [321, 322]. GO analysis is structured to 
characterise genes according to biological processes, molecular function and 
cellular component. Rather than analysing gene expression changes on an 
individual gene-orientated view, this instead makes analysis of large gene lists 
relevant to specific gene groups and increases the identification of important 
insights and relevant biological processes involved in the area under study 
[321].  
 
On the other hand, proteomic approaches help to characterise the 
transcriptomic information flow within cells with the associated protein 
pathways and networks activated under certain conditions [323]. The 
abundance of proteins present is modulated by additional post-transcriptional 
modifications and protein degradation mechanisms altering the level of protein 
expression which cannot be detected by transcriptomic analysis alone [324]. 
As a result, gene-expression data may not accurately reflect active cellular 
functions. Profiling phosphorylation in particular is a key strategy for identifying 
responses to therapeutics, resistance and therapeutic targets, which widely 
involve deregulated kinases [325].  There are several technologies available 
for broad proteomic analysis. Mass-spectrometry-based technologies enable 
the analysis of thousands of proteins although complex sample preparation 
and lower-sensitivity for low-abundant proteins makes it difficult for analysing 
cancer signalling proteins [326] . Alternatively, reverse-phase protein array 
(RPPA) is a highly sensitive medium-throughput technique which allows 
screening of samples for a large panel of proteins of interest, including 
phosphoproteins. The method is based on protein microarray where 
simultaneously single arrays or spots containing protein lysate are incubated 
with a specific antibody. Its reliability however largely depends upon the quality 
of the antibodies [327].   
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The combined contribution of quantitative transcriptomic and proteomic 
approaches has been widely applied for profiling resistance mechanisms and 
have successfully yielded biomarkers and therapeutic targets in many different 
cancers [325, 328-330].  
 
Aims 
In order to determine potential mechanisms and alternative pathways of 
resistance under KRAS inhibition, I took a genome-wide approach to 
investigate the transcriptional and proteomic programming of H358-R and 
H358-A cells treated with various KRAS inhibitors (Table 3.2). 
 
Using these approaches, I aimed to: 
• Identify gene signatures associated with emerging resistance in acutely 
treated (H358-A) and long-term (H358-R) treated cells 
• Determine any differences between different mechanisms of RAS 
pathway inhibition 
• Determine if similar trends occur across transcriptomic and proteomic 
data 




















4.2.1  Comparison of gene expression between RNA-seq 
data sets  
RNA-seq was performed by BGI Genomics Co. Ltd. (Hong Kong) using 
BGISeq-500 and DNBSeq platforms to compare H358-R and H358-A cells 
cultured in the presence of KRAS inhibitors and vehicle controls (Table 4.1). 
Two sets of H358-R samples were processed independently (H358-R1 and 
H358-R2), enabling repeat conditions to be compared.  The second set 
included the more potent KRAS-G12C inhibitor ARS1620 and was processed 
alongside H358-A samples, enabling differences between early and late 
resistance mechanisms to be compared. 
 
 Run 1 Run 2 








DMSO ü ü ü 
PBS ü ü ü 
AZ6813 ü ü ü 
Selumetinib ü ü ü 
AZD4785 ü ü ü 
Selumetinib_DMSO ü û û 
ARS1620 û ü ü 
ASO CTRL û û ü 
Table 4.1: Summary of RNA-seq data sets processed by BGI Genomics. Two RNA-seq 
runs were processed separately at different times. Run 1 was performed using the BGISEQ-
500 platform for the indicated chronically treated samples. Run 2 was performed using the 
comparable DNBSeq platform for both acute and chronically treated samples. 
 
The RNA samples were prepared using Trizol extraction and a total RNA 
sample QC was carried out using the Agilent 2100 Bioanalyzer and Agilent 
RNA 6000 Nano Kit to determine RNA concentration, RIN value, 28S/18S and 
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fragment length distribution. The library construction, sequencing and 
subsequent bioinformatic workflow was carried out by BGI Genomics Co. Ltd. 
(Hong Kong). The analysis pipeline is shown in Figure 4.1.  
 
Figure 4.1: RNA-Sequencing bioinformatics workflow. 
Raw sequencing data was first filtered to remove low quality reads, reads with adaptors and 
reads with unknown bases. Clean reads were then mapped to the reference genome along 
with SNP/INDEL calling, novel gene prediction and gene-splicing detection. Gene expression 
levels were determined using RSEM [268], followed by detection of differentially expressed 
genes (DEGs) between samples. Finally, hierarchical clustering analysis and functional 
annotation using GO analysis and pathway analysis were carried out. 
 
An overview for each data set was produced, highlighting the total number of 
genes expressed for each condition as well as how many transcripts were 
high, low and medium expressed using different Fragments Per Kilobase 
Million (FPKM) ranges (Figure 4.2A). In all data sets, >15000 genes were 
identified, and a similar distribution of high, medium and low expressed genes 
were detected within and across data sets. In addition, the total number of 
shared genes within a data set were calculated, as well as the number shared 
by at least two conditions and the number of unique genes for each condition 
(Figure 4.2B). In all data sets the vast majority of genes >14000 were shared 















Figur 4.1 RNA-Seq bioinformatics workflow
Raw sequencing data was first filtered to remove low quality reads, reads with adaptors
and reads with unknown bases. Clean reads were then mapped to the reference
genome along with SNP/INDEL calling, novel gene prediction and gene splicing
detection. Gene expression levels were determined using RSEM, followed by detection
of differentially expressed genes (DEGs) between samples. Finally hierarchical
clustering analysis and functional annot tion using GO nalysi and pathway an lysis
were carried out.
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least two conditions. In H358-R1 and H358-R2 data dets, AZD4785-treated 
cells harboured the greatest number of uniquely expressed genes in 
comparison to other conditions.  
 
Furthermore, the number of shared genes expressed between control and 
treated samples within each data set were compared, alongside the number 
of unique genes and the number of those differentially expressed (DEGs) 
(Figure 4.3). In all data sets the majority of expressed genes are shared, with 
small fluctuations in the number of unique genes. Overall more DEGs are up-
regulated across the different conditions than are down-regulated and 
AZD4785-treated cells displayed the greatest number of DEGs in relation to 
their corresponding control.  
 
Next the number of DEGs shared between inhibitor treated samples was 
compared for each data set (Figure 4.4 A, C, E). The number of DEGs shared 
across H358-R1, H358-R2 and H358-A inhibitor treated samples were 267, 
728 and 312 respectively. However, when the same three inhibitors used in 
H358-R1 were compared, 189 DEGs were shared in H358-R2 (Figure 4.4C). 
Again, AZD4785-treated resistant cells exhibited the greatest number of 
uniquely expressed DEGs, which was not observed with acutely treated cells 
(H358-A). Hierarchical gene clustering was performed for each data set of 
shared DEGs which clearly highlighted the differential gene expression 
between control and treated cells (Figure 4.4 B, D, F). The majority of DEGS 
were up-regulated in treated cells compared to controls and few DEGs showed 
mixed responses in H358-R data sets. Additional comparison of DEGs shared 
across H358-R1 selumetinib and selumetinib_DMSO (SEL_DMSO) treated 
cells showed similar gene expression responses between the two conditions 
compared to DMSO treated cells (Figure 4.4B). Overall there were few mixed 
DEGs, highlighting that despite drug withdrawal, SEL_DMSO cells retained a 
resistant gene expression signature.  Hierarchical gene clustering was also 
performed combining all the DEGs across the three data sets and the resulting 
dendrogram presented to show the clustering of each sample (Figure 4.4G). 
Firstly, AZD4785-treated resistant cells from both data sets distinctively cluster 
together and show the greatest divergence from the other samples. 
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Figure 4.2: Comparison of the total number of expressed genes in each data set. 
(A) Shows the gene expression distribution of transcripts from each data set represented by 
Fragments Per Kilobase Million (FPKM). The dark grey indicates the number of highly 
expressed genes and the light grey the number of genes with low expression. The total 
number of genes sequenced for each condition are show at the top of each bar. (B) Venn 
diagrams for each data set to show the number of unique genes for each condition (turquoise), 
the total number of genes shared between at least two conditions (orange) and the number of 

































Figure? Comparison of the total number of expressed genes
(A) Shows the gene expression distribution of transcripts from each data set
represented by Fragments Per Kilobase Million (FPKM). The dark grey indicates
the number of highly expressed genes and the light grey the number of genes with
low expression. The total number of genes sequenced for each condition are show
at the top of each bar. (B) Venn diagrams for each data set to show the number of
unique genes for each condition (turquoise), the total number of genes shared
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Figure 4.3: Comparison of differentially expressed genes in each data set. 
Shows proportional comparisons of the number of differentially expressed genes (DEGs) 
between control and treated samples in each data set (H358-R1, H368-R2, H358-A). Venn 
diagrams highlight the number of unique genes between each treatment (in brackets), the 
total number of common genes (grey) and the number of these that were differentially 











































Fig?: Comparison of differentially expressed genes
Shows proportional comparisons of the number of differentially expressed genes (DEGs)
between contr l nd treated samples in each data set (H358-R1, H368-R2, H358-A). Venn
diagrams highlight the number of unique genes between each condition (in brackets), the
total number of common genes (grey) and the number of these that were differentially











































































In all data sets ASO has the most DEGs
More DEGs are up regulated in conditions than down regulated
There is some degree of fluctuation in unique genes but for each treatment there are
similar number of common genes (grey)
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Figure 4.4: Comparison of differentially expressed genes. 
(A, C, E) Shows comparisons of DEGs between the inhibitor treated samples from each data 
set. The total number of DEGs is shown in brackets for each treatment. Black circles represent 
the treatments included in the analysis, indicating the total number of unique DEGs and those 
in common between samples (joined circles). (B, D, F) Hierarchical clustering of pan gene 
expression values from each data set which have been logarithmically converted. #1 
represents genes that are up-regulated compared to the control, #2 are mixed responses and 
#3 are down-regulated genes compared to controls. (G) Hierarchical clustering of all pan 






















































































































































































































































Fig?: Comparison of differentially expressed genes
(A, C, E) Shows comparisons of DEGs between the inhibitor treated samples from each data
set. The total number of DEGs is shown in brackets for each condition. along with the total
number of unique DEGs and those in common between samples. (B,D,F) Hierarchical
clustering of pan gene expression values from each data set which have been logarithmically
converted. #1 represents genes that are up-regulated compared to the control, #2 are mixed
responses and #3 are down-regulated genes compared to controls. (G) Hierarchical
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The controls from H358-R1 cluster together alongside the ASO-CTRL of 
H358-A treated cells, whereas the remaining controls from H358-A and H358-
R2 also group separately. This potentially highlights some influence of 
experiment timing and processing. All small molecule inhibitors from both 
H358-R data sets also group together, highlighting similar DEG responses, 
and the H358-A inhibitor treated samples also cluster. As H358-A and H358-
R2 samples were prepared and processed at the same time, the differential 
clustering indicates there are clear differences between acute and long-term 
resistance gene expression responses.  
 
To compare DEGs for each inhibitor between different data sets, scatter plots 
were used to show correlation and to highlight if individual genes are regulated 
in the same way (Figure 4.5). Comparison of H358-R1 and H358-R2 indicated 
no overall correlation of AZ6813 DEGs although a general trend was observed 
for selumetinib DEGs and a good pattern of correlation for AZD4785 DEGs. 
On the other hand, comparison of H358-R2 and H358-A showed a majority of 
DEGs correlating for all inhibitors, highlighting greater consistency between 
these two data sets which were processed at the same time. 
 
4.2.2  GO analysis for differentially expressed genes 
DAVID (the database for annotation, visualisation and integrated discovery) 
was used for GO analysis, and GO terms associated with DEGs for each 
inhibitor were identified for links with relevant biological processes [331, 332]. 
GO terms were ranked according to significant p-values (<0.05) using EASE 
score, a modified Fisher Exact P-value. Distinctive enriched terms with higher 
numbers of genes involved were selected and presented in a heat map (Figure 
4.6). For H358-R GO terms, DEGs expressed in both H358-R1 and H358-R2 
data sets were selected for and GO analysis performed. Data labelled as 
‘combined’ represents the DEGs shared by all inhibitors presented in Figure 
4.4. In H358-A treated cells, microtubule and cell cycle processes stand out 
as highly significant across all individual inhibitors and combined data. 
Processes relating to cell stress, cell cycle and proliferation, as well as  
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Figure 4.5: Comparison of differentially expressed genes between data sets 
Scatter plots comparing genes that are differentially expressed in two long-term treatment 
conditions (H358-R1 v H358-R2) aswell as between acute and long-term conditions (H358-
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Scatter plots to show of the DEGs which correlate between samples. Identifies genes that are regulated in same or different way.
Indicates some influence of experiment timing, R2 and A samples show greater consistency.
For R1 v R2 ASO there is a pattern of correlating DEGs, for selumetinib there is a general trend and for AZ there is no correlation.
Whereas for R2 v A all inhibitors show a majority of DEGs correlating between data sets
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Figure 4.6: GO analysis for differentially expressed genes.  
Hierarchical clustering of significant GO terms based on p-values for H358-A and H358-R 
treated cells. H358-R represents the most significant terms from two independent RNA 
sequencing data sets. Terms highlighted in dark blue represent those with very high 
significance (p-value >1.0E-10).    
 
intracellular signalling were also very significant and enriched for, and overall 
a similar trend was observed for all inhibitors. On the other hand, resistant 
cells (H358-R) show different trends between inhibitors. Firstly, in AZD4785-
treated resistant cells a greater number of processes were significant including 
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Fig?: GO analysis for differentially expressed genes
Hierarchical clustering of significant GO terms based on p-values for H358-A and
H358-R treated cells. H358-R represents the most significant terms from two
independent RNA sequencing data sets. Terms highlighted in dark blue represent
those with very high significance (p-value >1.0E-10).
Acute observations - i combined inhibitors microtubule and cell cycle processes very significant, intracellular signalling important,
response to cell stress and proliferation. Inhibitors follow a similar trend
Long-term observations - Inhibitors show different trends.
1. ASO more processes significant, intracellular signalling significant, whereas others not. Cell adhesion, wounding, ECM structure and
migration significant for ASO and SEL but not G12C inhibitors.
2. Cell cycle and response to stress significant for all apart from selumetinib. Cell proliferation not important for sel. See greatest switch
from acute to longterm. Response to stress is significant for G12C inhibitors.
Acute v longterm observations - cell cycle most significant for both treatments. Switch from intracellular signalling significant acute to NS
in longterm. RTK signalling NS in acute but significant in ASO, Sel and ARS for longterm. Similar trend enzyme linked receptor signalling
(not ARS)
Omic profiling of H358-A and H358-R cells 100 
Moreover, cell adhesion, response to wounding, ECM structure and cell 
migration were significantly enriched in AZD4785- and selumetinib-treated 
resistant cells but not with cells chronically treated with KRAS-G12C inhibitors. 
Processes such as the cell cycle and response to stress were significant 
across all chronically treated samples with the exception of selumetinib-
treated resistant cells. In addition, processes associated with cell stress 
appeared specifically highly significant for cells treated with KRAS-G12C 
inhibitors. Comparison between acute (H358-A) and chronic (H358-R) 
treatments show cell cycle and microtubule processes as the most significant 
terms shared across both treatment conditions. Whereas intracellular 
signalling switched from being significant across all inhibitors with acute 
treatments, to being not significant in several chronic treatments. Alternatively, 
RTK signalling wasn’t significant under acutely treated conditions, but was 
significantly enriched for in AZD4785-, selumetinib- and ARS1620-treated 
resistant cells.  
 
4.2.3  KRAS-G12C inhibitors demonstrate similar 
responses  
A comparison between the KRAS-G12C inhibitors AZ6813 and ARS1620 was 
also carried out to investigate any differences in gene expression and 
associated biological processes (Figure 4.7). Scatter plots highlight that within 
H358-R2 and H358-A data sets the two KRAS-G12C inhibitors correlate well 
and share the vast majority of DEGs which are similarly up-regulated or down-
regulated (Figure 4.7A). Comparison of inhibitors between acute and long-
term treatment indicated a similar number of shared genes expressed 
although with both inhibitors more genes become down-regulated following 
longer treatment (Figure 4.7B). Hierarchical clustering of DEGs shows that the 
acute treated samples group together as well as the long-term treated 
samples, highlighting greater effect between treatment conditions rather than 
the inhibitors themselves (Figure 4.7C). Of the DEGs that correlate with both 
inhibitors, GO analysis showed the cell cycle and microtubule processes were 
again the most significant processes associated with KRAS-G12C inhibitors 
(Figure 4.7D). Whereas RTK signalling, cell growth and cell migration were 
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Figure 4.7: Comparison of G12C inhibitors between and across data sets.  
(A) Scatter plots showing correlation of DEGs between G12C inhibitors from each data set. 
(B) Comparisons of the number of differentially expressed genes (DEGs) between acute 
(H358-A) and long-term treated (H358-R2) samples. Venn diagrams highlight the number of 
unique genes between each condition (in brackets), the total number of common genes (grey) 
and the number of these that were differentially expressed, represented by up regulated (red) 
and down regulated (blue) DEGs. (C) Hierarchical clustering of DEG gene expression values 
from H358-R2 and H358-A data sets which have been logarithmically converted. (D) 
Hierarchical clustering of significant GO terms based on p-values for H358 cells treated with 
G12C inhibitors. Terms highlighted in dark blue represent those with very high significance (p-
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not significant with KRAS-G12Ci. Comparison of treatment conditions shows 
that with ARS1620 both cell adhesion and response to wounding switch 
between acute and long-term treatment, becoming insignificant following 
longer treatment. On the other hand, with AZ6813 intracellular signalling, 
second messenger signalling, and extracellular organisation are more 
significantly enriched for under acute treatment, whereas terms associated 
with cell stress become more significant with long-term AZ6813 treatment. 
Overall, despite having the same mechanism of action, this indicates some 
differences between cell resistance mechanisms between the two inhibitors, 
possibly influenced by the difference in potency and selectively of the two 
inhibitors.  
 
4.2.4  Comparison of protein expression between RPPA 
data sets  
RPPA analysis was carried out at the MD Anderson Cancer Center (USA) to 
analyse changes in protein levels and protein modifications in resistant (H358-
R) and acutely treated (H358-A) cells cultured in the presence of KRAS 
inhibitors and vehicle controls. Hierarchical clustering of all 466 antibodies was 
performed for both data sets (Figure 4.8A and B). In both H358-A and H358-
R data sets, the vehicle controls cluster together separately from the inhibitor 
treated cells. Acutely treated cells demonstrated greater up- and down-
regulation of proteins compared to the controls. Whereas in resistant cells, this 
trend is only present in AZD4785-treated cells. Combined hierarchical 
clustering of H358-R and H358-A data sets was also carried out (Figure 4.8C). 
As before all the controls from each data set cluster together as do the majority 
of inhibitor treated cells with only AZD4785-treated resistant cells clustering 
separately. AZ6813- and ARS1620-treated resistant cells clearly demonstrate 
fewer changes in protein expression compared to other inhibitor treated cells.  
 
To compare differentially expressed proteins and modifications for each 
inhibitor across H358-R and H358-A data sets, scatter plots were used to 
highlight correlations between individual RPPA proteins (Figure 4.9). 
Comparison of AZ6813-treated cells indicated a mixed correlation of total 
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Figure 4.8: Comparison of protein expression levels in H358-A and H358-R treated cells. 
Hierarchical clustering of RPPA protein expression levels from (A) H358-A and (B) H358-R 
treated cells. (C) Hierarchical clustering of all RPPA samples from both data sets combined. 
 
protein and modified protein expression, whereas ARS1620- and selumetinib-
treated cells showed a majority of proteins correlating across the two data sets. 
On the other hand, AZD4785-treated cells showed no overall correlation, 
indicating mixed expression changes across the majority of proteins. Proteins 
which show the greatest changes between acute and chronic treatments are 




































































































RPPA analysis of 466 antibodies. Log2 values of normalised data. Heat map
generated and hierarchical clustering.
Shows controls cluster together in both data sets, as do inhibitor treated
cells. Clearer difference in H358-A, although H358-R ASO has most up and
down regulated.
Describe combined clustering.
Compare to RNA seq
All
Figure ?: Comparison of protein expression levels in H358-A and H358-R treated cells
Hierarchical clustering of RPPA protein ression levels from (A) H358-A and (B) H358-R
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Figure 4.9: Correlation of total protein and modified protein expression levels between 
treatments.  
Scatter plots comparing total protein and modified (phosphorylated or cleaved) protein levels 




4.2.5  RAS pathway and cancer network analysis 
Having analysed the main comparisons between different conditions within the 
RNAseq and RPPA data, and demonstrating they show good coverage of 
gene and protein expression, the data was applied to identify potential 
mechanisms of resistance. As previously mentioned, resistance mechanisms 




































































Figure ?: Correlation of total protein and modified protein expression levels between
tr atments
Scatter plots comparing total protein and modified (phosphorylated or cleaved) protein
levels that are differentially expressed between acute and long-term treated cells (H358-A v
H358-R).
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pathways associated with the RAS-MAPK pathway [307]. Using the RAS 
network genes published by the RAS Initiative (National Cancer Institute), a 
RAS pathway was generated to map the signalling interactions of upstream 
and downstream effectors (Figure 4.10). Differential gene expression in Ras 
pathway genes was mapped for AZD4785-treated resistant cells in relation to 
control cells (Figure 4.11), which demonstrated the greatest pathway 
expression changes in comparison to the other inhibitors (Appendix 3).  
 
 
Figure 4.10: Network of the Ras Pathway.  
Diagram highlighting the upstream and downstream signalling pathways associated with the 
Ras pathway. 
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Figure 4.11: Ras Network Expression for H358-R AZD4785. 
Heat map illustrating RNA-Seq differential gene expression in Ras pathway genes. Red 
indicates positive log fold change and represents increased expression in inhibitor treated 
cells compared to the corresponding vehicle control, whilst blue indicates negative log fold 
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AZD4785 (ASO) vs PBS
Fig ?: Ras Network Expression
Heat map illustrating RNA-Seq differential gene expression in Ras pathway genes. Red
indicates positive log fold change and represents increased expression in inhibitor
treated cells compared to the corresponding vehicle control, whilst blue indicates
negative log fold change and a decrease in expression.
Omic profiling of H358-A and H358-R cells 107 
 
Figure 4.12: Expression changes of key nodes of the Ras Network. 
Heat map illustrating RNAseq differential gene expression in key nodes of the Ras pathway 
between H358-A and H358-R2 data sets. Red indicates a positive log fold change and 
represents increased expression in inhibitor treated cells compared to the corresponding 
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Fig?: Expression changes of key nodes of the Ras Network
Heat map illustrating RNAseq differential gene expression in key nodes of the Ras pathway
between H358-A and H358-R2 data sets. Red indicates a positive log fold change and represents
increa d expression in inhibitor treated cells comp r to the corresponding v hicle control,
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In summary the RTK, RAS-GEFs and downstream CDK4/6 Rb effectors 
showed the greatest collective up-regulation in the RAS pathway. As a result, 
expression changes in these gene groups, alongside the RAS isoforms, were 
investigated further across all inhibitors (Figure 4.12). Interestingly in 
comparison to acutely treated cells (H358-A), HRAS became upregulated in 
all chronically treated resistant cells (H358-R), whereas KRAS and NRAS 
were downregulated, potentially indicating RAS isoform switching. Acute 
inhibitor treatments generally demonstrated upregulation of several RTKs 
including EGFR, FGFR1-4, ERBB2, PDGFRB and INSR, although some 
demonstrated mixed responses between inhibitors. On the other hand, MET, 
ALK and PDGFRA (G12C inhibitors) were generally down regulated. In 
resistant cells EGFR and FGFR expression remains high, whereas ERBB2, 
PDGFRB and INSR demonstrate down-regulation with some inhibitors. The 
majority of RTKs however remain up-regulated for AZD4785-treated resistant 
cells. Similarly, RAS GEFs also show general up-regulation of SOS1/2, 
RASGRP1-4, RAPGEF2 and RASGRF1 in H358-A cells. In contrast SOS1/2 
along with RASGRP1/3 become down regulated in H358-R cells, although 
most RAS GEFs remain up-regulated for AZD4785-treated resistant cells. This 
highlights that RAS GEF mediated resistance mechanisms might not be a 
long-term mechanism. In contrast downstream CDK4/6 Rb effectors 
demonstrate similar up-regulation across acute and chronic treatments. 
 
Next a wider cancer gene network was generated from 10 key signalling 
pathways associated with tumorigenesis from the Cancer Genome Atlas and 
highlights further pathway members and interactions [333]. A heat map for the 
genes associated with these pathways was mapped for RNAseq H358-A and 
H358-R2 data sets (Figure 4.13). Hierarchical clustering showed that samples 
within each data set group together. The greatest number of up-regulated 
genes were associated with RTKs, cell cycle and Wnt signalling across both 
H358-A and H358-R2 treatments, whereas PI3K signalling was generally 
down-regulated. A heat map was also generated for RPPA H358-A and H358-
R data sets (Figure 4.14). Generally, components of the MAPK and PI3K 
pathways were up-regulated in acutely treated cells compared to chronically  
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Figure 4.13: Heat map of the Cancer Gene 
Network. 
H358-A and H358-R2 RNAseq data sets were 
compared and a heat map was generated for 
signalling pathways in the cancer gene network. 
Data is presented as log2 fold change of each 
inhibitor compared to its corresponding control 
(DMSO/PBS). Red indicates a positive log fold 
change and represents increased expression in 
inhibitor treated cells compared to the 
corresponding vehicle control, whilst blue 
indicates a negative log fold change and a 
























Fig?: Heat map of the Cancer Gene Network
H358-A and H358-R2 data sets were compared and a heat map was generated for
signalling pathways in the cancer gene network. Data is presented as log2 fold change of
each inhibitor compared to its corresponding control (DMSO/PBS). Red indicates a
positive log fold change and represents increased expression in inhibitor treated cells
compared to the corresponding vehicle control, whilst blue indicates a negative log fold
change and a decrease in expression.
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Figure 4.14: Heat map of RPPA cancer network protein expression. 
A heat map was generated for RPPA proteins involved in various signalling pathways in the 
cancer gene network. Data is presented as log2 fold change of each inhibitor compared to its 
corresponding control (DMSO/PBS). Red indicates a positive log fold change and represents 
increased expression in inhibitor treated cells compared to the corresponding vehicle control, 










































Figure?: Heat map of RPPA cancer network protein
expression
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treated resistant cells. In the MAPK pathway HER2/3, MAPK_pT202_Y204 
and p44-42-MAPK were all highly up-regulated in acutely treated cells. In 
resistant cells, RTKs remained largely upregulated, particularly IR-b in 
AZD4785-treated cells. Although in contrast, the majority of MAPK 
components were instead down-regulated in these cells including HER2/3, 
IGFRb, SHP2 and SHP-2_pY542. In the PI3K pathway INPP4b, AKT_pS473, 
Tuberin_pT1462, mTOR and mTOR_pS2448 were also highly upregulated in 
H358-A cells. Whereas the majority of PI3K pathway components had lower 
expression levels in H358-R cells, particularly AZ6813- and AZD4785-treated 
cells. AKT phosphorylation however remained upregulated in selumetinib-
treated resistant cells. In other cancer pathways, AMPKA, AMPKA_pT172, 
ULK1_pS757, ATM, p21, Notch 3 and Merlin were all up-regulated in acutely 
treated cells, whereas cell cycle related proteins cyclin-B1, cdc2_pY15, 
CDK1_pT14 and Rb_pS807_S811 were highly down-regulated. On the other 
hand, in AZD4785-treated resistant cells p53, cyclin D, CDK1_pT14, Rb and 
Rb_pS807_S811 were highly up-regulated and HES1 and b-catenin down-
regulated. In summary, whilst both the RNAseq and RPPA datasets showed 
distinct responses in acute vs chronically treated cell lines across a wide range 
of cancer-relevant pathways, there was a general concordance of responses 
between the RAS inhibitors albeit with some divergence by the AZD4785.  
 
To confirm the consistently altered expression of key RTKs seen throughout 
the RNA-seq and RPPA data, I further analysed changes in protein expression 
by western blotting (Figure 4.15). H358 cells treated with ARS1620 show an 
initial decrease in EGFR expression upon acute inhibitor treatment which 
increases back to control levels in chronically treated resistant (H358-R) cells, 
although this was accompanied by no change in pEGFR levels over time 
(Figure 4.15A). On the other hand, ERBB2 and pERBB2 abundance increases 
following 2 days of acute ARS1620 treatment and increased levels are 
maintained in resistant cells, whereas no changes in PDGFR-b and FGFR1 
levels were observed. Similar trends were observed in H358 cells treated with 
selumetinib (Figure 4.15B). However differential responses are observed with 
H358 cells treated with AZD4785 (Figure 4.15C). In these cells EGFR 
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expression appears to decrease over time with acute treatment, and in H358-
R cells pEGFR is absent. As with the other inhibitor treatments a similar 
increase in ERBB2 and pERBB2 expression is observed with acute treatment, 
however this response is absent in the chronically treated H358-R cells, and 
instead there are increases in PDGFR-b and FGFR1 protein levels. Overall 
these results are consistent to those observed for the RPPA proteomic data 
and further highlight the differential RTK signalling between acute and 
chronically treated resistant cells, as well as the differential reliance upon 
RTKs of AZD4785-treated resistant cells. 
 
 
Figure 4.15: RTK expression over an acute inhibitor time course and in resistant cells. 
H358 cells were treated with vehicle control (-) or IC90 concentrations of each inhibitor (A) 
ARS1620, (B) Selumetinib and (C) AZD4785 for 10 days with cells re-dosed every 48 hours. 
Cell lysates were prepared at the indicated time points and RTK protein expression levels 
were analysed by immunoblotting. Lysates from chronically treated resistant H358-R (R) cells 
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To further investigate potential isoform switching observed in the RNA-seq 
data and to identify any changes in RAS activity levels associated with 
resistance, a RAS activity pull-down assay was performed (Figure 4.16). An 
initial decrease in active Pan-RAS and KRAS expression was observed with 
acute ARS1620 treatment (Figure 4.16A). However consistent with the onset 
of resistance development previously identified (Chapter 3, section 3.2.6), 
KRAS activity levels increased again at day 7 as well as in long-term resistant 
cells. No changes in active HRAS or NRAS were observed. In H358 cells 
treated with AZD4785 a decrease in active Pan-RAS and KRAS expression 
was also observed (Figure 4.16B), indicating consistency with KRAS mRNA 
knockdown from the mechanism of ASO inhibition. These also remained 
downregulated in AZD4785-treated resistant (H358-R) cells. Instead a slight 
increase in active HRAS expression was observed which is consistent with the 
RNA-seq data for these cells (Figure 4.12).  
Figure 4.16: Changes in RAS activity over time 
H358 cells were treated with GTP (positive control), GDP (negative control), DMSO (vehicle 
control) or IC90 concentrations of (A) ARS1620 and (B) AZD4785 for 7 days with cells re-
dosed every 48 hours. Cell lysates were prepared at the indicated time points and lysates 
from H358-R (R) cells were also collected. A RAS activity pull-down assay was performed, 
and levels of active RAS expression were analysed by immunoblotting. Results are from a 
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Following upregulation of cell cycle gene expression, changes in cell cycle 
protein expression and the importance of cell cycle regulation in 
tumorigenesis, the interactions of cell cycle signalling was focused on in more 
detail (Figure 4.17). The major regulatory cell cycle checkpoints occur at the 
G1/S and G2/M boundaries, ensuring that cells can only continue to progress 
through these stages in the presence of the correct stimuli and absence of 
DNA damage. During the cell cycle, cyclins interact with cyclin-dependent 
kinases (CDKs) to promote cell cycle progression, whereas CDK inhibitors 
prevent it (Figure 4.17A). Both RNAseq and RPPA expression data, including 
phosphorylation sites were mapped to a network of the cell cycle (Figure 
4.17B). In acutely treated cells, CDKN1A (p21) protein expression and 
CDKN2C (p18) gene expression are highly upregulated across all inhibitor 
treatments, indicating inhibitory signalling for cell cycle progression. This 
response can be stimulated by DNA damage [334]. However downstream 
cyclin-D (CCND1-3), cyclin-E (CCNE1) and CDK expression showed mixed 
responses that suggested cell cycle progression. For example, CCND3, CDK2 
and CDK6 generally showed increased expression levels with the majority of 
inhibitors. Despite high RB1 gene expression, RB1 protein expression and 
phosphorylation was down-regulated, whilst E2F1-3 and TFDP1/2 gene 
expression was generally upregulated, also indicating cell cycle progression. 
The gene expression of cyclin-A (CCNA2) and cyclin-B (CCNB1-3), involved 
in the later cell cycle S phase and mitosis, were also upregulated, although 
again protein expression of CCNB1 was conflicting. However inactivating 
phosphorylation sites at the corresponding CDK1 showed down regulation, 
also indicating progression through the cell cycle. In contrast chronically 
treated resistant cells showed a notable loss of p21 protein expression, 
although p18 gene expression remained high. Consequently, downstream 
cyclin-E (CCNE1), cyclin-D (CCND3 and CCND2 for AZD4785-treated cells) 
and their corresponding CDKs (CDK2/4/6) had increased expression 
compared to acutely treated cells. This data therefore also suggests promotion 
of the cell cycle in H358-R cells. In addition, cyclin-B (CCNB1-3) and cyclin-A 
(CCNA1/2) expression remained generally high in H358-R cells, although 
notably inactivating phosphorylation of the corresponding CDK1-3 at site T14 
was upregulated in the majority of inhibitors. 
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Figure 4.17: Changes in gene expression of the cell cycle genes.  
(A)  Illustration of the cell cycle which includes four distinct phases G1 (Gap 1), S (DNA 
synthesis), G2 (Gap 2) and M (Mitosis). At G0 cells can enter and exit a quiescent state. 
Regulation of the cell cycle is controlled by the formation of heterodimers of cyclins (cyclin -A, 
-B, -D, -E) and cyclin dependent kinases (CDKs) (CDK -1, -2, -4, -6). Several checkpoints 
(G1/S and G2/M checkpoints) ensure cells containing damaged DNA do not enter mitosis and 
are regulated by cyclin-dependent kinase inhibitors p21 and p27. Cell cycle progression past 
the restriction point occurs from phosphorylation of Rb by Cyclin D + CDK4/6, enabling E2F-
mediated transcription of S-phase genes. (B) Network illustrating RNAseq differential gene 
expression and RPPA differential protein expression, including phosphorylation in cell cycle 
genes between H358-A and H358-R2 data sets. Red indicates a positive log fold change and 
represents increased expression in inhibitor treated cells compared to the corresponding 
vehicle control, whilst blue indicates a negative log fold change and a decrease in expression. 
































Fig?: Changes in gene expression of the cell cycle genes
(A) Illustration of cell cy le whic ncludes four distinct phases G1 (Gap 1), S (DNA synthesis),
G2 (Gap 2) and M (Mitosis). At G0 cells can enter and exit a quiescent state. Regulation of the cell
cycle is controlled by the formation of heterodimers of cyclins (cyclin -A, -B, -D, -E) and cyclin
dependent kinases (CDKs) (CDK -1, -2, -4, -6). Several checkpoints (G1/S and G2/M checkpoints)
ensure cells containing damaged DNA do not enter itosis and are regulated by cyclin-dependent
kinase inhibitors p21 and p27. Cell cycle progression past the restriction point occurs from
phosphorylation of Rb by Cyclin D + CDK4/6, enabling E2F-mediated transcription of S-phase
genes. (B) Network illustrating RNAseq differential gene expression and RPPA differential protein
expression, including phosphorylation in cell cycle genes between H358-A and H358-R2 data sets.
Red indicates a positive log fold change and represents increased expression in inhibitor treated
cells compared to the corresponding vehicle control, whilst blue indicates a negative log fold
change and a decrease in expression. Genes highlighted in bold represent those that are
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Another cancer pathway associated with resistance is the epithelial-
mesenchymal transition (EMT) pathway [335-337]. It was previously shown 
that in KRAS-G13D mutant CRC cells, MEK inhibitor resistance promoted 
ERK1/2 hyperactivation and induced ZEB1-dependent EMT and 
chemoresistance [300]. As a result, epithelial and mesenchymal markers were 
identified from both the RNAseq and RPPA data (Figure 4.18). A heat map for 
differential gene expression of EMT markers highlights the distinctive 
clustering of H358-A and H358-R2 data sets indicating differences in cell 
morphology and adhesion between acute and chronic treatment conditions 
(Figure 4.18A). The differential expression of these genes was also presented 
as a network along with protein expression data from the RPPA (Figure 
4.18B). In H358-A cells, expression of EMT transcription factors was mixed 
with SNAI1, TWIST1 and ZEB1 protein expression levels stable, despite 
changes in gene expression levels. Epithelial markers CDH1 (E-cadherin), 
TJP1, MUC1 (protein) were upregulated with all inhibitors, whereas DSG3 and 
LAMA2 were downregulated. In contrast the mesenchymal marker CDH2 (N-
cadherin) remained downregulated except for AZD4785-treated cells. 
However other mesenchymal markers VCAN, CTGF, FN1 and VIM were 
generally upregulated. In H358-R cells SNAI1 and ZEB1 transcription factors 
were more upregulated in comparison to acute treated cells, which was 
expected to have a more inhibitory effect on epithelial marker expression and 
a stimulatory effect for mesenchymal markers. As anticipated, this was 
accompanied by a decrease in CDH1 gene and protein expression, along with 
loss of TJP1 and MUC1 expression. Conversely epithelial markers DSG3 and 
COL1A1 surprisingly increased in expression. On the other hand, CDH2, FN1, 
VCAN, VIM and ACTA2 gene expression was highly upregulated, although 
CTGF became downregulated. To explore changes in EMT markers further, 
immunoblotting was carried out on H358-A and H358-R cell lysates (Figure 
4.18C) as well as immunofluorescence of several EMT markers (Appendix 4 
and 5). Immunoblotting showed the epithelial marker CDH1 was highly 
expressed in all cells with the exception of AZD4785-treated resistant cells, 
which showed a clear decrease in protein levels. Correlating to gene 
expression data, this was also coupled with an increase in vimentin expression  
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Figure 4.18: Gene and protein expression changes of the EMT Pathway. 
(A) Heat map of differential gene expression in EMT genes between H358-A and H358-R2 
data sets and (B) presented as a gene network adapted from [338], including RPPA protein 
expression data. Data is presented as log2 fold change of each inhibitor compared to its 
corresponding control (DMSO/PBS). Red indicates a positive log fold change and represents 
increased expression in inhibitor treated cells compared to the corresponding vehicle control, 
whilst blue indicates a negative log fold change and a decrease in expression. (C) H358-A 
and H358-R cells seeded and treated with IC90 inhibitor concentrations or DMSO/PBS control 
and re-dosed every 48hrs. Cell lysates were prepared and EMT markers were analysed by 
immunoblotting with the antibodies shown (CDH1, E-cadherin; CDH2, N-cadherin; VIM, 
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in these cells, indicating a more mesenchymal phenotype. A slight decrease 
in mesenchymal marker CHD2 expression was observed following KRAS-
G12C inhibition in H358-A cells relative to controls, although no other 
differences could be determined across H358-R cells. Vimentin protein 
expression following KRAS-G12C inhibition also remained low in both H358-
A and H358-R cells, suggesting these cells maintain an epithelial phenotype. 
Whereas selumetinib-treated resistant cells show some increase in vimentin 
expression. On the other hand, no clear phenotype distinctions could be 
determined by immunofluorescence with H358-A and H358-R cells expressing 
both E-cadherin and N-cadherin unanimously. 
 
To integrate both RNAseq and RPPA data for combined multi-omic analysis, 
the webtool PaintOmics (v0.45) was used enabling additional significant 
pathways and potential mechanisms to be identified [339, 340]. Top significant 
KEGG pathways associated with H358-A and H358-R2 data sets are detailed 
in Table 4.2.  Several KEGG pathways, particularly with chronically treated 
resistant cells are associated with the DNA damage response. A network heat 
map was also generated encompassing genes involved in the Fanconi anemia 
pathway for DNA interstrand crosslink (ICL) repair (Figure 4.19). In both 
acutely- and chronically-treated resistant cells there is up-regulation of DNA 
damage senor genes (ATR and ATRIP) as well as Fanconi anemia core 
complex genes which act as a scaffold for recruiting DNA damage repair 
proteins. In both treatment conditions BRCA1/2 genes were also 
transcriptionally upregulated, although discrepancies between gene and 
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DNA replication 1.5350e-8 DNA replication 5.3009e-8 
Biosynthesis of amino acids 1.6313e-4 Cell cycle 6.0473e-5 
Transcriptional mis-
regulation in cancer 
0.00170 Fanconi anemia pathway 2.3817e-4 
Mismatch repair 0.00391 P53 signalling 6.6208e-4 
Apoptosis 0.00758 MAPK signalling pathway 8.8032e-4 
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Central carbon metabolism 
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Figure 4.19: Changes in gene and protein expression involved in DNA damage 
recognition 
Network illustrating RNAseq differential gene expression and RPPA differential protein 
expression between H358-A and H358-R2 data sets. Red indicates a positive log fold change 
and represents increased expression in inhibitor treated cells compared to the corresponding 






























































Figure? Changes in gene and protein expression in DNA damage genes
Network illustrating RNAseq differential g ne expression and RPPA differential
protein expression between H358-A and H358-R2 data sets. Red indicates a
positive log fold change and represents increased expression in inhibitor treated
cells compared to the corresponding vehicle control, whilst blue indicates a
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4.3 Discussion  
In this chapter I have identified several cancer pathways, that are upregulated 
in cells treated with various KRAS inhibitors and which are associated with 
known mechanisms of resistance. RNAseq and RPPA analysis were 
performed to profile and determine changes in gene and protein expression. 
RNAseq analysis of acute (H358-A) and chronic (H358-R) treated cells 
demonstrated good coverage of the number of genes across data sets, 
highlighting consistent processing and quality of samples (Figure 4.2 and 4.3). 
However, some differences in the correlation of genes expressed between 
repeat H358-R data sets was also observed (Figure 4.5), indicating that the 
timing of sample preparation may have had some influence. Furthermore, 
variability between some RNA and protein levels were observed, which may 
be associated with the different measurements and sensitivities of RNAseq 
and RPPA, as well as mechanisms of translational control such as mRNA 
stability, transcription rates and protein degradation [324]. Overall clear 
differences in gene and protein expression between control and treated cells 
was observed from hierarchical clustering analysis (Figure 4.4 and 4.8). 
Additionally, similarities and differences between inhibitor treatments were 
observed. As anticipated, the two KRAS-G12C inhibitors elicited similar 
responses, and this was seen for both acute and chronic treatments (Figure 
4.7). On the other hand, AZD4785 (KRAS ASO) exhibited the greatest 
dissimilarity from the other inhibitors. For example a greater number of DEGs 
was observed in both H358-A and H358-R RNAseq samples (Figure 
4.4A,C,E), as well as displaying distinct hierarchical clustering (Figure 4.4G). 
Analysis of protein abundance highlighted that cells treated chronically with 
AZD4785 displayed more up- and down-regulated proteins (Figure 4.8). The 
fact that this inhibitor reduces both KRAS-WT and KRAS-mutant mRNA is the 
most likely explanation for this. However, GO analysis of differentially 
expressed genes demonstrated that several similar biological processes were 
enriched for across all inhibitors, including the cell cycle, response to DNA 
damage and cellular stress (Figure 4.6).  
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In order to investigate relevant network rewiring and potential resistance 
mechanisms in more detail, components of the RAS pathway were focused 
on (Figure 4.10-4.12). Up-regulation of RTKs, RAS-GEFs and downstream 
CDK4/6 Rb effectors was observed (Figure 4.12) which indicates evidence of 
RAS stimulatory inputs and RAS activation. The upregulation of various RTKs 
following relief of negative feedback upon RAS pathway inhibition via RAF and 
MEK inhibition has been previously identified in several studies [278, 341, 
342], and as I have shown also corresponds to direct KRAS inhibitors. 
Furthermore a recent study using the KRAS-G12C inhibitor ARS1620 also 
demonstrated upregulation of RTKs, in particular ERBB2/3, FGFR2/3 and 
PDGFRa/b following acute inhibitor treatment [343], which is consistent with 
results I have obtained. The high rate of GTP hydrolysis of the KRAS-G12C 
mutant compared to other RAS mutations [123], indicates a greater reliance 
on GEF-mediated activation. As KRAS-G12C inhibitors bind to the GDP-
bound form of KRAS-G12C [207, 223], differential activation of RTKs and 
RAS-GEFs to promote GTP-bound KRAS-G12C may impair inhibitor binding 
to target, thereby mediating resistance. Studies also suggest that SHP2 and 
SOS1/2, which regulate RAS activity downstream of RTKs, are required for 
reactivation of RAS under both MEK inhibition [164, 343], and KRAS-G12C 
inhibition [344, 345]. Subsequent co-inhibition of SHP2 or SOS1/2 supressed 
this reactivation and development of adaptive resistance [343-345]. SOS1/2 
are upregulated with acute treatment of AZ6813, ARS1620 and selumetinib, 
whereas with chronic AZ6813-, ARS1620-, selumetinib- and AZD4785-
treatment in resistant cells SOS1/2 were downregulated (Figure 4.12). This 
might suggest that SOS1/2 activation might not be a permanent or long-term 
resistance mechanism. Furthermore, additional RAS-GEFs including 
RASGRP1-4, RAPGEF1/2 and RASGRF1/2 also showed upregulation in both 
acute and chronic treatments (Figure 4.12), and therefore inhibiting a single 
RAS-GEF in combination may not be enough to prevent adaptive resistance. 
Interestingly, H358 cells treated with AZD4785 demonstrated increased 
upregulation of RTKs and RAS-GEFs not upregulated by other inhibitors, 
suggesting some reliance on different RTKs and RAS-GEFs and highlighting 
that loss of KRAS mRNA altogether still promoted RAS pathway activation via 
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alternative mechanisms. The reliance on different RTKs was also highlighted 
by western blotting (Figure 4.15) which showed increased ERBB2 expression 
in acutely treated cells, as well as differential upregulation of FGFR1 and 
PDGFR-b in AZD4785-treated resistant cells which were not observed with 
either KRAS-G12C or MEK inhibition. Consistent with increased RTK and 
RAS-GEF activity, KRAS activity itself was also reactivated in ARS1620-
treated resistant cells (Figure 4.16). This observation is consistent with those 
from other studies [220, 346], although these studies suggest differences in 
the mechanisms of KRAS activation, either by wildtype RAS or newly 
synthesised KRAS-G12C. However, in AZD4785-treated resistant cells, lower 
levels of KRAS activity from targeting KRAS mRNA were coupled with a small 
increase in HRAS expression, indicating potential reliance upon alternative 
RAS isoforms for pathway reactivation. Upregulation of HRAS gene 
expression was also observed from RNA-sequencing (Figure 4.12). 
 
Throughout the cancer network analysis differences between acute (H358-A) 
and chronic (H358-R) treatments was also apparent. Differentially expressed 
proteins were identified from outliers in scatter plots showing how RPPA 
proteins correlated between conditions (Figure 4.9 and Appendix 2). Again, 
cells treated with AZD4785 highlighted greater differences in expression 
between conditions, further highlighting the divergence of these cells. When 
proteins were characterised according to pathways (Figure 4.14), MAPK and 
PI3K pathways showed greater protein upregulation in all acutely treated cells 
compared to chronic treatments. This suggests cells continually adapt over 
time and mechanisms of adaptive resistance are flexible and changing [347-
349]. 
 
Gene and protein changes in the cell cycle signalling network highlighted 
mixed responses between inhibitors and treatments (Figure 4.17). Notably the 
loss of tumour suppressor CDKN1A (p21) protein expression as seen in H358-
R cells (Figure 4.17B), has been proposed to mediate a drug-resistance 
phenotype [350]. Along with reduced expression of CDKN2A (p16) and 
subsequent upregulation of CDK2/4, this suggests these cells have rewired 
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signalling to promote the cell cycle in the presence of KRAS inhibitors [351]. 
Therefore, they may be susceptible to cell cycle and CDK inhibitors as part of 
a therapeutic combination strategy [352].  
 
Expression analysis of the EMT pathway gave mixed results, though overall 
from transcriptomic data H358-A cells suggested a more epithelial phenotype, 
whilst H358-R cells suggested a more mesenchymal phenotype from the loss 
of CDH1 coupled with the increase of CDH2 and EMT transcription factors 
(Figure 4.18). In particular, AZD4785-treated resistant cells indicated the most 
mesenchymal phenotype from immunoblotting. Phenotype analysis by 
immunofluorescence was inconclusive and provide no clear distinction of EMT 
alterations (Appendix 4 and 5). Studies have also shown that NSCLC cells and 
patient-derived xenografts (PDXs) which express epithelial markers are more 
sensitive to EGFR inhibition, whereas those expressing mesenchymal 
markers are insensitive [255]. Interestingly it has been observed that following 
MEK inhibition in KRAS-mutant lung cells, EMT rewired RTK expression which 
resulted in differential activation of the MAPK pathway [258]. For example, 
epithelial cells activated MEK and AKT via ERBB3, whereas in mesenchymal 
cells this was via FGFR1. The combination of MEK inhibition and FGFR1 
inhibition promoted tumour shrinkage in vivo. Although some H358-A and 
H358-R cells demonstrated mixed EMT responses, the upregulation of certain 
RTKs observed in these cells may subsequently be linked to the EMT process 
which further supports therapeutically targeting these pathways. For example, 
the differential expression of FGFR1 in AZD4785-treated resistant cells is 
therefore likely to be linked to their more mesenchymal phenotype.  
 
Genomic instability from dysregulated DNA damage sensing and repair 
mechanisms is also a well-known hallmark of many cancers. Both H358-A and 
H358-R cells demonstrated upregulation of DNA repair genes, a common 
reprogramming mechanism associated with resistance (Figure 4.19) [353, 
354]. As a result, cells resistant to KRAS inhibitors may be vulnerable to 
inhibitors which target DNA repair and DNA stress pathways.  
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Other pathways which could be related to KRASi resistance mechanisms 
include altered cellular metabolism. In H358-R cells, a general decrease in 
mTOR and PI3K pathway protein expression from RPPA data, coupled with 
raised AMPKA protein expression could indicate a switch from protein 
synthesis to autophagy (Figure 4.14). This observation is in agreement with 
other studies which have shown increased autophagy following KRAS 
suppression and inhibition in KRAS-mutant PDAC cells [355, 356].  
 
Overall it is uncertain whether these changes in RTKs, RASGEFs, cell cycle 
and DNA damage pathways are a cause or a consequence of developing 
resistance to KRAS inhibitors. Throughout RNAseq and RPPA analysis they 
demonstrated consistently altered expression. These processes are directly 
linked to the RAS pathway and are also previously associated with known 
resistance mechanisms. As a result, I can now test different compounds 
targeting these pathways as potential strategies for combination therapies 








































5.1 Introduction  
To overcome the identified resistance mechanisms associated with targeted 
KRAS therapeutics, the identification of effective drug combinations will be key 
to determining their full therapeutic potential. Combinatorial inhibitor strategies 
circumvent resistance mechanisms by co-inhibition of horizontal or vertical 
pathways in a synergistic or additive manner with the aim of increasing tumour 
cell killing and reducing adaptive signalling re-wiring within cancer cells, whilst 
minimising overlapping toxicity [166]. However, this strategy is hugely 
challenging, with relatively few drug combinations successfully making it 
through to the clinic. Several examples targeting the RAS pathway that have 
been FDA approved and are used clinically include the combination of 
dabrafenib (BRAFi) with trametinib (MEKi) for advanced BRAF-V600E 
mutated melanoma [357], and also encorafenib (BRAFi) plus cetuximab 
(EGFRi) for BRAF-V600E mutated CRC [358]. Furthermore a phase III trial 
investigating encorafenib, binimetinib and cetuximab in BRAF-mutated CRC 
shows promising results and improved overall survival (NCT02928224) [359].  
 
The results presented in chapter 4 from omics analysis, showed consistently 
upregulated expression of RTKs, RAS-GEFs, cell cycle and DNA damage 
pathways in cells resistant to KRAS inhibitors, and therefore it is anticipated 
that they will be sensitive to inhibitors targeting these pathways and signalling 
nodes (summarised in Table 5.1). Indeed, other studies investigating KRAS-
G12C inhibitor resistance have also identified this can be driven by feedback 
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activation from multiple RTKs and highlight that vertical pathway inhibition can 
enhance the efficacy of KRAS-G12C inhibitors [220]. In particular inhibition of 
SHP2 (SHP2i), an RTK-associated phosphatase, has shown promising 
potential as a combination strategy [220]. SHP2i prevented RAS pathway 
feedback reactivation from multiple RTKs following KRAS-G12C inhibition and 
enhanced KRAS-G12C inhibitor efficacy via increased KRAS-GDP occupancy 
[344]. Similarly, inhibition of SOS1 was found to synergise with KRAS-G12C 
inhibitors by disrupting RAS activation [345]. Other studies have highlighted 
that targeting parallel and downstream survival pathways such as CDK4/6 or 
PI3K pathways represents another effective combination strategy to enhance 
KRAS-G12C inhibitor efficacy [360, 361]. These combinatorial approaches 
increased the suppression of phospho-S6, a ribosomal protein downstream of 
mTORC1 which represents a good predictor of inhibition of cell viability [360-
362]. In preclinical KRAS-mutant colorectal cancer models the combination of 
CDK4/6 and MEK inhibition showed good efficacy [314], and several clinical 
trials are currently being undertaken with CDK4/6 inhibitors for KRAS-mutant 
NSCLC (NCT03170206, NCT02022982, NCT02152631). In another 
preclinical study, the addition of both mTOR and upstream IGF1R inhibitors 
alongside KRAS-G12C inhibition further enhanced the suppression of cell 
proliferation through strong inhibition of AKT, S6 and ERK signalling [363]. 
Clinical trials of KRAS-G12C inhibitors are currently ongoing, and additional 
clinical trials combining KRAS-G12C inhibitors with other targeted inhibitors 
and chemotherapeutic agents have already started (Table 5.2). Identifying the 
best combination partners to maximise the benefit of targeted KRAS inhibitors 
will be crucial for effectively treating KRAS-mutant tumours.  
 
Table 5.1: Potential inhibitors for combination with KRAS inhibitors. 
Inhibitor Target Type of inhibition Mechanism Ref. 
SHP099 SHP2 Allosteric inhibitor 
SHP099 binds to the N-terminus and C-terminus of 
SHP2, and its tyrosine phosphatase domains. [364] 
RMC-4550 SHP2 Allosteric inhibitor 
RMC-4550 inhibits the activity of full-length wild-type 
SHP2 enzyme activated by a di-phosphotyrosine 
peptide but lacks activity against the free catalytic 
domain of SHP2. 
[365] 





Binds to the catalytic domain of SOS1 and prevents 
the interaction with KRAS-GDP. [366] 
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Binds to EGFR kinase domain and prevents EGFR 
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Binds to EGFR/ERBB2 kinase domains and prevents 







Selective for PDGFR kinase domain and inhibits 


















Binds to kinase domain and prevents receptor 
autophosphorylation. [374] 




Inhibits multiple CDKs including CDK1, CDK2, CDK4, 
CDK6, CDK7 and CDK9. Binds to the ATP-binding site 
of CDKs and directly inhibits kinase activity. Causes 









Potent inhibitor of CDK1/2/9 kinase activity. [376] 




Potent and selective inhibitor for CDK1, CDK2, CDK5, 
CDK7 and CDK9. Competes at ATP binding site and 









Selective inhibitor of CDK4/6 with little or no activity 
against other CDKs. Competes at ATP binding site 









Selective inhibitor of CDK4/6 with little or no activity 
against other CDKs. Competes at ATP binding site 





PARP1/2 Competitive inhibitor 
Inhibition of PARP enzyme activity by competitive 
inhibition of the catalytic domain. PARP inhibitors 
prevent the release of PARP enzymes from damaged 
DNA leading to persistent single/double strand breaks 
and interference of DNA damage repair, thus 






Inhibition of PARP enzyme activity by competitive 
inhibition of the catalytic domain, resulting in inhibition 






Inhibition of PARP enzyme activity by competitive 
inhibition of the catalytic domain, resulting in inhibition 







Inhibition of ATM kinase activity and subsequent 
prevention of DNA damage checkpoint activation. 
Causes disruption to DNA damage repair and prevents 








Inhibits ATR kinase activity and prevents DNA repair 










Inhibitor of Wee1 kinase. Prevents the phosphorylation 







Binds to the FKBP12 receptor which directly interacts 
with mTORC1, and thus inhibits its downstream 
signalling. This results in dephosphorylation of S6K1 








Binds to and occupies the ATP binding site on both 







Inhibits both mTORC1 and mTORC2. Occupies the 
ATP binding site to prevent mTOR phosphorylation. [391] 
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Table 5.2: Current KRAS-G12C inhibitor clinical trials. 
Drug Company Phase Clinical Trial Cancer Combinations 
MRTX849 
(Adagrasib) Mirati 
Phase 2 NCT04613596 KRAS-G12C NSCLC 
Pembrolizumab 
(PD1) 
























































In order to identify translational opportunities to overcome drug resistance 
mechanisms associated with direct KRAS inhibitors, I aimed to identify 
inhibitor combinations that are effective alongside KRAS inhibitors. This will 
be the first study to compare inhibitor combinations alongside multiple types 
of KRAS inhibitor, as well as comparison across multiple resistant cells lines. 
Insights into potential resistance mechanisms highlighted from the omics data 
(see Chapter 4) revealed upregulation of several components of the RAS 
pathway and some wider cancer pathways. Following this, I have tested 
various compounds targeting these pathways and have utilised these in 
different inhibitor combinations. Comparison between different resistant 
phenotypes will elucidate altered sensitivity or resistance across different 
inhibitor combinations. Using this approach, I aimed to: 
• Identify combinations of inhibitors that re-sensitise KRASi-resistant 
cells 
• Compare the sensitivities of different resistant cells to combined 
inhibitors 
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• Determine whether these combinations delay or overcome resistance 




5.2.1 Cells resistant to KRAS inhibitors showed differential 
sensitivity to other targeted inhibitors 
 
To evaluate combination strategies, resistant cells were treated with inhibitors 
targeting pathways of previously identified resistance mechanisms (Chapter 
4). Alongside changes in cell confluency (Figure 5.1), proliferation and 
cytotoxicity were also monitored (Appendix 6 and 7). Treatment with different 
RTK inhibitors showed differential sensitivity across the different resistant 
cells. For example, ARS1620-treated resistant cells (R-ARS) retained 
sensitivity to EGFR and ERBB2 inhibitors (erlotinib, gefitinib, lapatinib and 
tucatinib) as well as IGFR/INSR inhibition (NVP-ADW742) (Figure 5.1A). This 
is consistent with my previous transcriptomic and proteomic results where 
upregulation of these receptors was observed (Chapter 4). In comparison both 
selumetinib-treated resistant cells (R-Sel) and AZD4785-treated resistant cells 
(R-ASO) showed increased resistance to these inhibitors. In contrast, R-ASO 
cells were more sensitive to FGFR inhibition using AZD4547. On the other 
hand, PDGFR inhibition (CP-673451 and crenolanib) had no effect on any 
resistant cells. This highlights different dependencies of RTK signalling across 
resistant cells treated with different KRAS inhibitors.  
 
To assess whether feedback from multiple RTKs could be inhibited, I 
evaluated the effect of SHP2 and KRAS-SOS1 inhibition across the resistant 
cells. SHP2 inhibition (SHP099 and RMC-4550) was most effective in R-ARS 
cells, demonstrating comparable sensitivity to control DMSO-treated cells (R-
DMSO) (Figure 5.1B). R-ARS cells also showed sensitivity to KRAS-SOS1 
inhibition using BAY-293. However, R-Sel and R-ASO resistant cells still 
exhibited increased resistance to these modes of inhibition.  
 
Cross-inhibition of resistant cells with the original KRAS and MEK inhibitors 
used in this study (ARS1620, AZD4785 and selumetinib) highlighted increased 
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resistance to alternative KRAS inhibition in all cells (Figure 5.1C). Despite this, 
R-ASO cells were particularly sensitive to MEK inhibition with selumetinib 
which was comparable to control cells.  
 
Comparison of different inhibitors targeting the cell cycle demonstrated that all 
resistant cells were sensitive to the broad CDK inhibitor flavopiridol, as well as 
some sensitivity to AZD5438 at higher concentrations targeting CDK1/2/9 
(Figure 5.1D). R-ARS cells also showed selective sensitivity to roscovitine, 
another broad CDK inhibitor targeting CDK1 and CDK2/5, whereas selective 
CDK4/6 inhibitors (palbociclib and ribociclib) had no effect on all resistant cells.  
 
Furthermore, PARP inhibition (olaparib, talazoparib and niraparib) which 
prevents the ability of cells to repair damaged DNA, also showed no effect in 
resistant cells (Figure 5.1E). Little effect on cell proliferation was also observed 
in R-DMSO cells suggesting a higher inhibitor concentration might be required. 
Resistance to the ATR inhibitor berzosertib was also observed, although 
interestingly R-ASO cells demonstrated increased sensitivity to the ATM 
inhibitor AZD0156, highlighting increased dependency on this DNA repair 
pathway. Furthermore, all resistant cells showed some sensitivity to the Wee1 
inhibitor adavorsertib, although at higher concentrations. 
 
All resistant cells were sensitive to the mTOR inhibitors sapanisertib and 
AZD8055, particularly R-ASO cells which also demonstrated sensitivity to the 
mTORC1 inhibitor everolimus even at low concentrations (Figure 5.1F). The 
differential responsiveness of R-ARS and R-Sel cells to mTOR and mTORC1 
inhibitors might suggest that these cells can still signal via mTORC2 when 
mTORC1 is inhibited.  
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Figure 5.1: Dose responses of combination therapeutics in resistant cells.  
Resistant H358 cell lines treated with ARS1620 (R-ARS), selumetinib (R-Sel) and AZD4785 
(R-ASO), alongside naïve parental H358 cells treated with DMSO (R-DMSO) were treated 
with their previous IC90 inhibitor treatments (ARS1620, Selumetinib, AZD4785 and DMSO 
respectively) in combination with dose responses of additional targeted inhibitors (see table 
5.1); (A) RTKi, (B) alternative RASi, (C) cross treatment with KRASi and MEKi, (D) CDKi, (E) 
DNA damage pathway inhibitors, (F) mTORi. The change in confluency was recorded 
following 4 days of inhibitor treatment. Graphs are presented as mean percentages of vehicle 
controls ±SEM from technical triplicates of one-three independent experiments. Figure 
continued on next three pages. 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.2: Sensitivity profile of resistant cells to combined targeted therapeutics. 
Resistant H358 cell lines treated with ARS1620 (R-ARS1620), selumetinib (R-Selumetinib) 
and AZD4785 (R-AZD4785), alongside naïve parental H358 cells treated with DMSO (R-
DMSO) were treated with their previous IC90 inhibitor treatments (ARS1620, Selumetinib, 
AZD4785 and DMSO respectively) in combination with dose responses of additional targeted 
inhibitors The change in cell confluency of resistant cells compared to naïve cells is presented 
by a symbol for each cell type. Blue represents increased inhibitor sensitivity, red represents 
decreased inhibitor sensitivity and black represents a similar inhibitor sensitivity observed for 
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These differential responses are also summarised in Figure 5.2 which 
highlights the various signalling pathways targeted in this combinatorial 
screen. Overall this figure highlights that in general cells resistant to direct 
KRAS inhibitors also exhibit resistance to a variety of other inhibitors targeting 
different nodes of these signalling pathways. Cells resistant to KRAS-G12C 
inhibition (R-ARS1620) are most sensitive to EGFR/ERBB2, SHP2 and KRAS-
SOS1 inhibition, indicating some reliance on the MAPK pathway for cell 
survival. Whereas cells resistant to KRAS mRNA depletion (R-AZD4785) 
demonstrate greater reliance on alternative pathways and were most 
susceptible to mTOR inhibition.  
 
5.2.2  Identifying effective triple inhibitor combinations  
 
After identifying differential sensitivities of my resistant cells to inhibitors 
targeting recognised resistance mechanisms, appropriate triple inhibitor 
combinations (RAS/MEK inhibitor plus two additional inhibitors) were identified 
in order to improve the efficacy of vertical or horizontal pathway inhibition. 
Using this combinatorial approach may not only help to delay the onset of 
resistance, but also enable lower doses of individual drugs to be used as a 
result of increased synergy between them. Combenefit software was used to 
visualise dose responses (Figure 5.3) and identify synergistic effects between 
inhibitor combinations [392] (Figure 5.4, Appendix 8).  
 
The dose response matrices of the triple inhibitor combinations highlight that 
in most cases better responses and reduced cell viability are observed in R-
DMSO cells that had not been previously treated with a RAS or MEK inhibitor 
(Figure 5.3). Moreover, some combinations show differential responses 
across the panel of resistant cells. For example, upstream EGFRi and SHP2i 
was most effective in R-ARS cells, whereas R-Sel cells were less responsive 
and R-ASO cells exhibited no change in cell viability (Figure 5.3A). A similar 
response was observed using lapatinib, a dual EGFR and ERBB2 inhibitor, 
with SHP2i (Figure 5.3C), as well as with NVP-ADW742, a dual IGFR1/INSR 
inhibitor, with SHP2i (Figure 5.3F). Interestingly the combination of RTK 
inhibition and SHP2i showed the most synergy in R-DMSO and R-Sel cells, 
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Figure 5.3: Dose response matrixes of triple combination therapeutics in resistant cells.   
Resistant cell lines treated with ARS1620 (R-ARS1620), selumetinib (R-Selumetinib) and 
AZD4785 (R-AZD4785) and naïve H358 cells (R-DMSO) were treated with their previous IC90 
inhibitor treatments (ARS1620, Selumetinib, AZD4785 and DMSO respectively) in 
combination with dose responses of two targeted inhibitors (A-G). The change in confluency 
was recorded following 4 days of inhibitor treatment and data are presented as mean 
percentages of vehicle controls from triplicate repeats of a single experiment. Figure continued 
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Figure 5.3: Dose response matrixes of triple combination therapeutics in resistant
cells
Resistant cell lines H358-R ARS1620 (R-ARS), H358-R Selumetinib (R-Sel) and H358-R
ASO (R-ASO) and naïve H358-R cells (R-DMSO) were treate with their previous IC90
inhibitor treatments (ARS1620, Selumetinib, ASO and DMSO respectively) in combination
with dose responses of two targeted inhibitors. The change in confluency was recorded
following 4 days of inhibitor treatment and data are presented as mean percentages of vehicle
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albeit at higher concentrations (Figure 5.4A,C and F). 
 
On the other hand, substitution of SHP2i with mTORi in combination with 
upstream RTK inhibitors was more effective at reducing cell viability across all 
resistant cells (Figure 5.3B and D), although these combinations showed less 
synergy overall (Figure 5.4). Furthermore, substitution with the CDK inhibitor 
flavopiridol was also most effective in R-ARS cells, whereas the addition of 
lapatinib in this combination had no additional benefit in both R-Sel and R-
ASO cells (Figure 5.3E). Finally, the combination of FGFRi and MEKi, using  
AZD4547 and selumetinib, both of which previously showed selective 
effectiveness in R-ASO cells (Figure 5.1A and C), further reduced cell viability 
with highly synergistic effect (Figure 5.3G and 5.4G). Though interestingly the 
effect on cell viability of this combination was still less than other inhibitors 
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Figure 5.4: Synergy vs dose response matrixes of triple combination therapeutics in resistant cells.  
Synergy scores from double inhibitor combination assays were calculated using the Loewe model and plotted against dose responses (% viability) using 
Combenefit software [392]. Areas coloured blue indicate drug combinations that are synergistic. Figure continued on the next two pages.
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Figure 5.4: Synergy v dose response matrixes of triple combination therapeutics in
resistant cells
Synergy scores were plotted against dose responses from double inhibitor combination
assays using Combenefit software [39]. Areas coloured blue indicate drug combinations that
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Table 5.3: Triple combination inhibitor combinations. 
Set Inhibitors 
Cells 
R-DMSO R-ARS1620 R-Selumetinib R-AZD4785 
1 
RAS/MEKi IC90 DMSO IC90 ARS1620 IC90 Selumetinib IC90 AZD4587 
Gefitinib (nM) 50 250 250 250 
RMC-4550 (nM) 10 10 250 250 
2 
RAS/MEKi IC90 DMSO IC90 ARS1620 IC90 Selumetinib IC90 AZD4587 
Gefitinib (nM) 50 50 50 50 
AZD8055 (nM) 50 50 50 50 
3 
RAS/MEKi IC90 DMSO IC90 ARS1620 IC90 Selumetinib IC90 AZD4587 
Lapatinib (nM) 50 50 250 50 
RMC-4550 (nM) 50 50 250 50 
4 
RAS/MEKi IC90 DMSO IC90 ARS1620 IC90 Selumetinib IC90 AZD4587 
Lapatinib (nM) 10 10 10 10 
AZD8055 (nM) 10 10 10 10 
5 
RAS/MEKi IC90 DMSO IC90 ARS1620 IC90 Selumetinib IC90 AZD4587 
Lapatinib (nM) 50 50 50 50 
Flavopiridol (nM) 50 50 50 50 
6 
RAS/MEKi IC90 DMSO IC90 ARS1620 IC90 Selumetinib IC90 AZD4587 
NVP-ADW742 
(nM) 
250 50 250 50 
RMC-4550 (nM) 50 50 250 50 
7 
RAS/MEKi IC90 DMSO - - IC90 AZD4587 
AZD4547 (nM) 250 - - 50 
Selumetinib (nM) 10 - - 50 
 
Following inhibitor combination screening in H358-R cells, the most synergistic 
drug concentrations were determined for each set of inhibitor combinations 
(see Table 5.3). Where inhibitor concentrations resulted in a similar reduction 
of cell viability, the lower inhibitor concentration was chosen in order to 
minimise potential off-target toxicity issues. 
 
Using these synergistic inhibitor concentrations, the expression of 
downstream RAS signalling components was monitored over time in order to 
determine whether inhibitor combinations improved the inhibition of signalling 
pathways compared to monotherapy treatments (Figure 5.5). A comparison of 
vertical and horizontal combination strategies was performed using EGFRi 
with either SHP2i or mTORi across the panel of resistant cells.  
 
In DMSO-treated cells, no changes in pEGFR levels occurred with any of the 
monotherapy or combination treatments (Figure 5.5A). Inhibition of mTOR with  
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Figure 5.5: Changes in signalling pathways following vertical or horizontal inhibitor 
combination treatment in H358-R cells.  
H358-R cells were treated with IC90 concentrations of each inhibitor or control (A) DMSO, (B) 
ARS1620, (C) selumetinib and (D) AZD4785. Cells were also treated with the indicated 
inhibitor combinations for up to 7 days with cells re-dosed every 48 hours. Cell lysates were 
prepared at the indicated time points and RAS pathway components were analysed by 
immunoblotting. Lysates from H358-R (R) cells were carried out alongside. Results are from 
a single experiment. 
 
 
AZD8055 as both a monotherapy and combination with EGFRi initially 
decreased pAKT levels, although this was shown to rebound within 48 hours 
to 7 days. This was accompanied with a compensatory increase in pERK. On 
the other hand, following longer 7-day EGFRi and SHP2i monotherapy and 
combination treatments, a slight decrease in pERK was observed. Overall it 
was surprising that there was no complete loss of these downstream signalling 
pathways correlating to the decreased cell viability previously seen with these 
inhibitor treatments (Figure 5.1 and 5.3).  
 
In ARS1620-treated resistant cells, the combination of EGFRi and mTORi 
reduced pAKT compared to either monotherapy (Figure 5.5B). In addition, 
pERK was initially reduced following EGFRi and SHP2i, however with both 
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horizontal inhibition with EGFRi and mTORi demonstrated reduction of both 
pAKT and pERK signalling pathways, corresponding to the greater loss of cell 
viability previously observed with this treatment (Figure 5.3B).  
 
In comparison, in selumetinib-treated resistant cells, mTOR inhibitor treatment 
only initially decreased pAKT, which rebounded within 48 hours (Figure 5.5C). 
EGFRi and SHP2i also appeared to increase pAKT(S473) levels over time, 
highlighting greater reliance on this pathway under these conditions. On the 
other hand, pERK was reduced the most under the highly synergistic EGFRi 
and SHP2i combination.  
 
Finally, with AZD4785-treated resistant cells, no clear changes in pERK and 
pAKT protein levels were observed following EGFRi and SHP2i monotherapy 
or combination therapy (Figure 5.5D), which reflects the high cell viability 
previously observed with these treatments and resistance to vertical inhibition 
(Figure 5.3A). mTORi only initially reduced pAKT protein levels which also 
rebounded within 48 hours and was accompanied by slightly increased pERK.  
 
Overall these results highlight the reactivation of compensatory signalling 
mechanisms that arise with both horizontal and vertical inhibition mechanisms. 
Despite using the lowest inhibitor concentrations that exhibited good synergy 
and loss of cell viability, increasing inhibitor concentrations may help to 
improve inhibition of some downstream signalling pathways and further delay 
or reverse resistance developing.   
 
 
5.2.3 Combinations with RAS/MEK inhibitors prevent or delay 
resistance in H358 cells 
 
The synergistic inhibitor combinations were also used to treat naïve H358 cells 
in order to determine whether the onset of resistance to RAS or MEK inhibitors 
could be delayed or prevented (Figure 5.6). The majority of inhibitor 
combinations only marginally delayed the growth of H358 cells compared to 
the DMSO only control (Figure 5.6A). On the other hand, with the addition of 
ARS1620 (Figure 5.6B), cell confluency remained low with most of the inhibitor  




Figure 5.6: Triple inhibitor combinations in naïve H358 cells.  
H358 cells were seeded at 1000 cells per well in a 96-well TC treated plate and treated with 
IC90 concentrations of (A) DMSO, (B) ARS1620, (C) selumetinib, (D) AZD4785, plus 
synergistic concentrations (see table 5.2) of additional inhibitor combinations. Cells were re-
treated every 5 days and the change in confluency was recorded every 6 hours for 15 days. 
Inhibitors used; gefitinib (EGFRi), RMC-4550 (SHP2i), AZD8055 (mTORi), lapatinib 
(EGFR/ERBB2i), flavopiridol (CDKi), NVP-ADW742 (IGFR/INSRi), AZD4547 (FGFRi) and 
selumetinib (MEKi). Data are from triplicate repeats of four independent experiments. 
 
combinations. This highlights that despite the fact that resistance does 
develop to KRAS-G12C inhibitor monotherapy, the addition of a KRAS-G12C 
inhibitor in a combinatorial approach can dramatically reduce cell growth and 
therefore help delay or prevent the onset of resistance in KRAS-G12C mutant 
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cells. This trend was also observed with cells treated with selumetinib (Figure 
5.6C). 
 
Surprisingly in all of these conditions, the horizontal combination strategy of 
lapatinib and AZD8055 (EGFR/ERBB2i + mTORi) was the least effective 
combination overall, whereas previously in resistant cells this combination was 
effective in all resistant cells (Figure 5.3D). This could be due to the lower 
synergistic inhibitor concentrations used in this combination, or because the 
inhibitory interplay only becomes important once resistance rewiring has 
already occurred. In cells treated with selumetinib, gefitinib and AZD8055 
(EGFRi + mTORi) treatment also demonstrated reduced efficacy over time, 
whereas corresponding RTK inhibitors with SHP2i were more effective at 
delaying cell growth, indicating that these cells are more sensitive to vertical 
RAS pathway inhibitor combinations. In contrast, cells treated with AZD4785 
inhibitor combinations demonstrated mixed responses and reduced sensitivity 
to certain combinations according to the RTK inhibitor used (Figure 5.6D). 
Furthermore, it is apparent that it also takes longer for resistance to develop 
in these cells. In naïve H358 cells, targeting IGFR/INSR, FGFR1 and ERBB2 
receptors appeared to be less effective than combinations with EGFR 
inhibition. This further highlights how these cells are differentially wired 
compared to chronic resistant cells which have become KRAS independent, 
and therefore the combinations based on overcoming this resistance are not 
as effective in naïve cells compared to those which have acquired sensitivity 
to these additional inhibitors. Overall, across all combinations, the use of a 
broad CDK inhibitor appeared to be the most effective at preventing any further 
cell growth regardless of the other inhibitors used in the combination. It 
appears the cells are killed before any resistance to other inhibitors can be 




In this chapter I have identified various KRAS inhibitor combinations which 
show increased efficacy in both naïve and resistant KRAS-mutant lung cancer 
cells. From initial compound screening, several inhibitors were identified that 
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re-sensitised different KRASi-resistant cells resulting in decreased cell viability 
(Figure 5.1). Interestingly RTK inhibitors demonstrated the most variable 
responses across the panel of resistant cells. For example, cells resistant to 
ARS1620 were most sensitive to gefitinib, lapatinib and NVP-ADW742, 
targeting the EGFR, ERBB2 and IGFR/INSR receptors which is consistent to 
my transcriptomic and proteomic data where I observed upregulation of these 
receptors in these cells (Figure 5.1A, 4.12, 4.14 and 4.15). Alternatively the 
increased resistance of long-term selumetinib-treated cells to RTK inhibitors 
could be due to increased dependence upon RAF or amplification of RAS 
signalling as a potential mechanism of resistance [242]. AZD4785-treated 
resistant cells showed the most resistance to these inhibitors, further 
confirming reliance upon alternative RTKs and pathway signalling for cell 
survival. Unlike ARS1620- or selumetinib-treated resistant cells, these cells 
were instead uniquely sensitive to FGFRi. Furthermore, cross inhibition of 
resistant cells with ARS1620, selumetinib and AZD4785 highlights the KRAS-
independent state of ARS1620- and AZD4785-treated resistant cells (Figure 
5.1C). The fact that AZD4785-treated resistant cells also uniquely exhibited 
some sensitivity to selumetinib could be attributed to the loss of KRAS-WT 
with this inhibitor, which has been shown to increase sensitivity to MEKi 
through disruption of KRAS-mutant and KRAS-WT dimerisation [393, 394]. 
Other interesting combination strategies identified from the initial compound 
screen include SHP2 and mTOR inhibitors (Figure 5.1B and F), which have 
shown previous efficacy as potential combination strategies to overcome 
KRAS-G12C inhibitor resistance [219, 220, 344, 363] and are currently 
undergoing clinical evaluation (Table 5.2). mTORi was effective across all 
resistant cells, indicating greater reliance upon the PI3K pathway for cell 
survival as a common resistance mechanism.  
 
Unexpectedly KRAS-SOS1 inhibitors (BAY-293 and BI-3406) were not as 
effective as expected from previous studies in KRAS-mutant NSCLC cells 
[345]. SOS1 is not the only RAS-GEF known to activate RAS and a loss of 
SOS1 gene expression was observed in all chronically treated H358-R cells, 
coupled with up-regulation of some alternative RAS-GEFs such as RAS-
GRP2/4 and RAS-GRF1/2 (Figure 4.12). This suggests potential involvement 
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of these alternative RAS-GEFs in chronically treated resistant cells. In 
addition, surprisingly there was a lack of sensitivity to several DNA damage 
pathway inhibitors, particularly PARP inhibitors in H358-R cells (Figure 5.1E). 
A previous study using similar drug concentration ranges also observed 
KRAS-mutant cell lines exhibited resistance to PARPi, yet were sensitive to 
combined PARPi and MEKi which induced greater DNA damage and 
apoptosis [395]. The lack of efficacy of PARPi monotherapy could be a result 
of restored homologous recombination and reliance upon alternative DNA 
repair pathways and cell cycle regulators in resistant cells treated with KRAS 
inhibitors [396]. Interestingly AZD4785-treated resistant cells demonstrated 
sensitivity to ATM inhibition, indicating reliance upon homologous 
recombination. Reduced cell viability was also observed with Wee1 inhibition 
(adavosertib) across all resistant cells. Inhibition of Wee1 blocks DNA 
damage-induced inhibitory phosphorylation of CDK1 and CDK2, and therefore 
compromises cell-cycle checkpoint function which can promote cell death 
during mitosis [397]. Cells with loss of p53 function, such as H358 cells, are 
particularly sensitive to this mechanism of synthetic lethality [398].  
 
Furthermore all H358-R cells showed resistance to CDK4/6 inhibitors (Figure 
5.1D), previously identified as potentially effective combination strategies in 
KRAS-mutant NSCLC from synthetic lethal screens [360, 399]. Despite this, 
results from the JUNIPER clinical trial of CDK4/6 inhibition as a monotherapy 
in KRAS-mutant NSCLC were not encouraging [400]. The resistance to 
CDK4/6 inhibitors observed in H358-R cells could be a result of cyclin E or 
E2F transcription factor upregulation (Figure 4.17), which could represent a 
mechanism to overcome CDK4/6 inhibition [401]. Alternatively, the broad CDK 
inhibitor flavopiridol demonstrated much greater efficacy and loss of cell 
viability. Flavopiridol is a first generation pan-CDK inhibitor, yet despite 
demonstrating significant anti-tumour activity in other preclinical studies [402, 
403], clinical studies reported insufficient efficacy for solid cancers at well 
tolerated concentrations with monotherapy treatment [404, 405]. Flavopiridol 
has since been evaluated as a combinatorial approach alongside other 
chemotherapies which has showed more promising results [406, 407]. Overall 
as well as identifying inhibitors which show efficacy in resistant cells, this 
Combination therapeutics for KRAS inhibitors  
 
150 
combinatorial screening has also identified ways in which initial KRAS or MEK 
inhibitor treatments can make the cells become more resistant to other types 
of inhibitors to which they would otherwise be sensitive.  
 
From this initial combinational screening in resistant cells, certain combination 
strategies were investigated further to determine whether combining two of 
these inhibitors, alongside the initial RAS or MEK inhibitor, could improve 
efficacy and delay or overcome resistance. Combinations using several RTKi 
that demonstrated initial effectiveness were combined with either SHP2 or 
mTOR inhibitors to compare vertical or horizontal signalling pathway inhibition 
strategies (Figure 5.3). Given the differential sensitivities to some RTK 
inhibitors, targeting SHP2 in combination could further prevent upstream 
signalling from multiple RTKs and supress feedback activation of the RAS 
pathway, whereas targeting mTOR would help to block alternative signalling 
from the PI3K pathway. In preclinical mouse studies targeting both MAPK and 
PI3K pathways showed efficacy in KRAS-mutant tumours [193]. For 
AZD4785-treated resistant cells, an additional combination using FGFRi with 
MEKi was also carried out, as these cells demonstrated unique sensitivity to 
both of these inhibitors.  
 
Overall the panel of resistant cells showed mixed responses to vertical and 
horizontal inhibition. For ARS1620-treated resistant cells, both strategies 
worked well to effectively reduce cell viability, regardless of targeting different 
RTKs (Figure 5.3). Downstream pERK and pAKT expression was also 
reduced following EGFRi with SHP2i or mTORi (Figure 5.5B). Previous 
studies have also independently identified that both vertical and horizontal 
inhibition strategies in combination with KRAS-G12C inhibitors are effective 
and help prevent resistance [220, 361, 363]. It will be interesting to see how 
well these combinations succeed in the ongoing clinical trial (NCT04185883). 
For selumetinib-treated resistant cells, increased sensitivity and synergy was 
observed with EGFR and SHP2 inhibitor combinations compared to targeting 
other RTKs with SHP2i (Figure 5.3 and 5.4). With this combination pERK 
expression was also reduced (Figure 5.5C), highlighting increased reliance 
upon MAPK vertical pathway signalling, which could be driven by pathway 
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feedback activation. On the other hand, AZD4785-treated resistant cells 
demonstrated resistance to EGFRi and SHP2i vertical combinations. 
Interestingly it has been identified that FGFR-dependent cells are often 
insensitive to SHP2i compared to EGFR-dependent cells [408]. Furthermore 
signalling from FGFR has been found to drive feedback-induced activation of 
RAS independently of SHP2 in a subset of BRAF-mutant tumours resistant to 
ERK and SHP2 inhibition [164]. Interestingly resistant cells treated with 
AZD4785 demonstrated increased sensitivity to the combination of FGFR1 
and MEK inhibition (Figure 5.3G). The high synergy observed with FGFR and 
MEK inhibitor combinations in these cells (Figure 5.4) could also be attributed 
to their more mesenchymal phenotype which has been previously attributed 
with high FGFR1 expression and reduced ERBB family expression following 
EMT induction [258]. This is also consistent with my earlier observations 
(Figure 4.15 and 4.18).  
 
Treatment with the same inhibitor combinations in naïve H358 cells revealed 
that some combinations were more effective at reducing cell proliferation over 
a longer time course than others, particularly vertical inhibitor combinations 
containing SHP2i alongside KRAS-G12C and MEK inhibitors (Figure 5.6). On 
the other hand, some combinations that were previously effective in resistant 
cells were not as effective in naïve H358 cells, such as EGFR/ERBB2i plus 
mTORi for combinations with KRAS-G12C and MEK inhibitors, and alternative 
RTKi for AZD4785 combinations, indicating that adaptive signal rewiring may 
not yet have occurred. This therefore implies that targeting multiple nodes of 
the MAPK pathway could be more effective for cells still dependent upon 
KRAS signalling [409, 410].  
 
As identified earlier, use of a broad CDK inhibitor flavopiridol proved to 
completely prevent cell proliferation and resistance developing in naïve H358 
cells, irrelevant of the inhibitor combination. This represents a highly promising 
therapeutic strategy for the treatment of KRAS-mutant cancers and further 
investigation into the clinical validity of flavopiridol to improve patient outcomes 
and reduce tumour growth is required. Despite other studies demonstrating 
flavopiridol-mediated cytotoxicity in KRAS-mutant NSCLC cell lines [402, 403], 
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the results presented here demonstrate sustained prevention of cell 
proliferation over a greater period of time and at much lower drug 
concentrations. Flavopiridol is still undergoing clinical evaluation for various 
cancer types, including NSCLC, though there remain some concerns over 
drug-related toxicity  [405, 411]. Results from this study suggest further 
investigation into the effectiveness of alternative targeted CDK inhibitors, 
particularly the additional targets of flavopiridol besides CDK4/6. Research 
into the pharmacology of flavopiridol identified that it appeared to exert its 
pharmacological effect through its ability to potently inhibit CDK9 [412]. CDK9 
plays a key role in the regulation of basal gene transcription and its ability to 
maintain levels of the anti-apoptotic protein MCL1 is considered to promote 
cancer cell survival [413, 414]. This important function coupled with the 
dysregulated transcriptional programs associated with tumours, have made 
CDK9 an attractive therapeutic target [415].  Subsequently there has been 
particular interest to develop more specific targeted CDK9 inhibitors for 
improving targeted therapeutic strategies with reduced overall toxicity [414, 
416]. With this in mind, combinations used in this study which include multiple 
specifically targeted inhibitors are currently favoured as more clinically 
relevant approaches, due to their synergistic potential to reduce potential 
toxicity issues and ability to target multiple signalling nodes.  
 
Based on this current data, a combination of EGFR and mTOR inhibition would 
be most recommended to re-sensitise acquired resistance to KRAS-G12Ci. 
This combination is associated with strongly decreased cell viability coupled 
with loss of both pERK and pAKT signalling pathways in ARS1620-treated 
resistant cells (Figures 5.3, 5.5). This approach also appears effective in 
combination with KRAS-G12C inhibitors to delay the onset of resistance 
initially developing in naïve cells (Figure 5.6). Moreover KRAS-G12C 
combinations with EGFRi and SHP2i are equally effective at slowing the 
emergence of resistance. Evaluating the combination strategies for AZD4785-
treated resistant cells also provides potential insight into effective strategies 
relevant for future pan-KRAS inhibitors [417]. To re-sensitise acquired 
resistance to this mechanism of KRAS inhibition, where both WT and mutant 
RAS signalling is targeted and the cells have become KRAS independent, 
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combinations with mTORi are most effective and reduced pAKT signalling 
(Figures 5.3 and 5.5). Additionally, FGFR and MEK inhibition are also 
recommended as alternative strategies that reduce cell viability and exhibit 
high synergy (Figure 5.3 and 5.4), though how this combination affects 
downstream signalling remains to be determined. However, to slow resistance 
from developing to pan-KRAS approaches in naïve cells, alternative 
combination approaches utilising EGFRi with either mTORi or SHP2i are still 
most effective.  
 
One of the biggest challenges in developing combination therapies of targeted 
inhibitors is minimising overlapping toxicities. There are limitations of 2D-
based in-vitro studies when it comes to extrapolating to potential clinical 
studies. The potential toxicities of drug combinations can be uncertain and 
misrepresented in preclinical cell-based work. Additional complexities from 
interactions with the tumour microenvironment, underlying tumour 
heterogeneity and differences in cell morphology are not accounted for. Future 
studies will need to confirm the tolerability and toxicity profiles of these 
combination strategies to determine their clinical potential. To more accurately 
reflect in-vivo therapeutic responses, these combinations should be assessed 
in more complex 3D cell models, including patient-derived organoids and 
xenografts (PDXs) [294, 418-422]. Furthermore, pre-existing tumour 
heterogeneity within in-vivo studies can help to identify intrinsic mechanisms 
of resistance giving rise to subpopulations of cells which are resistant to 
selected targeted inhibition. Currently there is little evidence on what de novo 
mutations may arise with KRAS inhibitor treatment, and therefore it would also 
be useful to identify any potential genetic alterations or secondary mutations 
that may occur following treatment.  
 
To summarise, drug resistance remains one of the greatest challenges in 
cancer therapy. As observed in this study, generally cells become increasingly 
resistant to multiple therapies and over time fewer treatments are effective. In 
order to pre-empt or overcome resistance, a greater understanding of these 
biological processes are required to anticipate how cancer cells will evolve so 
that weakness in the cells can be subsequently targeted. If it was possible to 
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completely prevent resistance, then all cancerous cells would need to be killed 
to prevent the outgrowth of new resistant clones, despite underlying tumour 
heterogeneity and cancer stem cell populations. Consequently, in patients, 
almost inevitably a subset of cells will develop alternative survival mechanisms 
and resist current therapy. Instead, strategies utilising cocktails of inhibitor 
combinations, with different mechanisms of action and targeting multiple 
signalling nodes, can make multi-drug resistance more difficult to be selected 
for. Exhausting potential evasion mechanisms, giving the cells no time to 
evolve can therefore help to improve patient outcomes and progression free 
survival [423]. The overall goal of this approach is to maximise synergistic 
effects in order to minimise overlapping toxicity. However due to underlying 
heterogeneity and complexity of tumour evolution, identifying how cancers will 
evolve and the best combination strategy to overcome drug resistance is 
challenging. Treatment outcomes also depend upon the maximum toxicity 
tolerance of patients and their unique resistance profile of tumours. Due to 
individual differences in mutations of cancer genes, some treatments might 
not be effective as a general strategy, warranting more personalised 
approaches.  
 
The multiple comparisons of inhibitor combinations, encompassing different 
KRAS inhibitors and resistant cells, performed in this study provides novel 
insights into effective strategies that may help to overcome acquired 
resistance to direct KRAS and MEK inhibitors in KRAS-mutant NSCLC. 
Combinations of EGFR and mTOR inhibition appear most effective at re-
sensitising acquired resistance to KRAS-G12C inhibitors, whilst both EGFR 
and mTOR/SHP2 inhibition are effective alongside KRAS inhibitors to delay 
initial resistance developing. These combinations are currently being clinically 
investigated in phase II clinical trials. Overall their potential clinical success 
will ultimately depend upon their ability to block RAS pathway and adaptive 
pathway signalling, whilst limiting the additive toxicity of combining multiple 
inhibitors. 













KRAS is one of the most frequently mutated oncogenes in cancer and its 
mutational activation plays a crucial role in cancer cell survival and 
proliferation. The recent breakthrough development of selective KRAS-G12C 
inhibitors provides significant promise to transform the treatment landscape of 
KRAS-mutant tumours and two inhibitors, sotorasib (previously known as 
AMG-510) and  adagrasib (previously known as MRTX849) have already 
advanced to FDA approval following positive phase 2 clinical trial results 
(NCT03600883, NCT03785249). Sotorasib is the first KRAS-G12C inhibitor to 
be clinically approved for locally advanced or metastatic NSCLC where 
patients have previously received at least one other cancer treatment. 
Accelerated approval was based on the encouraging results from the 
CodeBreak 100 multicentre clinical trial (NCT03600883), in which treatment 
with sotorasib shrank the tumours of 36% of NSCLC patients and showed a 
median overall response of 11 months [424]. The CodeBreak clinical 
development program was designed to address the longstanding unmet 
medical need to treat advanced KRAS-G12C mutant solid tumours, and since 
starting, trials so far have enrolled more than 500 patients across 13 tumour 
types. Continued approval of sotorasib is contingent upon verification of 
clinical benefit from further trials, including a phase 3 CodeBreak 200 trial for 
NSCLC (NCT04303780), and several phase 1b combination trials in KRAS-
mutant solid tumours (NCT04185883). Despite these encouraging results, 
there are also indications of varying responses among patients, with 50% of 
NSCLC and only 10% of CRC patients responsive to AMG-510 during the 
initial phase 1 trial (NCT03600883) [425]. The development of acquired drug 
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resistance is a major obstacle that frequently occurs with other targeted cancer 
therapies and the findings from early phase clinical trials suggests that 
acquired resistance will also limit the efficacy of these KRAS inhibitors [208, 
219]. Therefore, the focus of this research project has been to increase our 
understanding of acquired resistance mechanisms associated with KRAS 
inhibitors, which is crucial for improving treatment options, patient stratification 
and identifying suitable combination strategies that can achieve a more 
durable treatment response. In this chapter, the findings of this research are 
summarised, along with discussion of their wider implications and potential 
future directions.  
 
6.1  Mechanisms of resistance to KRAS inhibitors in 
KRAS-mutant cells 
 
In this study, initial validation of several KRAS inhibitors in a panel of NSCLC 
cell lines was performed to determine their sensitivity and specificity (see 
chapter 3). Three direct KRAS inhibitors, AZ6813, ARS1620 and AZD4785, 
alongside the MEK inhibitor selumetinib were selected to generate resistant 
cells. At the time of this study starting, AZ6813 and ARS1620 were the only 
KRAS-G12C inhibitors readily available. This is the first study to date, to create 
a panel of resistant cell lines from different KRAS inhibitors, across both acute 
and chronic treatment regimes, enabling multiple comparisons of acquired 
resistance mechanisms to be performed. Monitoring of RAS pathway 
signalling showed that pathway reactivation of downstream signalling 
components occurred within days of treatment with high doses of targeted 
KRAS and MEK inhibitors, and resistant H358 cells exhibited permanent 
pathway rewiring. The reactivation of p-ERK1/2 and p-AKT under KRAS 
inhibition highlights the continual dependence of resistant cells on these 
pathways to maintain cell survival. Similar p-ERK1/2 pathway reactivation has 
since been observed following 48hr treatment with MRTX849 and ARS1620 
in other KRAS-G12C cell lines, including colon and pancreatic cells [219, 220]. 
This highlighted that direct KRAS inhibitors may not be clinically effective long-
term as single agent therapeutics and ultimately resistance to these inhibitors 
enables tumour growth.  
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Previous studies with other MAPK pathway inhibitors provided some 
understanding of the potential mechanisms of resistance that might also be 
observed with KRAS inhibitors (discussed in section 1.4). However, it 
remained unclear whether these mechanisms would be similar across different 
approaches of KRAS inhibition or change over the duration of treatment. In-
depth analysis was performed using RNA-seq and RPPA, which revealed 
genome-wide changes in gene and protein expression with different KRAS 
inhibitors across acute and chronic treatment regimens (see chapter 4). 
Comparisons across these different resistant models gave additional insights 
into generic and unique resistance mechanisms. Overall consistent up-
regulation of RTKs, RAS-GEFs and downstream cell cycle and DNA damage 
repair pathways were observed across both KRAS and MEK inhibition, 
indicating reliance on similar cell signalling pathways and processes for cell 
survival. The observation that multiple RTKs can drive pathway reactivation 
indicated that co-targeting with a single RTK inhibitor may be ineffective at 
preventing adaptive resistance (Figures 4.12 and 4.15). These findings were 
consistent with observations made by other groups working with KRAS-G12C 
inhibitors across NSCLC, pancreatic and colon KRAS-G12C cell lines [219, 
220]. Furthermore, distinct differences were also observed across acute and 
chronic treatments, indicating reliance on RTKs can alter over time. For 
example, acute treatment with KRAS or MEK inhibitors showed up-regulation 
of ERBB2, which was maintained in chronic resistant cells, with the exception 
of AZD4785-treated resistant cells (Figure 4.15). In these cells, loss of ERBB2 
expression was coupled with increased expression of alternative FGFR1 and 
PDGFRb receptors, which were not observed with other KRAS inhibitors. This 
highlighted that chronically targeting KRAS by different approaches can result 
in dependence of alternative RTKs.  
 
Another interesting observation was the increase in HRAS gene and protein 
expression coupled with the loss of KRAS expression and activity in AZD4785-
treated resistant cells, suggesting a loss of KRAS dependency for cell survival 
and proliferation (Figures 4.12 and 4.16). These results suggest that these 
cells activate other wildtype RAS isoforms to restore MAPK signalling as a 
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result of increased upstream RTK signalling. Alternatively, cells resistant to 
KRAS-G12C inhibition regained KRAS activity. This finding was also 
consistent with observations by other groups, whereby RAS pathway 
reactivation following KRAS-G12C inhibition was mediated via wildtype RAS 
[220]. Other groups have also found that acquired resistance to KRAS-G12Ci 
was dependent upon newly synthesised KRAS-G12C to regain KRAS activity 
[346]. It remains unclear which process acquired resistance is mediated 
through across the different KRAS inhibitory mechanisms. To follow this up, 
additional studies should be performed using protein standard absolute 
quantification and digital-droplet PCR to more accurate quantify changes in 
RAS isoform abundance or RAS mutant allele frequency [426, 427]. Clarifying 
this mechanism would help to provide additional understanding of resistance 
between generic and allele specific KRAS inhibitors. This could also provide 
clarification for utilisation of suitable pan-RAS combination approaches, such 
as targeting SOS1-GRB2 which is currently under clinical evaluation 
(NCT04111458). An additional consideration observed from this study is that 
despite being initially upregulated, following chronic KRASi SOS1/2 gene 
expression became downregulated and coupled with upregulation of 
alternative RAS-GEFs. As a result, targeting this single interaction may not be 
enough to prevent RAS activation long-term and overcome acquired 
resistance. In addition, it remains to be investigated whether alternative KRAS 
mutations could be selected for and promote resistance to KRAS-G12C 
inhibitors. Further genomic sequencing with sufficient depth to identify 
emergent mutations should also be performed.  Overall increasing our 
understanding of the development of drug resistance mechanisms can enable 
innovative treatment options with improved longer-lasting benefits to patients.  
 
6.2  Therapeutic combination strategies to delay or 
overcome acquired resistance to KRAS inhibitors  
 
Analysis of 25 targeted inhibitors against pathways of the recognised 
resistance mechanisms, identified 15 inhibitors which mitigated resistance to 
KRASi (see chapter 5). Of these, only 3 inhibitors, the broad CDK inhibitor 
flavopiridol and two mTOR inhibitors AZD8055 and sapanisertib, were 
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effective across all resistant cell lines. As such prior resistance to KRASi or 
MEKi can cause cells to become resistant to a range of other targeted 
inhibitors, both uniquely or collectively, including several RTK, DNA damage 
pathway and CDK inhibitors. Vertical and horizontal inhibitor combinations 
demonstrated mixed responses across resistant cells. EGFRi with mTORi 
were particularly effective at re-sensitising acquired resistance to KRAS-
G12Ci, which strongly decreased cell viability and downstream pERK and 
pAKT signalling pathways. On the other hand, mTORi, or alternatively FGFRi 
and MEKi were effective strategies to re-sensitise resistance that developed 
to pan-KRASi using AZD4785.  
 
Further investigation into multiple inhibitor combinations in naïve parental cells 
confirmed that to maximise the therapeutic potential of various KRAS 
inhibitors, co-inhibition with other targeted agents is required to overcome 
acquired resistance. Despite emerging resistance, the addition of a KRAS 
inhibitor was beneficial in a multi-combinational approach and dramatically 
delayed and prevented KRAS-mutant cancer cell growth. All 7 inhibitor 
combinations slowed the emergence of resistance, with EGFRi and mTORi or 
SHP2i being particularly effective in combination with all KRAS inhibitors. Due 
to this multi-targeted approach, in particular the specificity that allele specific 
KRAS inhibitors provide for targeting mutant KRAS, it is hoped that such 
combinations used at lower doses may be better tolerated in patients. 
Flavopiridol, a broad CDK inhibitor was also effective at preventing cell growth 
and resistance, however due to its ability to inhibit multiple CDKs, there are 
concerns over its potential clinical applications which instead warrants further 
investigation into additional targeted CDK inhibitors.    
 
Due to the limitations of 2D cell lines to accurately represent clinical 
responses, future work should build on these findings to validate these 
therapeutic combinations in advanced preclinical models. For example 3D 
cell-cultures and tumour-derived organoids enable differences in KRAS 
dependency, tumour microenvironment and heterogeneity to be accounted 
for, which can influence the extent of drug responses [428]. KRAS-mutant 
tumours are also complicated by a diversity of differential effector engagement 
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across cell lines and tissues [429]. A recent phosphoproteomics study also 
identified cell-type adaptive responses to KRAS-G12Ci according to the cell-
type EMT status, which were associated with different protein signalling 
responses [430]. This could have implications for driving tumour invasiveness 
and metastasis. Similar findings were observed in this study, where chronic 
treatment with AZD4785 promoted a more mesenchymal phenotype 
associated with differential RTK signalling (see chapter 4). This highlights a 
potential therapeutic rationale for stratification of treatment according to EMT 
characteristics and KRAS dependency. Due to the complexity of KRAS 
signalling and the high heterogeneity across different cancer types, a variety 
of combinational approaches may therefore be required, particularly for the 
treatment of advanced cancers. This warrants further validation of 
combinational approaches across additional KRAS-G12C mutant cancer 
types.   
 
Additional promising strategies for combination with KRAS inhibitors could 
also be investigated and compared across the panel of resistant cells. In 
particular immune checkpoint inhibitors, which target the programmed death 
protein 1 (PD-1) receptor and its ligand PD-L1, show promising therapeutic 
potential alongside KRAS inhibitors. From clinical trials it was identified that 
patients with KRAS mutations had increased PD-L1 levels and in terms of 
overall survival had greater benefit from anti-PD-1 immunotherapies [431, 
432]. Cell-based studies confirmed that mutant RAS signalling directly 
upregulates PD-L1 expression contributing to immunoresistance, and that 
treatment with a KRAS-G12C inhibitor significantly reduced its expression 
[433]. Furthermore in mouse-models, combined treatment of AMG-510 and 
anti-PD-1 inhibitors synergised well to promote complete tumour regression 
and also promoted a long-term tumour-specific T-cell response that protected 
against tumour re-challenge [208]. These responses were not observed with 
either agent alone, indicating specific KRAS inhibition can improve responses 
to PD-1 therapies. This combination strategy is therefore particularly 
interesting for the potential treatment of heterogeneous KRAS-mutant tumours 
and metastases in which KRAS mutational status can vary. Ultimately using 
immune-targeted drugs to modulate the patient’s immune response 
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represents a critical strategy for treating advanced tumours which may 
eventually relapse with standard targeted combination therapies. Currently 
both AMG-510 and MRTX849 are undergoing clinical evaluation with PD-1 
and PD-L1 immunotherapies (see Table 5.2).  
 
It also remains to be investigated what effect different inhibitor treatment 
strategies will have on therapeutic responses and whether the timing of drug 
administration can improve combination therapy, as well as reducing potential 
overlapping clinical toxicities [434]. Approaches such as sequential drug 
treatment or alternative dosing could yield major vulnerabilities within cancer 
cells or ‘collateral sensitivities’ as a result of evolutionary dynamics, that could 
then be targeted by a second treatment to selectively kill drug-resistant cells 
[235, 434]. This approach termed ‘evolutionary herding’ aims to exploit these 
weaknesses and control tumour cell growth by interrupting the growth of drug-
dependent cells, enabling greater competition with drug-sensitive cells. For 
example, upfront anti-PD-1 therapy followed by BRAF/MEK targeted therapy 
was found to prolong anti-tumour responses in BRAF-mutant melanoma [435]. 
Moreover, prior resistance to EGFR inhibitors in EGFR-mutant lung cancer 
was associated with greater sensitivity to AUKORA kinase inhibition and is 
currently being clinically evaluated (NCT04085315) [436]. Intermittent dosing 
of RAF, MEK and ERK inhibitors in BRAF-mutant PDXs inhibited tumour 
growth with minimum toxicity [437]. In this study, pre-treatment with KRAS or 
MEK inhibitors generally rendered cells more resistant to a range of alternative 
targeted inhibitors, however there were exceptions such as increased 
sensitivity to FGFR1 and mTOR inhibition in AZD4785-treated resistant cells 
(Figure 5.1). Whether these drug responses are translated to complex 
preclinical and in-vivo models remains to be investigated, but subsequently it 
would also be informative to assess the timings of treatment to optimise 
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6.3  Challenges for the prediction of cancer drug 
resistance 
 
The emergence of acquired drug resistance mechanisms is often described 
as an evolutionary process, supporting the survival of subpopulations of cells 
with favourable genetic alterations [263]. Branched evolutionary tumour 
growth supporting tumour heterogeneity provides the basis for the 
development of multiple parallel resistance mechanisms following treatment, 
which have been described both within tumours and across metastatic tumour 
sites [438]. Often these genetic alterations pre-exist treatment supporting 
clonal selection as an acquired resistance mechanism [439]. This 
heterogeneity represents a major challenge for recapitulating cancer 
evolutionary dynamics in preclinical models and for developing effective 
therapeutic strategies.  
 
In this study gene and protein expression profiling using RNA-seq and RPPA 
was used to determine resistance signatures associated with KRAS inhibitor 
treatment. This highlighted clinically relevant pathways that were enriched as 
potential mechanisms of resistance. However, underlying tumour 
heterogeneity can be overlooked when analysing cell populations collectively. 
Subsequently it remains to be investigated whether the resistance 
mechanisms identified in this study are expressed collectively throughout the 
cell population or whether certain mechanisms can be attributed to distinct cell 
subpopulations, which may ultimately influence tumour evolution and implicate 
potential future treatment strategies. In recent years technologies such as 
single-cell genome profiling has provided higher resolution and coverage of 
the genetic heterogeneity of resistance mechanisms following treatment, 
enhancing precision medicine. Studies have used single cell RNA-seq on 
PDXs which identified distinct genomic characteristics of individual tumour 
cells in order to elucidate changes associated with drug resistance  [440, 441]. 
Biomarkers of drug sensitive and drug tolerant populations could then be 
applied to identify tumours which would respond to combination therapy [441]. 
Whilst KRAS inhibitor combinations are evaluated in clinical trials, it will be 
important to assess the mechanisms and patterns of resistance that arise in 
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patients over time, to help assess disease progression and improve patient 
responses guided by the tumour’s evolution.  
 
As this study has highlighted, the identification of different gene and protein 
expression changes across acute and chronic treatments confirms that drug 
resistance to KRAS inhibitors is a continuous process whereby cells adapt 
accordingly. Currently the lung TRACERx clinical study is attempting to 
address the impact of tumour evolution and heterogeneity upon therapeutic 
outcomes and to define emerging genetic alterations following treatment 
relapse (NCT01888601)[442]. If the evolutionary trajectories of cancers 
following targeted treatments can be reasonably predicted, then it may be 
possible to optimise personalised treatment strategies for specific oncogene 
driven cancers in order to deliver better treatment outcomes and sustain 
relapse free survival. Other technologies that are being utilised to improve 
clinical prediction of treatment efficacy include artificial intelligence and 
mathematical predictive methods, which can help to understand cancer drug 
sensitivity and synergistic drug combinations by analysing gene-expression 





Recent progress in the development of direct KRAS inhibitors has provided 
hope for potential therapeutic treatments for this previously elusive cancer 
drug target. However as is the case with most targeted therapies, the 
development of acquired resistance often limits their efficacy and pre-clinical 
studies of KRAS-G12C inhibitors has provided evidence of this [425]. With 
KRAS-G12C inhibitors currently being tested in clinical trials and additional 
KRAS-mutant inhibitors in development, it is critical to be able to predict 
potential resistance mechanisms and develop suitable combination therapies. 
Relatively little is understood about the underlying mechanisms of this 
resistance, how this might change according to different mechanisms of KRAS 
inhibition as well as over the duration of treatment. This project aimed to 
identify resistance signatures associated with several KRAS inhibitors, 
including recently developed direct KRAS-G12C inhibitors, and to determine 
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potential combination strategies to prevent or delay the onset of acquired 
resistance (Figure 6.1).  
 
To summarise, a novel panel of resistant cell lines using different KRAS 
inhibitors was generated. Transcriptomic and proteomic approaches were 
used to identify potential resistance mechanisms associated with these 
different approaches of KRASi, across both acute and chronic treatments. An 
extensive list of genes and proteins that were differentially regulated across 
the panel of inhibitors were identified, and those directly involved in RAS 
pathway and known cancer networks were shortlisted. Consistent 
upregulation of RTKs, RAS-GEFs, cell cycle and DNA damage repair 
pathways was observed. Further characterisation of RTK signalling and 
changes in RAS activity provided insight into potential signalling rewiring 
mechanisms that occurred in resistant cells. Resistance to KRAS-G12Ci was 
associated with increased ERBB2 expression and regained KRAS activity. 
Whereas resistance to pan-KRASi showed differential upregulation of 
alternative RTKs FGFR1 and PDGFRb in chronically treated cells, coupled 
with KRAS independence, potential RAS isoform switching and a more 
mesenchymal phenotype. Consequently, this highlighted potential 
implications for overcoming resistance to different KRAS inhibitors which may 
require different therapeutic combination strategies. 
 
Screening of 25 different compounds and inhibitor combinations identified 15 
inhibitors which differentially mitigated resistance across the panel of resistant 
cells, with 3 inhibitors, flavopiridol - a broad CDK inhibitor and two mTOR 
inhibitors effective at re-sensitising all KRASi cells. Inhibitor combinations 
were also analysed alongside KRAS inhibitors in naïve parental cells to 
identify how well combinations prevented resistance from developing. The 
most effective included treatment with flavopiridol as well as inhibitor 









Figure 6.1: Acute and chronic acquired resistance mechanisms to KRAS inhibition and 
potential therapeutic combinations to overcome resistance  
Summary of acute and chronic responses from gene and protein expression analysis following 
KRAS inhibition with ARS1620 and AZD4785. Inhibitor combination screening identified the 
most effective inhibitor combinations to reverse resistance to KRAS inhibitors as well as 





Thus, multi-omic analysis of resistant cells and screening of directed 
combinatorial therapeutics has been fundamental for advancing our 
understanding of resistance mechanisms to new direct classes of KRAS 
inhibitors. This data provides insightful approaches for effective KRAS inhibitor 
therapeutic combinations to overcome and slow the emergence of resistance, 
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Appendix 2: RPPA log2fold protein expression levels which show the 
greatest change between acute and chronic treatment for each inhibitor. 
 









Chk1_pS296 CHEK1 p 1.50860002 -0.2585704 V 
STING STING1  1.21059002 0.34384956 V 
PAK_pT423_T402 PAK1-3 p 1.14189002 0.00933956 C 
NQO1 NQO1  1.10607002 -0.3635804 V 
p21 CDKN1A  0.96723002 -0.0997004 C 
Pdcd4 PDCD4  0.95650002 -0.0882904 C 
CRABP2 CRABP2  0.87381002 -0.2798704 V 
PKC-b-II_pS660 PRKCA/B/D/E/H/Q p 0.85551002 -0.0106904 V 
Annexin-I ANXA1  0.85389002 0.25309956 V 
INPP4b INPP4B  0.82486002 0.21652956 C 
G6PD G6PD  0.65129002 -1.0666104 V 
JNK_pT183_Y185 MAPK8 p 0.60614002 -0.3953204 C 
NF-kB-p65_pS536 RELA p 0.46269002 -0.5670704 C 
EMA MUC1  0.45768002 -0.6711904 C 
ACLY_pS455 ACLY p 0.16265002 0.60337956 V 
Cdc6 CDC6  -0.75115 0.08992956 V 
EphA2 EPHA2  -1.00404 0.09434956 V 
Hif-1-alpha HIF1A  -1.02464 -0.1124404 C 
S6_pS240_S244 RPS6 p -1.04885 -0.1317604 V 
EphA2_pS897 EPHA2 p -1.06784 0.03992956 C 
DUSP4 DUSP4  -1.12497 -0.4253104 V 
ARS1620 
p21 CDKN1A  1.24685002 0.05682425 V 
NQO1 NQO1  1.16227002 -0.2479657 V 
Pdcd4 PDCD4  0.98950002 0.16827425 C 
MTCO1 MT-CO1  0.87527002 -0.7753757 V 
PAI-1 SERPINE1  0.60533002 -0.3513257 C 
G6PD G6PD  0.50934002 -0.9814157 C 
CRABP2 CRABP2  0.17143002 -0.6182957 V 
CDK1_pT14 CDK1-3 p -0.63202 0.31330425 V 
Cyclin-B1 CCNB1  -0.68357 0.02257425 V 
S6_pS235_S236 RPS6 p -0.69625 -0.0078957 V 
S6_pS240_S244 RPS6 p -0.75796 -0.0680557 C 
Src_pY416 SRC p -0.81798 -0.1135257 V 
Selumetinib 
p21 CDKN1A  1.24091001 -0.28661 C 
STING STING1  1.03068001 -0.04249 V 
Chk1_pS296 CHEK1 p 0.94054001 -0.41717 V 
NQO1 NQO1  0.84892001 -0.54041 V 
PAR [PAR Modification]  0.55521001 -0.69821 C 
G6PD G6PD  0.30228001 -1.16498 V 
Cdc6 CDC6  -0.90635 -0.20326 V 
CDK1_pT14 CDK1-3 p -0.9254 -0.26334 C 
Aurora-B AURKB  -1.00472 -0.26974 V 
EphA2 EPHA2  -1.08133 -0.12011 V 
Cyclin-B1 CCNB1  -1.16279 -0.21848 V 
AZD4785 
(ASO) 
INPP4b INPP4B  1.46289476 -0.8888217 C 
Tuberin_pT1462 TSC2 p 1.06431476 0.03074826 V 
STING STING1  1.04071476 -1.3582317 V 
NQO1 NQO1  0.97038476 -2.0179717 V 
HER2 ERBB2  1.53644476 -0.3602917 V 
E-Cadherin CDH1  0.62361476 -0.8015317 V 
P-Cadherin CDH3  0.62035476 -0.3405017 C 
PAK1 PAK1  0.34876476 -1.2627417 V 
HMHA1 ARHGAP45  0.33192476 -0.9264617 V 
SHP2 PTPN11  0.00174476 -0.9807617 V 
Rab25 RAB25  0.47392476 -1.4541217 V 
Claudin-7 CLDN7  0.44588476 -1.5566717 V 
DRP1 DNM1L  0.36494476 1.00401826 V 
Bax BAX  0.34076476 1.12806826 V 
Transglutaminase TGM2  0.29777476 0.99099826 V 
PLC-
gamma1_pS1248 PLCG1 p 0.28166476 1.01936826 V 
MMP14 MMP14  0.27548476 1.14071826 V 
p53 TP53  0.26072476 1.10379826 C 
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IR-b INSR  0.22777476 1.16075826 C 
Myosin-IIa_pS1943 MYH9 p 0.19875476 -1.3985917 V 
PAX6 PAX6  0.13676476 0.95544826 V 
DDR1 DDR1  0.12313476 -1.2947317 V 
LAD1 LAD1  0.04692476 -0.9422117 V 
PLC-gamma1 PLCG1  0.04347476 0.82404826 V 
Myosin-IIa MYH9  0.04214476 -1.1792017 C 
Rb RB1  0.03760476 0.86163826 Q 
Connexin-43 GJA1  0.00821476 2.06941826 C 
Tau MAPT  -0.0041752 0.98907826 C 
Cyclophilin-F PPIF  -0.0072852 0.87006826 V 
FGF-basic FGF2  -0.0209452 2.84731826 C 
AceCS1 ACSS2  -0.0213052 1.04178826 V 
PKM2 PKM  -0.0752752 -1.4263417 C 
LC3A-B MAP1LC3A/B  -0.2240652 1.57739826 C 
b-Catenin CTNNB1  -0.2577952 -1.6715617 V 
Heregulin NRG1  -0.3182752 0.96224826 V 
Enolase-1 ENO1  -0.3257352 -1.1067917 V 
CRABP2 CRABP2  -0.4589752 -2.4334617 V 
VHL-EPPK1 EPPK1  -0.5491652 -1.4552117 C 
JAB1 COPS5  -0.5616352 -1.2197517 C 
CDK1_pT14 CDK1-3 p -1.0595752 0.83657826 C 
IGFBP2 IGFBP2  -1.0652852 -2.5723017 V 
MCT4 SLC16A3  -1.0825152 -3.2263717 V 
Cyclin-B1 CCNB1  -1.2232252 0.26762826 V 
Rb_pS807_S811 RB1 p -1.5226952 0.49924826 V 
S6_pS240_S244 RPS6 p -0.3672852 0.69354826 V 
eEF2 EEF2  -0.3694252 0.69709826 C 
PKA-a PRKAR1A  -0.4797652 0.62633826 V 
SLC1A5 SLC1A5  -0.5858952 0.79197826 C 
Cdc6 CDC6  -1.0609452 0.26993826  
Caveolin-1 CAV1  -0.9412352 0.13097826 V 
Cyclin-D3 CCND3  -0.1685652 0.69808826 V 
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Appendix 3: Ras Network Expression for H358-R AZ6813, H358-R AR1620 
and H358-R Selumetinib 
Heat maps illustrating RNA-Seq differential gene expression in Ras pathway genes. Red 
indicates positive log fold change and represents increased expression in inhibitor treated 
cells compared to the corresponding vehicle control, whilst blue indicates negative log fold 
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Appendix 4: Immunofluorescence of acutely treated H358 cells (H358-A) 
H358 cells were seeded onto coverslips and treated with vehicle or inhibitor for a total period 
of 8 days. Cells were re-dosed every 48hrs. Cells were stained with E-cadherin (red) or N-
cadherin (green) primary antibodies and immunofluorescence was imaged using the 40X lens 

















Fig?: Immunofluorescence of acutely treated H358 cells (H358-A)
H358 cells (P13) were seeded onto coverslips and treated with vehicle or inhibitor for a total
period of 8 days. Cells were re-dosed every 48hrs. Cells were stained with E-cadherin (red) or N-
cadherin (green) primary antibodies and immunofluorescence was imaged using the 40X lens on
a Nickon Ti-E microscope. Scale bar represents 20uM.
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Appendix 5: Immunofluorescence of resistant H358 cells (H358-R) 
H358-R cells were seeded onto coverslips and treated with corresponding vehicle or inhibitor 
until cells were confluent. Cells were re-dosed with fresh media containing inhibitor every 
48hrs. Cells were stained with E-cadherin (red) or N-cadherin (green) primary antibodies and 
















Fig?: Immunofluorescence of resistant H358 cells (H358-R)
H358-R cells (P29-34) were seeded onto coverslips and treated with corresponding vehicle or
inhibitor until cells were confluent. Cells were re-dosed with fresh media containing inhibitor
every 48hrs. Cells were stained with E-cadherin (red) or N-cadherin (green) primary antibodies
and immunofluorescence was imaged using the 40X lens on a Nickon Ti-E microscope. Scale
bar represents 20uM.
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Appendix 6: Dose responses of combination therapeutics in resistant cells (cytotoxicity) 
Resistant H358 cell lines treated with ARS1620 (R-ARS), selumetinib (R-Sel) and AZD4785 
(R-ASO), alongside naïve parental H358 cells treated with DMSO (R-DMSO) were treated 
with their previous IC90 inhibitor treatments (ARS1620, Selumetinib, AZD4785 and DMSO 
respectively) in combination with dose responses of additional targeted inhibitors (see table 
5.1). The change in IncuCyte Cytotox Green fluorescence was recorded following 4 days of 
inhibitor treatment. Graphs are presented as mean percentages of vehicle controls ±SEM from 
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Appendix 7: Dose responses of combination therapeutics in resistant cells (proliferation) 
Resistant H358 cell lines treated with ARS1620 (R-ARS), selumetinib (R-Sel) and AZD4785 
(R-ASO), alongside naïve parental H358 cells treated with DMSO (R-DMSO) were treated 
with their previous IC90 inhibitor treatments (ARS1620, Selumetinib, AZD4785 and DMSO 
respectively) in combination with dose responses of additional targeted inhibitors (see table 
5.1). The change in IncuCyte Nuclight Rapid Red staining was recorded following 4 days of 
inhibitor treatment. Graphs are presented as mean percentages of vehicle controls ±SEM from 
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Appendix 8: Synergy matrixes of triple combination therapeutics in resistant 
cells  
Synergy scores from double inhibitor combination assays were calculated using the Loewe 
model in Combenefit [392]. Areas coloured blue indicate drug combinations that are 
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Figure 5.4: Synergy matrixes of triple combination therapeutics in resistant cells
Synergy scores from double inhibitor combination assays were calculated using the Loewe
model in Combenefit [39]. Areas coloured blue indicate drug combinations that are











A) EGFRi + SHP2i
C) EGFR/ERBB2i + SHP2i
D) EGFR/ERBB2i + mTORi























































Figure?: Dose response matrix
Percentage viability of drug combinations in resistant ARS1620, Selumetinib and ASO cell lines compared
to DMSO cells.
E) EGFR/ERBB2i + CDKi
G) FGFR1i + MEKi
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